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1.1 Background and aim of the work  
Endothelial cells play a critical role in the progression, control, and resolution of 
inflammation. In their normal state, they serve as an antithrombotic and antiinflammatory 
barrier between blood and tissue, regulating blood flow and permeability of blood vessels to 
immune cells as well as to micro- and macromolecules. (Hennig et al.1999, Choy et al.2001) 
Under inflammatory conditions, endothelial cells become activated by exposure to 
proinflammatory stimuli such as TNF-α, promoting vasoconstriction, vascular permeability, 
expression of adhesion molecules, coagulation and thrombosis, as well as causing endothelial 
injury and apoptosis. Injury of the endothelial monolayer by induction of apoptotic cell death, 
e.g. by TNF-α, plays an important role in the pathophysiology and progression of 
atherosclerosis (Dimmeler et al. 1998, Rossig et al.2001, Mallat and Tedgui 2001). In order to 
counteract cell damage caused by the inflammatory response, endothelial cells can upregulate 
a set of protective proteins, such as the members of the family of heat shock proteins like 
HSP70 and HSP32 (Heme oxygenase-1, HO-1). Especially HO-1 has come into the focus of 
interest during the last years due to its prominent cytoprotective properties protecting 
endothelial cells from apoptosis (Siow et al 1999). In this context, the effects of the atrial 
natriuretic peptide, ANP, and aspirin on HO-1 in HUVEC were investigated. 
ANP is a polypeptide hormone playing an important role in the regulation of blood pressure 
and cardiovascular homeostasis. The vasoactive peptide is mainly synthesized and secreted by 
the atrium of the heart in response to atrial stretch and pressure and exerts a variety of potent 
regulatory effects in the cardiovascular system, such as diuresis, natriuresis and 
vasorelaxation (Levin et al.1998, Misono 2002). In addition to its well-characterized renal and 
cardiovascular actions, ANP possesses a much broader biological profile than assumed a 
couple of years ago. First observations pointing to additional biological functions of ANP, 
e.g. in the immune system, were the detection of the expression of ANP and its receptors in 
macrophages (Vollmar and Schulz 1994, Vollmar and Schulz 1995, Kiemer and Vollmar 
1997) and in the thymus (Vollmar and Schulz 1990a), indicating that ANP might also 
influence immunological functions. Recent works confirmed the important role of ANP in the 
immune system, as it was shown to reduce the expression of important mediators of 
inflammation in macrophages, such as TNF-α (Kiemer et al.2000a, Tsukagoshi et al.2001), 
cyclooxygenase-2 (Kiemer et al.2002a) and nitric oxide synthase (Kiemer and Vollmar 1997, 
Kiemer and Vollmar 1998). In addition to its inhibitory action on inflammatory mediators, 
induction of protective proteins by ANP was hypothesized to confer protection against TNF-
α-induced apoptosis, a central event in inflammatory diseases, such as atherosclerosis, septic 
shock and rheumatoid arthritis. To date, mechanisms leading to the upregulation of 
cytoprotective proteins such as heat shock proteins remain unknown and were therefore the 
subject of the first part of the present work. 
Aspirin is a well-known anti-inflammatory drug, introduced for the treatment of 
inflammatory disorders and joint diseases, such as rheumatoid arthritis, in 1899, based on its 
analgesic and antiinflammatory effects (Jack 1997). These widely documented properties of 
aspirin have been ascribed to its ability to inhibit prostaglandin production by inhibition of the 
enzymatic activity of cyclooxygenases (COX). In recent years, an increasing number of 
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studies has reported additional protective effects of this non-steroidal antiinflammatory drug 
against colon cancer (Thun et al.1991) and cardiovascular disease (Mehta 1998, Lauer 2002), 
as well as its ability to delay the onset of Alzheimer disease (Flynn and Theesen 1999). 
Inhibition of COX activity can only in part account for these recently observed effects, 
suggesting that aspirin may exert part of these activities by modulating COX-independent 
pathways. In this context, aspirin treatment has been demonstrated to result in increased 
expression of the heat shock protein HSP70 and HSP60 (Jin et al.1999, Amberger et al.1999), 
inhibition of iNOS expression (Amin et al.1995, Katsuyama et al.1999), inhibition of NF-κB 
(Kopp et Gosh 1994), suppression of adhesion molecule expression, and down-regulation of 
MCP-1 (Amberger et al.1999). However, it is widely unknown if aspirin is able to influence 
the expression of HO-1, especially basal levels of this important heat shock protein. Therefore 
the aim of the second part of this work was to characterize the effect of aspirin on the heat 
shock protein HO-1, as a potential new cytoprotective target. 
In this context, the following questions were to be answered: 
I) Influence of ANP on HUVEC: 
1.) Is ANP able to induce the expression of the cytoprotective proteins HO-1 and HSP70 
in human umbilical vein endothelial cells, HUVEC? 
2.) Which receptor mediates the induction of HO-1 observed after treatment with ANP? 
3.) What is the molecular mechanism of HO-1 induction by ANP? 
a) Does ANP influence HO-1 mRNA levels? 
b) Does ANP have an impact on the activity of the transcription factor AP-1? 
c) Does ANP modulate AP-1 activity via the phosphorylation status of MAP kinases? 
d) Is there a causal relationship between the effects of ANP on the transcription factor  
AP-1 and ANP-induced upregulation of HO-1 protein? 
4.) Do HUVEC treated with TNF-α under the employed cell culture conditions die by 
apoptosis or necrosis? 
5.) Does the upregulation of HO-1 protein by ANP confer protection against TNF-α-
induced cytotoxicity? 
II) Influence of aspirin on HUVEC: 
1.) Is aspirin able to influence HO-1 expression in HUVEC? 
2.) What is the molecular mechanism of the detected upregulation of HO-1 protein 
levels? 
a) Does aspirin influence HO-1 mRNA levels? 
b) Does aspirin affect AP-1 DNA-binding activity? 
c) Does aspirin affect AP-1 by influencing the activity of MAP kinases? 
d) Is there a causal relationship between the effects of aspirin on the transcription  
  factor AP-1 and aspirin-induced upregulation of HO-1 protein? 
3.) Is aspirin able to protect HUVEC against TNF-α-induced apoptosis? 
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1.2 The heme oxygenase-1 
1.2.1 The family of heat shock proteins 
Heat shock proteins (HSP), also called stress proteins, play a role in development and normal 
cell function. Constitutively expressed HSP function as molecular chaperones and participate 
in protein synthesis, protein folding, oligomeric assembly, transport, and translocalization 
processes between intracellular compartments, as well as switches between active/inactive 
protein conformations (Hendrick and Hartl 1993). These processes require the existence of 
proteins in an unfolded or partially folded conformation, which exposes interactive regions 
within the proteins that can lead to deleterious protein aggregation. Heat shock proteins bind 
to these interactive regions, thus preventing aggregation and enabling the folding of 
polypeptides (Becker and Craig 1994). Besides constitutive expression, stress proteins can 
also be induced by a variety of stress situations, including hyperthermia, viral infection, 
exposure to heavy metals, ischemia, anoxia, and oxidative stress (Goldbaum and Richter-
Landsberg 2001, Wagner et al. 1999).  
Heat shock proteins are classified into subfamilies according to their molecular weight 
(Goldbaum and Richter-Landsberg 2001). The HSP70 family comprises multiple members. 
The constitutive cytosolic form HSC70 has a molecular weight of 73kDa and is only 
moderately inducible. The inducible form HSP70 with a molecular weight of 72 kDa is only 
weakly constitutively expressed and is strongly induced during oxidative stress conditions 
(Goldbaum and Richter-Landsberg 2001). Members of the HSP70 family fulfil important 
chaperone functions. They bind to and stabilize newly synthesized unfolded precursor 
proteins, thus preventing improper protein interactions, misfolding, and aggregation of these 
precursors. HSP70 proteins therefore contribute to correct protein synthesis, translocation 
across biological membranes, and protein folding and assembly into organelles (Becker and 
Craig 1994). During stress conditions, HSP70 proteins prevent cell damage by binding to 
damaged or denatured proteins and preventing protein aggregation, thus providing the 
opportunity for either correct refolding or degradation of these damaged proteins (Becker and 
Craig 1994). Besides, HSP70 is able to attenuate the inflammatory response by interfering 
with the activation of the proinflammatory transcription factor NF-κB and consequently with 
the expression of inflammatory enzymes (Feinstein et al. 1996) and cytokines like TNF-α 
(Snyder et al. 1992). HSP70 expression is induced in response to various cellular stress 
stimuli and enables the cell to cope with inflammatory conditions such as 
ischemia/reperfusion injury (Chen et al. 1997) or sepsis (Hotchkiss et al.1993) and other 
inflammatory diseases (Kohn et al. 2002, Feinstein et al. 1996), as well as apoptosis 
(deMeester et al. 1997). 
HSP32 is a small stress protein and belongs to the heme oxygenase family of proteins. It is 
synthesized in response to heat shock, heme, and oxidative stress. Accumulating evidence 
suggests its role in protecting cells from oxidative stress, as described in detail under 1.2.2. 
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1.2.2 The heme oxygenase system 
1.2.2.1 Physiological function 
Heme oxygenase (HO), originally discovered in 1968 by Tenhunen et al., catalyzes the initial 
and rate limiting step in the oxidative degradation of heme (Tenhunen et al. 1968). Together 
with the heme synthetic enzyme δ-aminolevulinate synthase it regulates the cellular levels of 
the prooxidant heme, yielding equimolar amounts of biologically active catabolites. Heme 
released from oxidized free hemoglobin constitutes a potentially harmful molecule due to its 
ability to intercalate into cell membranes where it promotes deleterious iron-dependent 
reactions leading to ROS generation and membrane lipid peroxidation (Ryter and Tyrell 
2000). Acting in concert with NADPH-cytochrome P450 reductase as reducing agent, HO 
catabolizes the breakdown of heme, released mainly from hemoglobin of senescent 
erythrocytes, from myoglobin or cytochromes (Maines 1997). HO-1 cleaves the α-methene 
carbon bridge and yields equimolar amounts of biliverdin IXα, carbon monoxide (CO), and 
iron (Ryter and Tyrell 2000). In mammalian cells, biliverdin is subsequently converted to 
bilirubin by bilverdin reductase, and released iron is used in intracellular metabolism or 
sequestered into ferritin (figure 1). 
 
figure 1: heme degradation by heme oxygenase-1 
Heme Biliverdin IXα
Heme 
oxygenase
3 NADPH
3 O2
3 NADP+
3 H2O
+ CO + Fe II
Bilirubin IXα
Biliverdin 
reductase
NADPH
NADP+
cGMP Ferritin
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1.2.2.2 The three heme oxygenases 
To date, three isoforms of the HO protein have been identified, all of which are encoded by 
separate genes. HO-1 is the inducible isozyme (Ryter et al. 1999). Under basal conditions, the 
32 kDa protein is expressed at low levels in endothelial cells, as well as in kidney, liver, and 
most abundantly in spleen, where senescent erythrocytes are sequestered and red blood cell 
hemoglobin is degraded (Maines 1997). Apart from its major substrate heme, HO-1 synthesis 
is known to be up-regulated by a variety of non-heme inducers, including heavy metals, 
cytokines, hormones, endotoxins, oxidants, and heat shock (Otterbein and Choi 2000, Choi 
and Alam 1996). Induction of HO-1 is also highly sensitive to exposure to agents causing 
oxidative stress, such as UV irradiation, sodium arsenite, hyperoxia and glutathione depletion, 
indicating that HO-1 induction may be a protective strategy of the cell in the cellular defense 
mechanism against oxidative and inflammatory damage (Keyse and Tyrrell 1989, Elbirt et al. 
1998, Oguro et al. 1998, Otterbein et al. 1999). HO-2 is a constitutively expressed 36 kDa 
protein and can be detected mainly in the brain, endothelium and testes. The only inducers of 
HO-2 identified to date are adrenal glucocorticoids (Maines 1997). The more recently 
discovered third isoform HO-3, 33 kDa in size, is like HO-2 constitutively expressed, but 
exhibits only low catalytic activity and may function in heme binding and heme sensing 
(Immenschuh and Ramadori 2000). It has been found in brain, heart, kidney, liver, testes and 
spleen (Siow et al.1999).  
Each isozyme is highly evolutionary conserved in its amino acid and nucleotide sequence. 
Between HO-1 and HO-2, however, the similarity of amino acid and nucleotide sequence is 
merely 43% (Maines 1997). HO-3 is closely related to HO-2 and shares 90% amino acid 
homology. A 24-amino acid segment is completely conserved among all forms, with only 
exeption of a single residue, and forms a hydrophobic pocket (heme pocket) that binds the 
heme pyrrol rings 1 and 2 through electrostatic interactions (Maines 1997). 
1.2.2.3 Regulation of heme oxygenase-1 
Stimulation of HO-1 expression by most stimuli is primarily controlled at the transcriptional 
level and involves gene activation and de novo enzyme protein synthesis. Several response 
elements located in the 5‘ distal flanking region and the promotor of the HO-1 gene have been 
identified and characterized, including consensus sequences necessary for the binding of 
transcription factors such as activator protein 1, NF-κB, and heat-shock factor 1 (Choi and 
Alam 1996, Maines 1997, Hartsfield et al. 1998, Hartsfield et al. 1999). AP-1 seems to play a 
crucial role in the control of the heme oxygenase 1 gene as demonstrated by a multitude of 
reports stressing the importance of this transcription factor in the induction of HO-1 in 
response to diverse stimuli (e.g. Camhi et al. 1998, Alam et al. 1995, Wiesel et al. 2000). 
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Upstream signaling pathways implicated in the regulation of HO-1 expression include redox 
signaling, protein kinase C, protein kinase A, protein kinase G, as well as the mitogen-
activated protein kinases, described in detail under 1.7 (Immenschuh and Ramadori 2000). 
1.2.2.4 Cytoprotective potential 
Accumulating evidence suggests that HO-1 induction in addition to its role in heme 
degradation might confer cellular protection against oxidant insults and serve a vital function 
in maintaining cellular homeostasis. HO-1 has a diverse spectrum of cytoprotective effects 
that, apart from its ability to remove the pro-oxidant heme molecule, are mostly associated 
with the different end products of heme catabolism.  
The HO product biliverdin is rapidly converted into the bile pigment bilirubin which 
possesses potent free radical scavenging and antioxidant properties (Stocker et al. 1987, Clark 
et al. 2000). Bilirubin has been demonstrated to provide cellular protection to neuronal cells 
exposed to oxidative injury by hydrogen peroxide (Dore et al. 1999) as well as in a model of 
ischemic heart injury (Clark et al. 2000). Iron, released during the enzymatic degradation of 
heme, is cytotoxic due to its ability to generate ROS by Fenton chemistry, but is promptly 
sequestered into the iron storage protein ferritin, the synthesis of which is upregulated by iron. 
Ferritin exerts antioxidative effects that can be ascribed to its capacity to sequester iron, 
which lowers the prooxidant state of the cell by removing free iron, and to its ferroxidase 
activity, catalyzing the oxidation of ferrous iron to ferric iron to enable intracellular storage of 
iron in biological systems (Balla et al. 1992). HO-1 also upregulates an iron ATPase located 
in the endoplasmatic reticulum resulting in augmented cellular iron efflux (Ferris et al. 1999, 
Barañano et al. 2000). CO, the third catalytic product of HO-1 activity, can also mediate 
important cellular functions and has been shown to exhibit potent cytoprotective effects. This 
gaseous messenger can promote vasodilatation via activation of soluble guanylate cyclase and 
subsequent formation of cGMP. Therefore CO can maintain blood circulation at sites of 
inflammation, counteracting the deleterious effects of coagulation and thrombosis (Sammut et 
al. 1998) Via the same mechanism, CO is able to suppress platelet activation or aggregation. 
Most interestingly, CO has also been reported to protect endothelial cells from undergoing 
apoptosis (Brouard et al. 2000, Brouard et al. 2002) and to provide protection in models of 
lung injury (Otterbein et al. 2000), effects that are reported to be mediated via cGMP-
independent pathways, such as activation of p38 MAPK. 
HO-1 induction is observed in a number of disease states, such as ischemic stroke or 
Alzheimer’s disease (Panahian et al. 1999, Papolla et al. 1998). Evidence that the induction of 
HO-1 has therapeutic implications in the treatment of diseases associated with oxidative stress 
has been provided by various in vitro studies demonstrating a cytoprotective potential of this 
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heat shock protein in models of lung injury (Otterbein et al. 1999), TNF-α-induced apoptosis 
(Polte et al. 1997, Petrache et al. 2000) or ischemia/reperfusion injury (Katori et al. 2002). 
Recent studies in HO-deficient mice have further strengthened the important cytoprotective 
role of this protein. The mice lacked the ability to reuse iron and were characterized by 
progressive anemia, tissue iron deposition, chronic inflammation, and delayed growth, as well 
as increased susceptibility to oxidative stress (Poss and Tonegawa 1997). These results in 
HO-1 knockout mice were additionally confirmed by a first case of human HO-1 deficiency. 
The boy displayed the same pathological findings, but compared to HO-1-targeted mice, 
endothelial cells and the reticuloendothelial system were even more affected (Yachie et al. 
1999, Kawashima et al. 2002). 
In view of this significant antiinflammatory and cytoprotective potential of HO-1 protein, 
induction of HO-1 gene expression by non-stressful stimuli appears to be a promising target 
and a novel approach to the therapeutic treatment of diseases associated with oxidative stress, 
such as atherosclerosis, septic shock, and rheumatoid arthritis. Cytotoxic injury, mostly the 
induction of apoptosis, of endothelial cells plays a pivotal role in the pathophysiology of 
inflammatory diseases such as atherosclerosis (Choy et al. 2001, Guevara et al. 2001, 
Takahashi et al. 2002) and sepsis (Haimovitz-Friedmann et al. 1997, Munshi et al. 2002). 
Therefore, the next chapter deals with the characteristics and mechanisms of the two forms of 
cell death that can be distinguished. 
1.3 Forms of cell death 
When investigating cell death, two basic forms of death associated with characteristic 
morphological changes can be distinguished: apoptosis and necrosis. 
1.3.1 Necrosis 
Necrosis, also referred to as accidential cell death, is a passive death process occuring after 
major pathological cellular injuries, characterized by failure of cellular homeostasis (Raffray 
and Cohen 1997). Whereas apoptosis can affect single cells, necrotic cell death mainly occurs 
in cell groups and is often observed when cells are confronted with severe and sudden injury, 
such as ischemia, sustained hyperthermia, or high doses of toxic agents. Morphological 
changes characteristic for necrosis are intense eosinophilia, cell and organelle swelling, 
vacuolization, as well as simultaneous protein denaturation and hydrolysis (Majno and Joris 
1995). Necrotic cells display progressive cell and organelle membrane dysfunction, which 
disturbs ion homeostasis and finally leads to the collapse of internal homeostasis. Nuclear 
changes include karyolysis, the non-specific DNA breakdown by increased DNase activity. 
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Finally, membrane rupture of the necrotic cell results in the liberation of cellular contents 
which activate the host inflammatory response (Raffray and Cohen 1997). 
1.3.2 Apoptosis 
1.3.2.1 Overview 
Apoptosis, also referred to as programmed cell death, is an evolutionary conserved 
physiological process of cellular autodestruction. This active, energy requiring process plays a 
central role in development, maintenance of homeostasis and host defense of multicellular 
organisms. Apoptotic cell death occurs during normal morphogenesis, tissue remodelling as 
well as in response to pathogenic infections or other irreparable cell damage and enables the 
elimination of unwanted cells and cells damaged by disease or toxic agents (Chang and Yang 
2000). Due to the crucial physiological role of apoptosis, dysregulation of this process is 
implicated in a variety of diseases associated with a lack of apoptosis, such as cancer, viral 
infections or autoimmune disorders, as well as with diseases involving pathologically 
increased apoptosis, such as AIDS and neurodegenerative disorders like Alzheimer’s disease 
or Parkinson’s disease (Thompson 1995). 
Apoptosis was first described in 1972 by Kerr et al. and given its name according to the image 
of leaves dropping off from a tree (apó, meaning “from”, ptósis, meaning “a fall”) (Kerr et al. 
1972). Cells dying from apoptosis exhibit characteristic morphological changes, including 
plasma membrane blebbing, followed by cell (body) shrinkage and fragmentation of the cell 
into membrane-bound apoptotic bodies, which are finally phagocytosed by macrophages or 
neighbouring healthy cells and eventually degraded in lysosomes. Biochemical changes 
typical for apoptosis are DNA fragmentation into discrete fragments of multiples of 180 bp, 
chromatin condensation and exposure of phosphatidylserine residues on the cell surface, 
which mark the cell for elimination by macrophages. Since plasma membrane integrity is 
maintained throughout the whole process of apoptosis, intracellular contents are not released 
into the circulation and potentially harmful inflammatory responses do not occur, in contrast 
to necrosis, which is accompanied by pronounced inflammation. 
1.3.2.2 Mechanisms 
Apoptosis is a highly conserved and strictly regulated form of cell death, which is reflected in 
the stereotypic morphological changes that occur during the execution of the apoptotic 
programme.  
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The crucial component of this apoptotic machinery is a family of proteases, called caspases. 
Caspases are cystein proteases that cleave their target proteins after specific aspartic acid 
residues (name “caspase” originates from cysteinyl aspartate-specific proteinase) (Green 
2000). According to their substrate specificity, the 14 caspases identified to date can be 
divided into subgroups of which the initiator (caspase-6, -8, -9, -20) and effector caspases 
(caspase-2, -3, -7) are involved in apoptosis (Chang and Yang 2000). Caspases can be found 
in all mammalian cells where they are synthesized as inactive proenzymes (zymogenes). 
Activation occurs by proteolytic processing, mostly by other caspases. 
 
Activation of initiator caspases 
Two distinct pathways leading to the activation of initiator caspases can be distinguished. The 
first is triggered by ligand binding to death receptors, the second involves the mitochondria. 
Upon ligation of a death receptor, adaptor proteins, such as FADD, are recruited to the 
cytoplasmic tail of the receptor via their death domain. FADD in turn recruits procaspase-8 
and –10 via the death effector domain, which brings these zymogenes into proximity with one 
another and allows the autocatalytic processing of the procaspases to form the mature 
enzymes (Ashkenazi and Dixit 1998). The activated initiator caspases can then cleave and 
activate several downstream caspases, the effector caspases. (see 1.4. for more detail). Via the 
cleavage of the proapoptotic bcl-2 family protein Bid, caspase-8 can activate the 
mitochondrial pathway by inducing cytochrome c release (Green 1998). 
The mitochondrial pathway is associated with a drop in the mitochondrial membrane 
potential, involving the opening of a mitochondrial channel at the inner membrane, called the 
permeability transition pore (Green 1998). This leads to swelling of the mitochondrial matrix, 
rupture of the outer membrane and release of cytochrome c into the cytoplasm. Cytochrome c 
associates with Apaf1, procaspase-9 and dATP to form the apoptosome complex, which 
results in activation of caspase-9. Cytochrome c release is triggered by various cellular 
stresses, including cytotoxic drugs, growth factor withdrawal, heat, free radicals, hypoxia, and 
DNA damage (Chang and Yang 2000, Green 1998).  
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figure 2: pathways of caspase activation and apoptosis  
 
Execution of apoptosis 
The initiator caspases activate effector or executioner procaspases, acting in a caspase cascade 
(Thornberry and Lazebnik 1998, Chang and Yang 2000). Effector caspases cleave a variety of 
cellular substrates possessing a specific tetrapeptide recognition sequence. The cleavage of 
these key substrates in the cell finally leads to the execution, packaging and disposal of the 
cell. Among the targets of effector caspases are several proteins stabilizing the cell structure, 
such as actin, lamin A, and α-fodrin. Cleavage of these proteins results in destruction of cell 
structures, such as the cytoskeleton and the nucleus. Moreover, caspases inactivate various 
regulatory proteins that possess anti-apoptotic properties, including the DNA repair enzyme 
PARP (poly(ADP-ribose) polymerase) and the antiapoptotic Bcl-2 family proteins Bcl-2 and 
Bcl-xL (Chang and Yang 2000, Thornberry and Lazebnik 1998). Taken together, caspases 
lead to the elimination of the dying cell, by cutting off cell-cell-contacts, reorganization of the 
cytoskeleton, inhibition of DNA repair and replication, destruction of DNA and nuclear 
structure, induction of phosphatidylserine exposure which targets the cell for phagocytosis, 
and disintegration into apoptotic bodies. 
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1.3.2.3 Apoptosis in vascular disease 
Endothelial cells regulate the homeostasis of the vessel wall by influencing vascular tone, 
adhesion of platelets and monocytes, growth of smooth muscle cells, and production of 
extracellular matrix (Alvarez et al. 1997, Vane et al. 1990). Injury of the endothelial 
monolayer by apoptotic cell death is regarded as a critical event in the pathophysiology and 
progression of inflammatory diseases, such as atherosclerosis, endotoxic shock or 
ischemia/reperfusion injury (Brouard et al. 2000, Choy et al. 2001). Endothelial apoptosis is 
an initial event in the development of atherosclerosis, since it leads to increased endothelial 
cell turnover which critically impairs the function of the endothelium (Hennig et al. 1999). 
The resulting loss of vascular wall integrity and increase in vascular permeability promotes 
the migration and deposition of lipids, monocytes and smooth muscle cells into the intima, 
where they can cause further damage and initiate plaque development (Choy et al. 2001). 
Infiltrating leucocytes secrete growth factors and cytokines which stimulate smooth muscle 
cell proliferation. Moreover, endothelial apoptosis, e.g. induced by cytokines like TNF-α, 
propagates atherogenesis by increased coagulation, since apoptotic endothelial cells become 
procoagulant by exposure of phosphatidylserine residues and extracellular matrix on the 
surface (Guevara et al. 2001). Coagulation can further increase proliferation of smooth muscle 
cells and macrophages.  
Taken together, apoptosis of endothelial cells plays a fundamental role in the pathophysiology 
of inflammatory diseases, as it compromises the physiological functions of the endothelium, 
important for vascular homeostasis, leading to endothelial dysfunction (Choy et al. 2001). 
Cytoprotective proteins counteracting proapoptotic events therefore represent a promising 
target for the therapy of atherosclerosis as they affect atherosclerotic lesion formation at an 
initial step. The heat shock protein HO-1, discussed in detail under 1.2, possesses potent 
antiinflammatory (Willis et al. 1996, Poss and Tonegawa 1997) and antiapoptotic properties 
(Petrache et al. 2000, Brouard et al. 2002) and therefore constitutes such an interesting target. 
The present work analyzes the mechanisms leading to upregulation of HO-1 in response to 
ANP and aspirin and investigates whether upregulation of HO-1 can confer protection against 
apoptosis induced by TNF-α, a cytokine produced during inflammatory conditions. Since 
TNF-α plays an important role in the propagation of inflammatory diseases the next chapter 
gives an introduction into effects and signaling mechanisms of this important cytokine. 
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1.4 Tumor necrosis factor 
1.4.1 Overview 
Tumor necrosis factor α (TNF-α) is a potent proinflammatory cytokine, produced by many 
cell types, including macrophages, monocytes, lymphocytes, and fibroblasts, in response to 
inflammation, infection, injury, and other environmental challenges (Baud and Karin 2001). 
TNF-α belongs to a growing family of cytokines that, apart from lymphotoxin, LTα, are 
expressed as membrane-bound surface proteins from which the soluble forms are released by 
proteolytic cleavage. First reports about the existence of a biological substance, possessing 
anticancer activity, date back to the 19th century, when Coley observed the shrinkage of 
tumors in patients undergoing a severe bacterial infection (Idriss and Naismith 2000). 
However, it was only in 1984 that human TNF was isolated from activated macrophages and 
T-cells and its cDNA cloned. In the meantime, TNF-α is known to exert a broad spectrum of 
effects, including lymphocyte and leukocyte adhesion, activation and migration, induction of 
other cytokines and immunoregulatory molecules, fever, shock, acute phase response, cell 
proliferation, differentiation, and apoptosis (Baud and Karin 2001, Liu et al. 1996). Therefore, 
TNF-α plays a key role in the regulation of immune function and the inflammatory response. 
Sustained elevation of TNF-α has been implicated in a variety of different inflammatory 
diseases, such as atherosclerosis, sepsis, and rheumatoid arthritis (deMartin et al. 2000). 
1.4.2 Signaling by TNF-α 
TNF-α exerts its numerous effects by interaction with two distinct cell surface receptors, the 
TNF-R1 (p55) and the TNF-R2 (p75). These receptors belong to the TNF receptor 
superfamily, the members of which possess an intracellular tail, a single transmembrane 
domain and an extracellular ligand-binding domain (Wajant and Scheurich 2001). TNF-α 
occurs in the circulation as a homotrimer of soluble TNF or as the membrane-bound form. 
Upon binding to TNF-R1 or TNF-R2 it leads to receptor trimerization, triggering a number of 
intracellular events that eventually result in such diverse effects as induction of apoptosis, 
activation of NF-κB or activation of MAP kinases or Akt (Wajant and Scheurich 2001).  
The TNF-R1 possesses an intracellular protein-protein interaction motif of about 90 amino 
acids, called the death domain (DD) (Wallach et al. 1997). After binding of TNF-α to the 
TNF-R1, several adapter proteins are recruited to the receptor. The first protein recruited to 
the TNF-R1 via its DD is TRADD (TNFR1–associated death domain protein) which serves as 
a platform for three further signaling proteins, the DD containing RIP (receptor-interacting 
protein-1) and FADD (Fas-associated death domain protein), and the non-DD containing 
TRAF-2 (TNF-receptor-associated factor-2) (Chen and Goeddel 2002). These proteins recruit 
key enzymes to the receptor that mediate the downstream signaling events (figure 3).  
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figure 3: signaling by TNF-R1 
 
TRAF-2 and RIP mediate the activation of NF-κB by recruiting the IκB kinase multiprotein 
complex to the receptor where the catalytic IKKα and IKKβ subunits become activated by 
phosphorylation, a step that has been associated with different kinases, such as NIK (NF-κB-
inducing kinase) and MEKK-1 (Baud and Karin 2001, Wajant et al. 2001). The activated IKK 
complex in turn phosphorylates IκB, resulting in its ubiquitination, degradation and 
translocation of the released NF-κB to the nucleus where it initiates the transcription of 
different genes, frequently involved in acute and chronic inflammatory states, such as 
adhesion molecules and other cytokines (Baud and Karin 2001). On the other hand, NF-κB 
activation mediates the expression of a variety of early responsive anti-apoptotic genes after 
binding of TNF-α to the TNFR-1, such as the bcl-2 member A1 (Ackermann et al. 1999) and 
members of the inhibitor of apoptosis family, cIAP1 and 2 (Devereaux et al. 1999).  
TNF-R1
D
D D
D
D
D
TRADDTRADD
FADD
caspase-8
effector caspases
TRAF-2
RIP
D
D D D
D
E
D
D
D
IKK-α/βIκB/NF- κB
NF- κB
MEKK1/2
MKK4/7
JNK
TNF
D
D D
D
D
D
D
D
D
E
D
D
D
  
22 
TRAF-2 has also been shown to mediate the activation of the three MAP kinase pathways 
leading to activation of JNK, p38 MAPK and ERK (Wajant and Scheurich 2001). As outlined 
in chapter 1.7, all three MAP kinases have been implicated in the regulation of DNA binding 
activity of the transcription factor AP-1, providing another opportunity for TNF-α to 
influence the activity of important target genes. 
Apart from regulating gene transcription by activation of important transcription factors, 
another important effect elicited by TNF-α via the TNF-R1 is activation of the caspase 
cascade resulting in apoptosis. TNF-α initiates apoptosis by recruiting FADD to the TNF-R1-
TRADD complex. FADD serves as an adapter protein for caspase-8 with which it can interact 
via its death effector domain (Ashkenazi and Dixit 1998, Chen and Goeddel 2002). 
Recruitment to the receptor leads to autocatalytic activation of caspase-8, initiating the 
activation of the caspase cascade including effector caspases such as caspase-3 (see chapter 
1.3.2.2). 
Binding of TNF-α to the TNF-R2 which does not possess a death domain leads to the direct 
recruitment of TRAF-2 to the receptor. TRAF-2 in turn mediates the activation of the MAP 
kinases and NF-κB as well as the antiapoptotic components cIAP1 and 2. Since this receptor 
lacks a death domain, it is not involved in the induction of apoptosis by TNF-α (Wajant and 
Scheurich 2001).  
1.4.3 TNF-α and the endothelium 
The endothelium constitutes a major target for proinflammatory cytokines such as TNF-α, 
which has been reported to play a central role in the pathophysiology and progression of 
inflammatory diseases, such as atherosclerosis. TNF-α-induced endothelial injury by 
apoptosis of endothelial cells is regarded as a critical event that can initiate the development 
of atherosclerosis (Choy et al. 2001) (for the role of apoptosis in vascular disease see 1.3.2.3). 
Moreover, TNF-α is also able to induce reorganization of the cytoskeleton resulting in 
formation of intercellular gaps, increase the expression of adhesion molecules, and induce the 
release of vasoactive substances (Wójciak-Stothard et al. 1998, Madge and Pober 2001). 
Exposure of endothelial cells to TNF-α, produced during inflammatory processes, thus 
critically compromises the physiological functions of the endothelium and can therefore serve 
as the initial trigger for the development of atherosclerosis. Consequently, it is of great 
interest to elucidate signaling mechanisms leading to the expression of cytoprotective proteins 
that are able to block TNF-α-induced apoptosis as the initial event in atherosclerotic lesion 
formation. In this context, ANP and aspirin were tested for their ability to upregulate heat 
shock proteins and to interfere with TNF-α-induced apoptotic cell death. 
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1.5 The natriuretic peptides 
1.5.1 History 
In 1981 de Bold et al. made the interesting observation that i.v. application of atrial muscle 
extracts into rats resulted in a massive natriuresis and diuresis (de Bold et al. 1981). It was 
assumed that the atrial extract contains a potent natriuretic factor and soon afterwards the first 
member of the family of natriuretic peptides, the “atrial natriuretic peptide”, ANP, was 
isolated and cloned (Kangawa and Matsuo 1984). A few years later, a structurally 
homologous peptide with similar pharmacological spectrum to ANP was isolated from acidic 
extracts of porcine brain and therefore designated “brain natriuretic peptide”, BNP, but was 
soon discovered to be predominantly expressed in the ventricle (Sudoh et al. 1988). In 
addition to BNP, another natriuretic peptide was isolated from porcine brain and named “C-
type natriuretic peptide”, CNP, according to ANP and BNP (Sudoh et al. 1990). In the kidney, 
the atrial natriuretic peptide gene as well undergoes alternative processing of the precursor, 
yielding a modified peptide, called urodilatin which was isolated from human urine (Schulz-
Knappe et al. 1988, Forssmann et al. 2001). The latest member of the natriuretic peptide 
family was isolated from the venom of the snake Dendroospis angusticeps by Lisy et al. and 
named DNP, possessing potent natriuretic activity in humans (Lisy et al. 1999). 
1.5.2 Structure 
The common structural feature of the natriuretic peptides is a 17-amino acid peptide ring, 
formed by a disulfide-bond between two cystein residues (at positions 105 and 121). The 
amino acids in the ring structure are highly conserved and this structure appears to be 
essential for receptor recognition and biological function (Inagami et al. 1987). Due to the 
strong homology within the ring structure, 10 of these amino acids are identical in all 
natriuretic peptides, whereas the amino acids either amino-terminal or carboxy-terminal to the 
ring structure are quite divergent (figure 1). 
ANP: ANP is a 28 amino acid peptide. Its amino acid sequence is almost identical throughout 
mammalian species with the only exeption at position 110, which is methionine in humans, 
dogs, and cows, compared to isoleucine in rodents, such as mouse, rat, and rabbit. 
BNP: BNP is composed of 32 amino acids and its ring structure differs from that of ANP in 
only 5 amino acids. Its amino acid sequence exhibits only 59% sequence homology between 
different species and is therefore much less conserved compared to ANP (Rosenzweig and 
Seidmann 1991). 
CNP: CNP contains only 22 amino acids and possesses the primary structure with the greatest 
difference compared to the other natriuretic peptides, since it completely lacks the C-terminal 
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tail and ends at the C-terminus after the last cystein participating in the formation on the 17-
residue ring (Rosenzweig and Seidmann 1991). 
Urodilatin: Urodilatin is the product of the atrial natriuretic peptide gene expressed in the 
kidney and is generated by alternative biochemical processing of the ANP prohormone. It 
only differs from ANP in 4 additional amino acids added to the N-terminus (Schulz-Knappe 
et al. 1988). 
 
figure 4:  structure and amino acid sequence of the human natriuretic peptides (ANP, 
BNP, CNP and urodilatin). The homologous amino acids are shaded black. 
 
1.5.3 Biosynthesis 
Each natriuretic peptide is encoded by a separate gene. As characteristic for peptide 
hormones, the natriuretic peptides are synthesized as pre-pro-hormones. ANP is synthesized 
primarily in the cardiac atria as a precursor of 152 amino acids, called prepro-ANP. Cleavage 
of a signal peptide at the N-terminus yields a prohormone of 126 amino acids that is stored in 
atrial granules (Rosenzweig and Seidmann 1991). In response to certain stimuli, such as 
increases in atrial strech or pressure, pro-ANP is cleaved by serine proteases into equimolar 
amounts of a 98 amino acid amino-terminal fragment (ANP 1-98) and the biologically active 
28 amino acid carboxy-terminal fragment, the active ANP (ANP 99-126) (Rosenzweig and 
Seidmann 1991). The amino-terminal fragment is further cleaved into smaller fragments 
(ANP 1-30, ANP 31-67, ANP 79-98) which also possess biological activity, but information 
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regarding their biological significance is limited. The mature ANP is released from atrial 
myocytes into the circulation by exocytosis (Dagnino et al. 1991). The synthesis of the other 
natriuretic peptides is analogous to ANP, the synthesis of a precursor protein, followed by 
cleavage into biologically active fragments. 
 
1.5.4 NP Receptors and Signaling 
1.5.4.1 History 
The discovery of the natriuretic peptides and their potent natriuretic and diuretic properties 
raised the question how these effects are mediated. The first step towards an understanding of 
the signaling mechanisms of ANP and its relatives was the observation that injection of ANP 
results in formation of cyclic guanosine-3‘, 5‘-monophosphate (cGMP) (Cantin et al. 1984). 
Further studies were able to demonstrate that cGMP is the second messenger mediating most 
of the effects of ANP (Leitmann and Murad 1986). Investigation of the binding sites for ANP 
demonstrated the presence of two binding proteins of different size. Only interaction with one 
of these proteins leads to the formation of cGMP (Leitmann et al. 1986). The other non-
guanylate cyclase coupled receptor was characterized by Maack et al. and termed „clearance 
receptor“, since it was found to be responsible for the clearance of natriuretic peptides from 
the circulation (Maack et al. 1987). In 1989 Schulz et al. identified the cDNA sequence of two 
guanylate cyclase coupled receptors, which were designated NPR-A and NPR-B. 
1.5.4.2 Structure and ligand selectivity 
Figure 5 shows the structure of the NP receptors which are single transmembrane domain 
receptors. The two guanylate cyclase-coupled receptors, 120-140 kD in size, consist of an 
extracellular ligand binding domain, a single transmembrane sequence and an intracellular 
domain containing a juxtamembrane domain, kinase homology domain, dimerization domain, 
and the guanylate cyclase catalytic domain (figure 2) (Sharma 2002, Misono 2002). Thus, in 
these receptors, receptor and effector systems reside in one molecule. The NPR-C, 60 kD in 
size, is the most abundant receptor of the NPR and possesses a similar extracellular domain 
compared to the other NPR, but only a truncated intracellular tail of 37 amino acids (Levin 
1993, Tremblay et al. 2002). 
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Due to the fact that the amino acid sequence of the extracellular domain is only 30-40% 
homologous (Cohen et al. 1996), the three receptors exhibit different ligand selectivity. The 
NPR-A binds NP in the order ANP>BNP>>CNP, whereby BNP is 10-fold less potent in 
stimulating this receptor (Misono 2002, Lucas et al. 2000). CNP is the specific ligand for the 
NPR-B with the highest affinity for this receptor (Suga et al. 1992). The NPR-C exhibits 
much lower ligand selectivity and binds all three ligands with the following degree of affinity: 
ANP>CNP>BNP (Maack et al. 1996, Silberbach and Roberts 2001). 
figure 5:  model of the structure of the three natriuretic peptide receptors  
 (NPR-A, NPR-B, NPR-C) 
 
1.5.4.3 Signal transduction 
The intracellular domain of the two guanylate cyclase-coupled receptors (NPR-A and NPR-B) 
contains a guanylate cyclase (GC) catalytic domain as well as a kinase-like domain. At the 
basal state the kinase homology domain (KHD) interacts with the GC-like domain 
suppressing its activity (Chinkers and Garbers 1989, Lucas et al. 2000, Sharma 2002). In the 
absence of ligand, the receptors exist in a homo-oligomerized state, each monomer being 
phosphorylated on key serine and threonine residues within the KHD (Chinkers and Wilson 
1992, Potter and Hunter 1999). Oligomerization and phosphorylation are required for high 
affinity ligand binding. Binding of ligand induces a conformational change of the KHD 
leading to the binding of ATP to a glycine rich region in the KHD. ATP binding causes an 
allosteric change in the GC-like domain resulting in the derepression of guanylate cyclase 
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activity and subsequent conversion of guanosine triphosphate into cGMP (Kurose et al. 1987, 
Chang et al. 1990, Chinkers et al. 1991, Potter and Hunter 1998). Besides, association of ATP 
with the KHD results in a reduction in ligand affinity of the extracellular domain (Larose et 
al. 1991) as well as in dephosphorylation of the KHD (Potter and Garbers 1992, Potter and 
Hunter 1999, Potter and Hunter 2001), which desensitisizes the receptors to ATP and ligand. 
The primary function of the NPR-C is to act as a clearance receptor. After binding of ligand, 
the receptor complex is internalized, followed by lysosomal hydrolysis of the ligand and 
subsequent recycling of the receptor to the cell surface (Cohen et al. 1996). However, several 
studies provide evidence that this receptor has additional biological functions, such as the 
inhibition of adenylate cyclase activity (Savoie et al. 1995, Anand-Srivastava 1997). 
Moreover, ANP and NPR-C-selective analogues have been demonstrated to be able to 
activate phospholipase C. Both effects seem to be mediated via a signaling mechanism 
involving the participation of G-regulatory proteins (Levin 1993, Anand-Srivastava 1996, 
Murthy et al. 2000). The interaction of the NPR-C with these two intracellular effector 
systems, adenylate cyclase and protein kinase C, might explain some of the observed NPR-C-
mediated effects, such as inhibition of endothelin production (Hu et al. 1992), proliferation 
and invasion of matrix by endothelial cells (Pedram et al. 1997), activation of endothelial NO 
synthase in gastric smooth muscle cells (Murthy et al. 1998), inhibition of COX-2 (Kiemer et 
al. 2002a), or inhibition of MAPK in astrocytes (Prins et al. 1996). 
 
1.5.5 Distribution and known effects of the natriuretic peptides 
ANP and BNP are both predominantly found in the heart as cardiac hormones. In adults the 
highest concentration of ANP is found in the left atrium, followed by the right atrium, the 
right ventricle and finally the left ventricle (Venugopal 2001). 1% of the total atrial mRNA 
codes for ANP (Venogupal 2001). Apart from the heart, ANP is also expressed in lower 
concentrations in the tissues of the lung, brain, kidney, adrenals, gastrointestinal tract, thymus 
and the eye (Vollmar and Schulz 1990b, Sahai and Ganguly 1992, Salzmann et al. 1998). The 
main pharmacological actions of ANP include the inhibition of the renin-angiotensin-
aldosterone system and enhanced glomerular filtration rate, resulting in diuresis and 
natriuresis, increased vascular permeability, relaxation of the vascular smooth muscle, 
resulting in a reduction of blood pressure, as well as antimitogenic effects on endothelial, 
smooth muscle, and myocardial cells (Levin et al. 1998, Venugopal 2001, Suzuki et al. 2001). 
The central effects include inhibition of salt appetite and water drinking as well as inhibition 
of vasopressin secretion (Levin et al. 1998). 
BNP is primarily expressed in the ventricles and atria of the heart followed by the brain and 
the amnion (Venugopal 2001). Like ANP, BNP is secreted to the circulation and exerts 
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similar biological effects. However, circulating levels of BNP are much lower than ANP 
levels. 
CNP is predominantly synthesized in the nervous system and the endothelium of the blood 
vessels and exerts primarily autocrine and paracrine actions (Stingo et al. 1992, Venugopal 
2001, Silberbach et al. 2001). CNP lacks the renal effects of ANP and BNP and therefore has 
no natriuretic or diuretic properties. It decreases arterial pressure (Stingo et al. 1992) and has 
also been implicated in cell growth control (Suga et al. 1993). 
1.5.6 Cytoprotective effects of ANP 
In the first years after the discovery of the natriuretic peptides, they were mainly associated 
with the regulation of blood pressure and cardiovascular homeostasis (Levin et al. 1998). 
Intensive research in the following years demonstrated the expression of the natriuretic 
peptides and their receptors in a variety of tissues outside the cardiovascular and renal system, 
including thymus (Vollmar and Schulz 1990a) as well as macrophages (Vollmar and Schulz 
1994). The role of ANP in the immune system was further confirmed by the observation that 
ANP inhibits thymocyte proliferation and thymopoesis (Vollmar et al. 1996, Vollmar 1997). 
The antiinflammatory potential of ANP became obvious with the finding that ANP reduces 
the NO production in LPS-stimulated macrophages by inhibiting the expression of the 
inducible NO synthase at the transcriptional and posttranscriptional level (Kiemer and 
Vollmar 1997, Kiemer and Vollmar 1998). Other inflammatory systems attenuated in their 
expression by ANP are cyclooxygenase-2 (Kiemer et al. 2002a) and TNF-α (Kiemer et al. 
2000a, Tsukagoshi et al. 2001). Due to these interesting effects, ANP might interfere with 
diverse pathological conditions associated with inflammatory responses. For instance, ANP 
has been demonstrated to confer protecion against ischemia/reperfusion injury (Gerbes et al. 
1998, Bilzer et al. 1994), the induction of heat shock proteins being a possible mechanism, 
since ANP has been shown to evoke a heat shock response in rat livers undergoing ischemia 
and reperfusion (Kiemer et al. 2002b). Protective effects of ANP have also been reported for 
drug-induced nephrotoxicity (Polte et al. 2002, Capasso et al. 2000, Murakami et al. 1999) 
and for ventricular hypertrophy (Silberbach et al. 1999, Kishimoto et al. 2001). However, 
mechanisms mediating the expression of cytoprotective proteins in endothelial cells have as 
yet not been elucidated. 
Taken together, the results of the past years indicate that ANP has a much broader 
pharmacological profile apart from its cardiovascular functions, suggesting that it plays a role 
in the immune system and exhibits immunomodulatory, antiinflammatory, and cytoprotective 
effects. To further elucidate the cytoprotective potential of ANP it is necessary to identify the 
intracellular targets as well as the signal transduction mechanisms mediating these protective 
effects. Heat shock proteins, especially HO-1, constitute a possible target for ANP in 
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endothelial cells and might contribute to its antiinflammatory, antiatherogenic, and 
cytoprotective potential. However, information on the influence of ANP on HO-1 in 
endothelial cells is rare and completely lacking concerning signal transduction mechanisms. 
The first part of the present work therefore investigates the mechanisms leading to 
upregulation of HO-1 after ANP treatment and the cytoprotective potential of this effect. 
1.6 Aspirin  
Aspirin and its active metabolite salicylate are the oldest known members of the family of 
nonsteroidal antiinflammatory drugs (NSAIDs), aspirin being the most widely used NSAID. 
The world production of aspirin has been estimated to amount to many thousand tons a year, 
with an average consumption of about 80-100 tablets per person per year in industrialized 
nations (Vane et al. 1990, Vane and Botting 1998). 
1.6.1 History 
The history of aspirin dates back until about 3,500 years ago, when in ancient Egypt, the 
Ebers papyrus already recommended the use of salicylate containing plants for the therapy of 
rheumatic pains. 1,000 years later, Hippocrates described the use of willow bark, containing 
salicylic acid, to reduce the pain of childbirth and to reduce fever (Vane et al. 1990). In the 
18th and 19th century the first clinical trials were performed with willow bark, but it took until 
1859 that the active compound, salicylic acid, was synthesized chemically by Herrmann 
Kolbe, resulting in the broad application of the drug as an external antiseptic, antipyretic, and 
antirheumatic drug (Vane and Botting 1998). In 1897, Felix Hoffmann, working as a chemist 
at Bayer, synthesized acetylsalicylic acid, by acetylating the hydroxyl group on the benzene 
ring of salicylic acid in order to eliminate the unpleasant taste of salicylic acid. This new drug 
was introduced in 1899 under the name aspirin, the “a” coming from acetyl and the “spir” 
coming from Spirea ulmania, the plant from which salicylic acid was originally isolated (Jack 
1997). By the early 1900s, the therapeutic spectrum of aspirin was known to include 
antipyretic, antiinflammatory, and analgesic effects. Later, several other drugs were 
discovered that shared some or all of these effects, such as phenacetin, acetaminophen 
(paracetamol) and phenylbutazone. Due to the similarities in their therapeutic actions, these 
drugs were classified into one group, the aspirin-like drugs, also called nonsteroidal 
antiinflammatory drugs, to clearly distinguish them from the also antiinflammatory 
glucocorticoids (Vane et al. 1990, Jack 1997). 
  
30 
1.6.2 Known effects 
Despite their diverse chemical structure NSAIDs possess the same therapeutic properties. 
They relieve the swelling, redness, and pain of inflammation, reduce general fever, and cure 
headache. Moreover, they also share the same side effects, causing gastric upset, delay the 
birth process, and in high doses damage the kidney. The antithrombotic effect is now 
recognized as a therapeutic action and used for the therapy of cardiovascular disease (Vane et 
al. 1990, Vane et al. 1998). The fact that this chemically diverse group of drugs all exert the 
same therapeutic actions and side effects strongly suggested that these drugs possess a 
common mode of action. 
It was not until 1971 that Vane et al. found the inhibition of prostaglandin synthesis by 
inactivation of the enzyme cyclooxygenase to be responsible for the therapeutic actions of 
aspirin (Vane 1971). The enzymatically active cyclooxygenase, also called prostaglandin 
endoperoxide synthase (PGHS) was isolated in 1976 (Hemler and Lands 1976) and cloned in 
1988 (Merlie et al. 1988) and catalyzes the first step in the biosynthesis of prostaglandins. It is 
a membrane-bound heme- and glycoprotein with a molecular weight of 71 kDa and two 
catalytic sites. The site exhibiting cyclooxygenase activity cyclases arachidonic acid and adds 
the 15-hydroperoxy group to yield prostaglandin G2 (PGG2). At the peroxidase site, PGG2 is 
converted to prostaglandin H2 (PGH2), which is subsequently converted to the prostaglandins 
D2, E2, F2α, I2 (prostacyclin) and TXA2 by specific synthases. Both cyclooxygenase and 
peroxidase activity are combined in the same bifunctional protein molecule (Amann and 
Peskar 2002).  
Two COX isoforms encoded by different genes are known to exist. The first isoform, COX-1, 
is constitutively expressed in the endoplasmatic reticulum of most cells and possesses 
physiological functions, playing an important role in tissue homeostasis. The inducible 
isoform, COX-2, is expressed in very low levels in the cells and can be upregulated by 
proinflammatory stimuli, such as LPS, and by cytokines, such as TNF-α, as well as growth 
factors (Xie et al. 1992). COX-2 produces prostaglandins that are involved in the 
inflammatory and mitogenic response. Aspirin inhibits both isoforms of COX by irreversible 
acetylation of a specific serine residue (serine 530 of COX-1, serine 516 of COX-2), 
abolishing the binding of arachidonic acid at the cyclooxygenase active site (Vane et al. 1998, 
Awtry and Loscalzo 2000). Since COX-2 is considered as a crucial mediator of inflammation, 
it has been suggested that the antiinflammatory actions of NSAIDs are due to the inhibition of 
COX-2, whereas the adverse effects, irritation of the stomach, renal toxicity, can be attributed 
to inhibition of the constitutive COX-1. 
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1.6.3 New therapeutic aspects and limits of the prostaglandin 
hypothesis 
In recent years, the theory that inhibition of prostaglandin synthesis solely accounts for the 
therapeutic effects of aspirin has been questioned due to the observation that doses of aspirin 
that are effective in the treatment of inflammatory diseases are much higher than those 
required for inhibition of COX. Moreover, salicylic acid, lacking an acetyl group, was shown 
to be a weak inhibitor of COX, but is equally effective against arthritis compared to aspirin 
(Abramson and Weissmann 1989, Weissmann 1991). Finally, in recent years an increasing 
number of studies has reported additional protective effects of this non-steroidal anti-
inflammatory drug against colon cancer (Thun et al. 1991, Sandler et al. 1998, Gupta et 
DuBois 1998), its ability to delay the onset of Alzheimer disease (Flynn and Theesen 1999, 
Breitner 1996), as well as protective effects in cardiovascular disease (Mehta 1998, Diener 
1999). Inhibition of COX activity can only in part account for these recently observed effects, 
suggesting that aspirin may exert part of its antiinflammatory and antitumor activity by 
modulating cyclooxygenase-independent pathways.  
Especially the beneficial therapeutic effect of aspirin in vascular disease is increasingly 
recognized (Numano et al. 1995, Lauer et al. 2002). The protection of the vasculature 
conferred by aspirin is primarily ascribed to the prevention of thrombus formation, but also to 
the aspirin-mediated protection of endothelial cells against the cytotoxic effects of activated 
platelets (Numano et al. 1995). In addition to its inhibitory action on platelet activation, 
representing a central event in vascular damage, aspirin has also been demonstrated to exert 
direct cytoprotective effects against oxidant-induced endothelial damage (Podhaisky et al. 
1997). To further understand these cytoprotective actions of aspirin, it is necessary to 
elucidate the intracellular targets and the signal transduction mechanisms mediating these 
effects. In this context, new targets for the pharmacologic actions of aspirin have been 
described. Aspirin has been reported to interfere with enzyme systems, such as the mitogen-
activated protein kinases (Tegeder et al. 2001) as well as with the activation of transcription 
factors, such as NF-κB (Kopp and Gosh 1994), which frequently initiates the transcription of 
different genes, such as adhesion molecules and cytokines, implicated in acute and chronic 
inflammatory states. Moreover, aspirin treatment has been demonstrated to result in inhibition 
of iNOS expression (Amin et al. 1995, Katsuyama et al. 1999), suppression of adhesion 
molecule expression and down-regulation of MCP-1 (Amberger et al. 1999), altogether 
important mediators of the inflammatory response. In several cell models, including 
endothelial cells, aspirin has been shown to increase the expression of the heat shock proteins 
HSP70 and HSP60 (Jin et al. 1999, Amberger et al. 1999). However, apart from one report 
describing an inhibitory action of aspirin on LPS/IFN γ-induced HO-1 expression (Chen et al. 
2002), information on the influence of aspirin on this important heat shock protein, especially 
on basal HO-1 levels, is completely missing. Therefore, the second part of the present work 
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investigated the influence of aspirin on HO-1 expression, the signal transduction mechanisms 
involved and its potential cytoprotective action. 
 
1.7 The MAP kinase family  
Chapter 1.2 deals with heme oxygenase as a potential target, mediating cytoprotection against 
apoptosis of endothelial cells. This heat shock protein is regulated at the transcriptional level, 
mainly via the transcription factor AP-1. The members of the MAP kinase family are 
critically involved in the regulation of this transcription factor. The following chapter 
therefore gives an introduction in the complex network of this enzyme family. 
The mitogen-activated protein kinases represent an evolutionary conserved signal 
transduction system activated in response to a great variety of extracellular stimuli, such as 
cytokines, growth factors, neurotransmitters, hormones, cellular stress, and cell adherence 
(Widmann et al. 1999). By regulating intracellular processes such as gene expression, cell 
proliferation, differentiation, survival or death, this family of serine/threonine protein kinases 
enables the cell to respond to such external stimuli (Barr and Bogoyevitch 2001). Mitogen-
activated protein kinases are expressed in all eukaryotic cells. To date, more than twelve MAP 
kinases have been identified in mammalian cells, that form a complex network of signaling 
and belong to three different subfamilies: the extracellular-signal-regulated kinases (ERK), 
the c-jun N-terminal kinases/stress-activated protein kinases (JNK/SAPK), and the p38 
MAPK (Widmann et al. 1999) (figure 6).  
figure 6: mitogen-activated protein kinase (MAPK) signal transduction pathways 
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All MAP kinases characteristically phosphorylate substrates on serine or threonine residues 
adjacent to proline residues and are therefore termed proline-directed serine/threonine kinases. 
Another characteristic feature of the MAP kinases is their activation by a phosphorylation 
cascade that consists of at least three kinases (Widmann et al. 1999). The first component of 
this pathway is a MAPK kinase kinase (MKKK). MKKK are serine/threonine kinases that are 
activated either by phosphorylation through a MAPK kinase kinase kinase (MKKKK) or by 
interaction with small GTP-binding proteins of the Ras or Rho family. Upon activation, 
MKKK phosphorylate and activate the next downstream MAPK kinase (MKK) (Widmann et 
al. 1999). MKK are dual-specificity enzymes that recognize and phosphorylate a threonine-X-
tyrosine motif (X can be different amino acids depending on the respective MAP kinase) in an 
amino acid sequence called the activation loop of their MAP kinase substrates. This 
phosphorylation induces a conformational change of the activation loop, aligning the catalytic 
amino acid residues and enabling substrate binding and catalytic activity. Phosphorylation on 
both threonine and tyrosine is required for activation of  MAP kinases, which then in turn 
phosphorylate and activate substrates on serine and threonine residues. Substrates for MAP 
kinases include transcription factors, other protein kinases, phospholipases, and cytoskeleton-
associated proteins (Widmann et al. 1999). 
In addition to the regulation by phosphorylation of a characteristic motif in the activation loop 
by the upstream kinases, MAP kinase activity is controlled by a family of dual-specificity 
MAPK phosphatases (MKP), which remove the phosphates of the critical tyrosine and 
threonine residues. The MKP can be devided into two groups. Either, they are encoded by 
growth factor or stress-inducible genes and are predominantly expressed in the nucleus, or 
they are not transcriptionally regulated and located in the cytosol. Different MKP specifically 
dephosphorylate and inactivate the members of the different MAPK subfamilies (Pearson et 
al. 2001).  
1.7.1 Extracellular signal-regulated kinase (ERK) 
This subfamily includes the kinases ERK-1 and ERK-2, which are ubiquitously expressed 44- 
and 42-kDa isoforms, activated by extracellular stimuli, such as growth factors (EGF, PDGF) 
or mitogenic stimuli. Many different receptor types are capable of activating the ERK 
pathway, such as tyrosine kinase receptors, G-protein coupled receptors, and cytokine 
receptors. Ligand binding of these receptors mostly leads to the recruitment of Ras to the 
receptor via different adapter proteins, promoting formation of Ras:GTP (Downward 1996) at 
the plasma membrane, which recruits the MKKK Raf1 to the membrane, where it is activated 
by phosphorylation at tyrosine, serine and threonine residues (Marais and Marshall 1996). 
This in turn leads to the activation of MEK-1/2, the MKK in the phosphorylation cascade of 
the MAPK. MEK-1 and MEK-2 act as dual threonine/tyrosine kinases, phosphorylating the 
Thr-Glu-Tyr sequence in the activation loop of the catalytic domain of ERK-1/2 (Whitmarsh 
and Davis 1996).  
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Activated ERK-1/2 phosphorylate substrate proteins at serine or threonine residues located 
within a proline-directed motif. Cytosolic proteins reported to be phosphorylated by ERK are 
the p90 S6 kinase RSK, MAP kinase-interacting kinase (Mnk), cytosolic phospholipase A2 
and the juxtamembrane region of the EGF receptor (Lin et al. 1993, Seger and Krebs 1995, 
Whitmarsh and Davis 1996). Besides, ERK-mediated phosphorylation of the EGF receptor, 
Raf1 and Mek1 reduces their activity, providing a negative feedback mechanism for the 
control of the activity of the ERK pathway (Whitmarsh and Davis 1996). Apart from the 
modulation of cytoplasmatic proteins, activated ERK translocates to the nucleus, where it can 
phosphorylate a number of different transcription factors, such as Elk1, c-Myc, Ets1 or STAT 
proteins (Widmann et al. 1999). 
ERK activation is associated with enhanced cell proliferation (Seger and Krebs 1995, Pages et 
al. 1993) and differentiation (Qui and Green 1992) and implicated in cell cycle regulation in 
some cell types (Tanemoto et al. 1992). Moreover, activation of ERK is reported to confer 
protection against apoptosis in several cell types (Xia et al. 1995, Gardner and Johnson 1996). 
This cytoprotective effect is suggested to occur by inhibition of cytosolic caspase activation 
and phosphorylation of the proapoptotic Bcl2-family protein Bad (Cross et al. 2000). 
1.7.2 The c-jun N-terminal kinase (JNK) 
This subfamily of the MAP kinases was identified in 1991 and comprises isoforms that are 
the products of 3 different genes. Differential splicing and selection of alternative exons 
results in a total of 10 different JNK isoforms (Gupta et al. 1996). JNK1 and JNK2 are 
expressed ubiquitously, whereas JNK3 is restricted predominantly to the brain and testes 
(Yang et al. 1997). JNK have been demonstrated to be activated in response to various 
extracellular stimuli, such as growth factors, cytokines, and cellular stress, like heat shock, 
hyperosmolarity, UV-radiation, DNA damage, and ischemia/reperfusion (Barr and 
Bogoyevitch 2001). JNK can be activated through different receptor types, including the TNF 
receptor family, G-protein coupled receptors, tyrosine kinase receptors, and cytokine 
receptors. Activation of the JNKs occurs by phosphorylation at threonine and tyrosine in the 
Thr-Pro-Tyr motif within the activation loop by MKK4 and MKK7 (Widmann et al. 1999). 
Upstream of MKK-4/7, several MKKKs have been implicated in the activation of the JNK 
pathway, including MEKK-1-4. These MKKKs phosphorylate MKK4/7 and activate their 
kinase activity (Barr and Bogoyevitch 2001). Further upstream, the small GTP-binding 
proteins of the Rho family, especially Rac and Cdc42, have been reported to function as 
upstream activators of the JNK pathway (Barr and Bogoyevitch 2001, Widmann et al. 1999). 
The majority of the JNK substrates identified to date are transcription factors, such as c-jun, 
ATF-2, Elk-1, p53, DPC4 and NFAT4, resulting in efficient transcription of the target genes, 
since JNKs have the ability to activate transcription factors as well as to stabilize them 
(Widmann et al. 1999). In addition to transcription factors and nuclear proteins, further 
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substrates have been idenfied to be phosphorylated by JNK, such as the antiapoptotic bcl 
proteins Bcl-2 and Bcl-xL (Kharbanda et al. 2000, Shia et al. 2001), suggesting a role for JNK 
in the regulation of apoptosis. 
Activation of JNK is generally associated with stress responses, inflammation, and apoptotic 
cell death, and has been shown to be involved in apoptosis induction in response to growth 
factor withdrawal, stress, DNA damage, and binding of FasL on the cell surface (Widmann et 
al. 1999). A role for JNK in apoptosis has been described in several in vitro models (Xia et al. 
1995, Hu et al. 1999, Wang et al. 1998). Initiation of c-jun-dependent transcription during 
apoptosis is suggested to lead to the expression of pro-apoptotic proteins, such as Fas ligand 
(Kasibhatla et al. 1998). However, there are also investigators reporting that JNKs are not 
involved in the apoptotic response (Liu et al. 1996) and can even enhance cell survival under 
certain circumstances (Roulston et al. 1998). 
 
1.7.3 p38 MAPK pathway 
The p38 family consists of four homologous isoforms (α, β, γ, δ) that are the products of 
different genes. HUVEC produce p38 α, β, γ protein, whereas p38 δ is not found in these cells 
(Herlaar and Brown 1999). Different p38 MAPK are activated by cellular stress, such as UV 
irradiation, osmotic shock, heat shock, lipopolysaccharide, protein synthesis inhibitors, by 
certain cytokines, such as TNF-α or IL-1, and by G-protein coupled receptors (Whitmarsh 
and Davis 1996, Herlaar and Brown 1999). Similar to ERK and JNK, p38 MAPK is activated 
by phosphorylation on threonine and tyrosine in the Thr-Gly-Tyr activation motif (Raingeaud 
et al. 1995). MKK3 and MKK6 are the protein kinases responsible for this phosphorylation 
step, and these MAPKK themselves are in turn targets for the upstream regulators MKKK, 
such as Tak1 or the p21-activated kinase (Pak), that has been shown to be activated by the 
small G-proteins of the Rho family, Cdc42 and Rac1 (Bagrodia et al. 1995, Zhang et al. 
1995). Other MAPKKK are discussed to play a role in MKK3/6 activation, including Tak1, 
Ask1, and Sprk (Widmann et al. 1999). 
Upon activation, p38 MAPK can phosphorylate and activate a number of different substrates, 
such as MAPK-activated protein (MAPKAP) kinase 2 and 3 which in turn phosphorylate 
small heat shock proteins such as the 27-kDa heat shock protein HSP27 (Rouse et al. 1994), 
an F-actin binding protein involved in cytoskeleton structure. Other substrates targeted by p38 
MAPK are transcription factors. p38 MAPK phosphorylates ATF2, Elk1, as well as Chop, a 
member of the C/EBP family of transcription factors. 
Like JNK, p38 MAPK is implicated to play a role in apoptosis (Schwenger et al. 1997, 
Brenner et al. 1997, Takahashi et al. 2002). Moreover, it is suggested to affect many different 
biological functions, such as the production of cytokines in hematopoetic cells, cytokine-
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stimulated  cell proliferation, platelet activation or cardiac hypertrophic growth (Widmann et 
al. 1999). Therefore, p38 MAPK plays a major role in cytokine signaling and production and 
is associated with stress responses, inflammation and apoptosis. 
All three MAP kinases are involved in the regulation of the transcription factor AP-1, that 
plays a pivotal role in the transcriptional regulation of HO-1. Therefore, the next chapter 
outlines the regulation of AP-1 activity by MAP kinases. 
1.7.4 Regulation of the transcription factor AP-1 by MAP 
kinases 
The redox-sensitive, inducible transcription factor AP-1 comprises a family of related 
transcription factors, the majority of which consists of either c-jun/c-fos heterodimers or c-
jun/c-jun homodimers. AP-1 has been implicated in the regulation of a wide range of genes 
involved in a great variety of biological processes, such as cell proliferation, differentiation, 
inflammatory processes, and apoptosis. AP-1 activity has been reported to be regulated by 
several members of the MAP kinase family at the level of transcription of jun and fos genes 
as well as by posttranslational modifications. Due to the described role of AP-1 in HO-1 
induction (Camhi et al. 1998, Lavrovsky et al. 1994), the following chapter will give an 
overview of the regulation of AP-1 activity by MAP kinases. 
ERK activation leads to the phosphorylation of the transcription factor Elk1, which stimulates 
its ability to bind to the serum response elements (SRE) in the promotor of the c-fos gene, 
forming ternary complexes with serum response factor and DNA and activating transcription. 
Therefore, activated ERK stimulates AP-1 activity through induction of c-fos expression, 
since increased amounts of c-fos protein can combine with c-jun after translocation to the 
nucleus to form AP-1 dimers (Karin 1995, Pearson et al. 2001). Moreover, ERK 
phosphorylation and activation of the S6 kinase p90rsk results in translocation of this kinase 
to the nucleus, where it regulates c-fos and c-jun activity (Widmann et al. 1999). c-jun is also 
a direct target for ERK, but phosphorylation by ERK does not occur at the N-terminal 
stimulatory sites, but instead at one of the inhibitory sites located next to the C-terminal DNA 
binding domain, therefore resulting in decreased DNA binding (Karin 1995, Pearson et al. 
2001).  
p38 MAPK is reported to activate ATF-2 by phosphorylation at Thr-69 and Tyr-71 within its 
N-terminal activation domain, resulting in increased transcriptional activity and therefore 
induces c-fos expression (Widmann et al. 1999, Barr and Bogoyevitch 2001). Elk1 is also 
phosphorylated by p38 MAPK on several residues within the C-terminal transactivating 
domain (Widmann et al. 1999, Barr and Bogoyevitch 2001, Pearson et al. 2001). 
JNK regulates AP-1 activity by phosphorylating c-jun and activating transcription factor-2 
(ATF-2), stimulating their ability to heterodimerize and activate transcription via the TPA 
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(12-O-tetradecanoylphorbol-13-acetate) response element (TRE), therefore inducing 
increased c-jun expression (Karin 1995). Elk1, involved in the induction of the c-fos gene, is 
another direct target of JNK (Widmann et al. 1999, Barr and Bogoyevitch 2001). Moreover, 
JNK-mediated phosphorylation of serine 63 and 73 within the N-terminal activation domain 
of c-jun leads to a posttranslational upregulation of c-jun activity. This phosphorylation 
results in increased stability of c-jun and increases its DNA binding affinity as well as 
transcriptional activity as either homodimer or heterodimer with c-fos (Karin 1995, Pearson et 
al. 2001, Barr and Bogoyevitch 2001). 
Given the pivotal role of AP-1 in the transcriptional control of the heme oxygenase gene, the 
influence of ANP and aspirin on MAPK and AP-1 activity were investigated in the present 
work. 
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2.1 Materials 
 
Rat ANP 99-126 (“ANP”) was purchased from Calbiochem (Schwalbach, Germany). 8-Br-
cGMP was from Sigma (Taufkirchen, Germany), and cANF from Saxon Biochemicals 
(Hannover, Germany). Tumor Necrosis Factor-α was obtained from Sigma-Aldrich Chemie 
GmbH, (Taufkirchen, Germany) and etoposide from Calbiochem (Schwalbach, Germany). 
Cell culture medium (M 199) and penicillin/streptomycine were from PAN (Aidenbach, 
Germany). Fetal calf serum (FCS) was from Biochrom (Berlin, Germany) and Endothelial 
Cell Growth Medium (ECGM) from Promocell (Heidelberg, Germany). Endothelial Cell 
Growth Supplement was purchased from Sigma-Aldrich Chemie GmbH (Taufkirchen, 
Germany). Plastic ware was from Peske, Aindling-Pichl, Germany. The enhanced 
chemoluminescence protein detection kit was from NEN (Köln, Germany), Complete from 
Roche (Mannheim, Germany). Antiserum against the “von Willebrand-factor” was obtained 
from Serotec LTD (Wiesbaden, Germany). Anti-phospho-JNK and anti-phospho-ERK 
monoclonal mouse anti-human antibodies and anti-phospho-p38 polyclonal rabbit anti-human 
antibody were from Cell Signaling (Frankfurt/M., Germany), peroxidase-conjugated goat 
anti-mouse and goat anti-rabbit antibodies were from Jackson Immunolab (Dianova, 
Hamburg, Germany) and anti-p38 antibody from Calbiochem (Schwalbach, Germany). Anti-
HSP70 antibody was obtained from Santa Cruz (Heidelberg, Germany) and anti-HSP32 (HO-
1) monoclonal mouse anti-human antibody from BD Transduction Laboratories (Heidelberg, 
Germany). The primers for RT-PCR for GAPDH and HO-1 were purchased from MWG-
Biotech AG (Ebersberg, Germany). All other materials were obtained from either Sigma-
Aldrich Chemie GmbH (Taufkirchen, Germany) or Merck-Eurolab (Munich, Germany). 
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2.2 Cell culture 
2.2.1 Solutions 
PBS (phosphate buffered saline): PBS (phosphate buffered saline)+: 
Na2HPO4 1.48 g (8.0 mmol/L) NaCl 8.00 g 
KH2PO4 0.43 g (1.5 mmol/L) KCl 0.20 g 
NaCl 7.20 g (160 mmol/L) Na2HPO4 1.15 g 
H2O ad 1,000 mL KH2O4 0.20 g 
  MgCl2 x 6 H2O 0.10 g 
  CaCl2 0.10 g 
  H2O ad 1,000 mL 
 
Trypsin/EDTA: 
Trypsin (diluted 1:250 in PBS) 0.05 g 
EDTA (Sigma)  0.20 g 
PBS  ad 100 mL 
 
 
2.2.2 Cell isolation of HUVEC 
Human umbilical vein endothelial cells (HUVEC) were isolated by digestion of umbilical 
veins with 0.1 g/L of collagenase A (Roche, Mannheim, Germany) according to the method  
described by Jaffe et al. (Jaffe et al. 1973). Cells were either grown in endothelial cell growth 
medium (ECGM, Promocell, Heidelberg, Germany) or in M199 (PAN, Aidenbach, Germany) 
supplemented with 20% heat-inactivated fetal calf serum (FCS), 1 x endothelial cell growth 
supplement (ECGS, Sigma, Taufkirchen, Germany) and penicillin (100 U/mL)/ streptomycine 
(100 ng/mL). In order to compensate for inter-individual differences cells of at least two 
umbilical cords were combined for experiments. Cells were grown at 37°C and 5% CO2 in an 
Heracell incubator (Heraeus Instruments, Munich, Germany). 
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2.2.3 Cultivation of HUVEC 
2.2.3.1 Passaging 
After reaching a confluent state, the cells were subcultered 1:3 in culture flasks or seeded in 
plates for experiments. For passaging of HUVEC, the medium was removed and the cells 
were washed three times with PBS. After addition of 1 ml or 2 ml trypsin/EDTA per 25 cm2 
or 75 cm2 flask, respectively, the cells were incubated for 1-2 min at 37°C. HUVEC were 
carefully detached by gently tapping and the digestion was stopped by addition of M199 
containing 10% FCS. The cells were centrifuged at 218 x g at 4°C for 10 min, the supernatant 
was discarded and the cells were resuspended in M199 supplemented with 20% heat-
inactivated FCS, 1x endothelial cell growth supplement and penicillin (100 U/mL)/ 
streptomycine (100 ng/mL). For experiments, cells of passage three or four were grown until 
confluence in 6-, 12-, 24- or 96-well plates. Experiments were performed in M199 containing 
10% FCS, in the absence of endothelial cell growth supplement, and the cells were allowed to 
adapt to the medium for 2 h before the start of the respective experiments. 
 
2.2.3.2 Freezing, storage and thawing 
For long-time storage, confluent HUVEC were detached with trypsin/EDTA, centrifuged at 
218 x g at 4°C for 10 min, and the pellet was resuspended in 1.5 ml freezing medium (M199 
supplemented with 20% heat-inactivated FCS, 1x endothelial cell growth supplement, 
penicillin (100 U/mL), streptomycine (100 ng/mL) and 10% [v/v] DMSO) per 75 cm2 flask. 
The cell suspension was transferred to cryovials and frozen at –20°C for one day, afterwards 
at –86°C for one week, and then stored at –196°C in liquid nitrogen. This procedure was done 
in order to ensure gradual freezing of the cells. For thawing, HUVEC were warmed up and 
the cell suspension transferred into M199 supplemented with 10% FCS. In order to remove 
DMSO, cells were centrifuged at 218 x g at 4°C for 10 min. The supernatant was discarded 
and the cells resuspended in complete culture medium and transferred to a 75 cm2 culture 
flask. 
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2.3 Characterization of HUVEC by means of von 
Willebrand factor 
2.3.1 Immunfluorescence 
2.3.1.1 Solutions 
Methanol/acetone: mixture 1:1 
PBS: see under 2.2.1 
 
2.3.1.2 Antibody 
Sheep anti-human von Willebrand Factor (Serotec LTD, Wiesbaden, Germany), FITC labeled 
 
2.3.1.3 Experimental procedure 
HUVEC were grown in 24-well plates until confluence. Cell Culture medium was removed 
and the cells were washed twice with PBS. Cells were fixed and permeabilized with ice cold 
methanol/acetone 1:1 at 4°C for 5 min. After washing with PBS, 200 µl sheep serum (20% 
[v/v] in PBS) was added in order to saturate unspecific binding sites. The plates were 
incubated for 30 min at room temperature. After addition of 10 µl von Willebrand antibody, 
incubation was continued for 30 min on ice in the dark. Cells were again washed with PBS 
and examined with a Zeiss Axioskop MC 80 DX microscope (Zeiss, Munich, Germany) with 
a 400- or 1,000-fold magnification (excitation: 450 nm = blue, emission: 520 nm = green). 
 
2.3.2 Flow cytometry 
2.3.2.1 Solutions 
FACS buffer: 
NaCl 8.12 g 
KH2PO4 0.26 g 
Na2HPO4 2.35 g 
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KCl 0.28 g 
Na2EDTA 0.36 g 
LiCl 0.43 g 
Na-azide 0.20 g 
H2O ad 1,000 mL, pH 7.37 
 
PBS: see under 2.2.1 
Trypsin/EDTA: see under 2.2.1 
 
 
2.3.2.2 Experimental procedure 
HUVEC were grown in 24-well plates until confluence. Cell culture medium was removed 
and the cells were washed three times with PBS and trypsinized with 200 µl per well for 1-2 
min at 37°C. The digestion was stopped by addition of M199 containing 10% FCS, and the 
cell suspension was transferred into FACS tubes. After centrifugation (218 x g, 4°C, 10 min) 
the cell pellet was washed twice with PBS. Cells were incubated with 0.25% 
paraformaldehyde for 1 h at 4°C to fix the cells. Subsequently, the cells were centrifuged (218 
x g, 4°C, 10 min) to remove the paraformaldehyde, and the pellet was resuspended in 1 ml 2% 
Tween ([v/v] in PBS). After permeabilization for 15 min at 37°C, the cells were again 
centrifuged and washed twice with PBS. Afterwards, the cells were incubated with 10 µl of 
20% sheep serum ([v/v] in PBS) for 30 min at room temperature to saturate unspecific 
binding sites, followed by incubation with von Willebrand antibody for 30 min on ice in the 
dark. Afterwards, the cells were washed once more with PBS and resuspended in 300 µl PBS 
for flow cytometric analysis. For the adjustment of instrument settings, control cells were 
prepared according to the procedure described above, but without addition of the antibody. 
For storage, cells were fixed with paraformaldehyde. The purity of the cells was judged by 
measuring the antibody treated cells indicating the percentage of von Willebrand positive 
cells. L929 cells treated as decribed above served as negative control. 
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2.4 Western blot analysis of proteins 
2.4.1 Solutions and antibodies 
RIPA buffer (lysis buffer) : 
NaCl 150 mmol/L 
Tris-HCl   50 mmol/L 
Nonidet P40 1.00% (m/v) 
Deoxycholat 0.25% (m/v) 
SDS 0.10% (m/v) 
 
+ Na3VO4   1 mmol/L 
+ PMSF   1 mmol/L added 
+ Complete Protease inhibitor, 25x stock solution freshly  
NaF 50 mmol/L  before 
Na4P2O7 50 mmol/L  use 
 
SDS sample buffer (5x): 
Tris-HCl (pH 6.8) 3.125 mol/L   2  mL 
Glycerol  10  mL (50% (v/v)) 
SDS 20% (m/v)    5  mL 
DTT 16% (m/v)  2.5 mL 
Pyronin Y 5% (m/v) 0.1 mL 
H2O  ad 20 mL 
 
 
Resolving gel 10%: 
Acrylamide 30%-bisacrylamide 0.8% solution (Roth) 5.0   mL 
1.5 mol/L Tris-base pH 8.8 (Roth) 3.75 mL 
10% SDS   0.15 mL 
H2O dest.   6.1   mL 
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The solution was degassed for 10 min, since polymerization requires anaerobic conditions. 
Afterwards, the polymerization reaction was started by addition of: 
15 µl TEMED (cross linker) 
75 µl APS 10% (m/v) (radical starter) 
 
Stacking gel: 
Acrylamide 30%-Bisacrylamide 0.8% solution (Roth) 1.7 mL 
1.25 mol/L Tris-base pH 6.8  1    mL 
10% SDS   0.1 mL 
H2O   7    mL 
The solution was degassed for 10 min. Afterwards, the polymerization reaction was started by 
addition of: 
20 µl TEMED (cross linker) 
100 µl APS 10% (m/v) (radical starter) 
 
Electrophoresis buffer: 
Tris base   3    g 
Glycin 14.4 g 
SDS   1    g 
H2O dest. ad 1,000 mL 
 
Anode buffer I pH 10.4: 
Tris base   30 g 
Methanol 200 mL 
H2O dest. 800 mL 
 
 
Anode buffer II pH 10.4: 
Tris base     3 g 
Methanol  200 mL 
H2O dest. 800 mL 
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Cathode buffer pH 7.6: 
ε-Amino-n-caproic acid     5.2 g 
Methanol  200    mL 
H2O  800    mL 
 
Tris buffered saline solution containing Tween, pH 8.0 (TBS-T): 
Tris base      3 g     (0.02 mol/L) 
NaCl 11.1 g     (0.2 mol/L) 
Tween 20   1    mL (0.1 %) 
H2O dest. ad 1,000 mL 
 
Primary antibodies: 
Anti-HSP32 (HO-1) monoclonal mouse anti-human antibody 
Anti-HSP70 polyclonal goat anti-human antibody 
Anti-phospho-p38 MAPK polyclonal rabbit anti-human antibody 
Anti-phospho-ERK monoclonal mouse anti-human antibody 
Anti-phospho-JNK/SAPK monoclonal mouse anti-human antibody 
Anti-α-tubulin rabbit antibody 
 
Secondary antibodies:  
Peroxidase-conjugated goat anti-rabbit IgG 
Peroxidase-conjugated goat anti-mouse IgG 
Peroxidase-conjugated donkey anti-goat IgG 
 
 
2.4.2 Sample preparation 
For detection of proteins, whole cell lysates of HUVEC were prepared. HUVEC were 
cultured in 12-well plates until confluence and were either left untreated or stimulated with 
ANP (10-9 – 10-6 mol/L), 8-Br-cGMP (10-3 mol/L) or cANF (10-6 mol/L). After the indicated 
times, the medium was removed, cells were washed three times with ice cold PBS and lysed 
by addition of 100 µl RIPA buffer. In some cases, Western blots were performed after 
pretreatment of HUVEC with U0126 (50 µmol/L), PD 98059 (50 µmol/L), or SP 600125 (10 
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µmol/L) for 1 h. After addition of RIPA buffer, the cells were scraped off the plates with a 
cell scraper, the lysate was transferred into reaction tubes (Eppendorf), and sonicated 
(Sonoplus, Bandelin, Germany) for approx. 5 sec. The homogenized samples were clarified 
by centrifugation at 21,910 x g for 10 min at 4°C and the resulting supernatants were 
collected and subsequently quantified for protein according to the method of Lowry (Lowry 
1951). 5x sample buffer was added to the remaining probes and the samples were heated to 
95°C for 5 min to achieve protein denaturation. Afterwards, the samples were either subjected 
to SDS/PAGE or stored at -20°C until further analysis. 
 
 
2.4.3 SDS polyacrylamide electrophoresis 
The separation of proteins was carried out by denaturing SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) according to Laemmli (Laemmli 1970). The separation of 
proteins solely according to their size is achieved by addition of SDS which complexes 
proteins in a constant weight ratio and masks their charge by its own strongly negative charge 
resulting in identical charge densities on the surface. Disulphide bridges are cleaved by 
reducing agents (DTT). The molecular weight of the separated proteins was determined by 
comparison with a molecular weight standard (biotinylated protein marker, Cell Signaling, 6.5 
kDa – 165 kDa). The electrophoresis was carried out with a BioRad Mini Protean II Cell 
(BioRad, München, Germany). 
 
 
2.4.4 Semidry blotting 
Using a trans-blot semidry system (BioRad), the separated proteins were electrophoretically 
transferred to a polyvinylidenfluoride membrane (Immobilon-P, 0.45 µm pore size, 
Amersham) which was incubated for 5 min in methanol, for 5 min in water, and stored in 
anode buffer II before usage. Six sheets of blotting paper were soaked with anode buffer I and 
three sheets with anode buffer II and rolled onto the blotter without bubbles. The membrane 
and the gels were added and covered with nine sheets of blotting paper moistened with 
cathode buffer. Blotting was carried out for 1 h at 64 mA. Afterwards,  the membrane was 
dried at 80°C for appox. 30 min. Unspecific binding sites were saturated by shaking the 
membrane in 5% (m/v) Blotto (BioRad) in TBS-T. 
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2.4.5 Incubation with antibodies 
Antibody solutions were prepared 1:1,000 or 1:10,000 in 1% Blotto in TBS-T. The blots were 
incubated with the first antibody overnight at 4°C under constant shaking. Following three 
washes with TBS-T, the second horseraddish peroxidase-conjugated antibody was added and 
incubated for at least 1 h at room temperature. After another three washes with TBS-T, the 
protein bands were visualized by a chemoluminescence reaction using an enhanced 
chemoluminescence protein detection kit (NEN, Cologne, Germany), containing the enzyme 
substrate luminol and chemical enhancers, and a Kodak Image station (Kodak digital science, 
Stuttgart, Germany). Luminol is oxidized in the presence of H2O2 and peroxidase, releasing 
light (428 nm) which is aquired by the Kodak Image station. 
 
figure 7: principle of the chemoluminescence reaction 
 
2.5 cGMP measurement 
2.5.1 Solutions 
IBMX (3-Isobutyl-1-methylxanthine): 
• inhibitor of phosphodiesterase, preventing rapid degradation of generated cGMP 
• stock solution: 0.5 mol/L in DMSO 
• final concentration: 0.5 mmol/L 
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SNP (sodium nitroprusside): 
• activator of soluble guanylate cyclase 
• stock solution: 1 mg/mL, was prepared freshly before usage 
• final concentration: 10 µg/mL 
 
 
2.5.2 Experimental procedure 
For determination of cGMP content, performed with a commercially available kit (Amersham 
Pharmacia), HUVEC were cultured in 24-well plates until confluence. The cell culture 
medium was replaced with 270 µl M199 containing 10% FCS and IBMX in a final 
concentration of 0.5 mmol/L. After preincubation for 10 min at 37°C, cells were either left 
untreated or treated with ANP (10-6 mol/L), aspirin (100 µmol/L) or SNP (10 µg/mL) for up 
to 4 h. Subsequently, 30 µl lysis buffer A, contained in the kit, were added to each well giving 
a final volume of 300 µl. The plate was incubated for 10 min on a rocking platform at room 
temperature and stored at –86°C until further analysis. 
The cGMP kit employed is based on a cGMP competitive enzyme immunoassay system. 
Briefly, the 24-well plate was thawed on ice, cells were scraped with a cell scraper, cleared by 
centrifugation (21,910 x g, 4°C, 10 min) and transferred onto a 96-well plate. By acetylation 
with a mixture of 1 volume of acetic anhydride and 2 volumes of triethylamine, the sensitivity 
of the assay was increased from 50 fmol/well to 2 fmol/well. 20 µl of the acetylation reagent 
were added to each sample and mixed on a microtitre plate shaker for 5 min. In the meantime, 
100 µl of a specific cGMP antiserum were pipetted into a pre-coated microtitre plate. 
Afterwards, 50 µl of the acetylated samples were transferred into the appropriate wells of the 
immunoassay microtitre plate and incubated at 4°C for 2 h, followed by addition of 100 µl of 
peroxidase-conjugated cGMP and incubation at 4°C for 1 h. Subsequently, the wells were 
washed 4 times with wash buffer and 200 µl enzyme substrate were pipetted into the wells. 
After incubation on a horizontal shaker for 30 min at room temperature the reaction was 
stopped by addition of 100 µl of 1 M sulphuric acid to the wells and optical density was read 
at 450 nm with an SLT Spectra ELISA reader (SLT Labinstruments, Crailsheim, Germany). 
The assay is based on a competition reaction between unlabeled cGMP produced by the cells 
and a fixed quantity of peroxidase-labeled cGMP for a limited number of binding sites on a 
cGMP-specific antibody bound to an immunoassay microtitre plate. Detection is achieved by 
measuring the OD of the coloured product of the peroxidase reaction. With fixed amounts of 
antibody and peroxidase-labeled cGMP, the OD at 450 nm is inversely proportional to the 
concentration of unlabeled cGMP in the samples. 
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Principle of the EIA: 
 
 
 
figure 8: principle of the cGMP EIA (according to amersham pharmacia instruction   
                manual) 
 
 
2.6 Detection of mRNA 
2.6.1 Isolation of RNA 
For isolation of total RNA (totRNA), HUVEC were grown in 25 cm2 flasks until confluence 
and were either left untreated or treated with ANP (10-6 mol/L) in the presence or absence of 
U0126 (50 µmol/L) which was added to the cells 30 min before stimulation with ANP for up 
to 6 h. totRNA was extracted using a commercially available RNA isolation kit (RNeasy, 
Qiagen, Hilden, Germany). Briefly, cells were washed with PBS and lysed with a highly 
denaturing guanidine isothiocyanate containing buffer which inactivates RNases and ensures 
isolation of intact RNA. Cells were disrupted by centrifugation through a shredder column 
(Qiagen). After addition of ethanol 70% (v/v) the homogenized samples were applied to 
RNeasy mini spin columns contained in the kit. The addition of ethanol 70% creates suitable 
conditions for the selective binding of RNA to the silica-gel based membrane of the RNeasy 
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column. After several washing steps to wash away contaminants, totRNA was eluted in 
RNase free water. This isolation procedure yields RNA with a size distribution comparable to 
that obtained by centrifugation through a CsCl gradient, since RNA molecules longer than 
200 nucleotides are isolated. Small RNAs do not bind quantitatively under the conditions of 
this kit.  
All steps were carried out wearing protective gloves with materials that were taken directly 
from the original packaging or freshly autoclaved to avoid contamination of the samples with 
RNases. RNases are very stable and active enzymes that require no cofactors for their 
function and degrade RNA very quickly. 
 
2.6.2 Determination of RNA concentration 
Nucleic acids have an UV light absorption maximum at 260 nm due to the aromatic ring 
systems of the bases contained in the RNA. Therefore, RNA concentrations of the samples 
were determined by measuring the OD at 260 nm with a Perkin Elmer spectrophotometer. 
The purity of the RNA was evaluated according to the ratio E260/E280 which should be 2.0 +/- 
0.3 since pure RNA has a ratio of 2.0. Proteins have an absorption maximum at 280 nm based 
on the absorption of aromatic amino acid residues. A high absorbance at 280 nm resulting in a 
low A260/A280 ratio therefore indicates the presence of contaminating proteins or phenol. 
 
2.6.3 Agarose gel electrophoresis 
Solutions: 
Ethidium bromide stock solution: 10 mg/mL 
0.01 M NaH2PO4 
 
Experimental procedure: 
The integrity of RNA was evaluated by agarose gel electrophoresis. 2.5 µg RNA as 
determined by OD measurement were adjusted to a volume of 20 µl with RNase-free water.   
4 µl blue/orange 6x loading dye (Promega, Mannheim, Germany), were added and the 
samples were run on a 1.2% (m/v) agarose gel in 0.01 M NaH2PO4 electrophoresis buffer pH 
7.0 at 90 V for approx. 3 hours. Immediately before casting of the gel, 5 µl ethidium bromide 
stock solution (final concentration: 0.5 µg/mL) were added. This fluorescence dye intercalates 
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with RNA and therefore allows visualization of the bands in UV light (254 nm). The 28 S and 
the 18 S band should ideally be visible at a ratio of 2:1. This represents a measure of quality 
and intactness of the isolated RNA. RNA bands were visualized using a Kodak Image station 
(Kodak digital science, Stuttgart, Germany). 
 
 
2.6.4 Reverse transcription 
Reverse transcription was performed using a reverse transcription system kit (Promega, 
Mannheim, Germany) and a GeneAmp PCR System 9700 (PE Applied Biosystems, 
Weiterstadt, Germany). 2.5 µg RNA were dried in a Speed VacPlus SC 110A (Thermo Life 
Sciences GmbH, Egelsbach, Germany), dissolved in 10 µl RNase-free water and put on ice. 
After addition of the reaction mixture (see below), the samples were incubated at 42°C for 25 
min. The reaction was stopped by heating at 99°C for 5 min, the samples were cooled down 
on ice and stored at –20°C. 
 
 
Reaction mixture for one sample: 
MgCl2 (25 mmol/L)   4      µl (5mmol/L) 
10x Transcription buffer   2      µl 
dNTP mix (10 mmol/L)   2      µl (1 mmol/L/dNTP) 
RNAsin ribonuclease inhibitor (40 U/mL)   0.5   µl = 20 U (1 U/µl) 
Oligo(dT)15primer (500 µg/mL)   1      µl = 0.5 µg (0.5 µg/µg RNA) 
AMV reverse transcriptase (20 U/µl)   0.75 µl = 15 U (15 U/µg RNA) 
 10.25 µl 
 
 
AMV RT:  Avian Myeloblastosis Virus Reverse Transcriptase catalyzes the polymerization  
 of DNA using DNA, RNA or RNA:DNA hybrids as template. It requires a primer  
 as well as Mg2+ or Mn2+. 
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2.6.5 Polymerase Chain Reaction 
2.6.5.1 Used primers 
 
 sense primer antisense primer 
GAPDH ACC-TAA-CTA-CAT-GGT-TTA-CAT-GTT GGT-CTT-ACT-CCT-TGG-AGG-CCA-TGT-G 
HO-1 CAG-GCA-GAG-AAT-GCT-GAG-TTC GCT-TCA-CAT-AGC-GCT-GCA 
table 1: primers used for PCR 
DNA sequences are indicated from 5`to 3`terminus according to convention 
 
2.6.5.2 Conditions 
 
 pretreatment denaturing annealing extension posttreatment cylcles 
GAPDH 93°C; 1.06 min 93°C; 24 sec 55°C; 30 sec 73°C; 1 min 73°C; 10 min 30 
HO-1 95°C; 2 min 94°C; 30 sec 58°C; 1 min 72°C; 1 min 72°C; 10 min 30 
table 2: conditions for PCR experiments 
 
cDNA was amplified using Taq DNA Polymerase. DNA polymerases are enzymes that 
polymerize ssDNA to dsDNA, provided that there is a short double-stranded region as 
initiator available. This is achieved by addition of strand-specific primers, one being 
complementary to the coding strand, one being complementary to the non-coding strand. 
As a first step, the DNA double-strand is separated by heat denaturation allowing the primers 
to bind to their target sequence (annealing). The resulting double strand serves as starting 
point for the Taq DNA Polymerase, synthesizing the complementary strand (extension). The 
repetition of this procedure leads to a doubling of the DNA after each cycle and an 
exponential duplication of the DNA sequence. 
The reaction mixture was prepared on ice and PCR was run with a GeneAmp PCR System 
9700 (PE Applied Biosystems, Weiterstadt, Germany) according to the conditions mentioned 
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in the table above. cDNA was denatured at 93°C or 95°C resp. (pretreatment), followed by 30 
cycles of denaturing, annealing (primer hybridization), and extension (synthesis of the DNA 
strand). During posttreatment all DNA fragments were finished by the DNA polymerase. 
 
Reaction mixture for 1 sample: 
BSA (1%)  0.5 µl (0.005%) 
MgCl2   6    µl (1.5 mmol/L) 
dNTP (dATP, dCTP, dGTP, dTTP)   1    µl (1.0 mmol/L) 
10x buffer 10    µl 
Oligo sense primer   1    µl 
Oligo antisense primer   1    µl 
Taq Polymerase   0.5 µl (2.5 U) 
H2O 60    µl 
 
Taq Polymerase:  thermostable enzyme from Thermophilus aquaticus, replicates DNA at  
 74°C, catalyzes the polymerization of nucleotides into dsDNA in the  
 5’→3’ direction in the presence of Mg2+ 
 
Amplification products were separated on a 2.5% agarose gel (m/v) in TAE buffer (90 V, 
approx. 3 h). The size of the PCR products was determined by comparison to DNA fragments 
of well-defined size (phIX174 DNA/Hinf I Markers, 24 to 726 base pairs, Promega, 
Mannheim, Germany) loaded on the same gel. 
 
TAE buffer 50x: 
Tris base         242    g (2 mol/L) 
EDTA sodium salt         100    mL 0.5 mol/L EDTA (pH 8.0) (0.05 mol/L) 
Glacial acetic acid           57.1 mL 
H2O ad 1,000    mL 
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2.7 Electrophoretic Mobility Shift Assay 
Electrophoretic mobility shift assays were kindly performed by Nina Weber and Brigitte 
Weiss. 
2.7.1 Isolation of nuclear and cytosolic protein 
Solutions: 
Buffer A: Buffer B: 
HEPES pH 7.9 10    mmol/L HEPES pH 7.9 20    mmol/L 
KCl 10    mmol/L NaCl   0.4 mmol/L 
EDTA   0.1 mmol/L EDTA   1.0 mmol/L 
EGTA   0.1 mmol/L EGTA   1.0 mmol/L 
in H2O  Glycerol (100%) 25% 
  in H2O 
DTT 1.0    mmol/L 
PMSF    0.5 mmol/L 
DTT stock solution:   1 ml of a 1 mol/L solution was aliquoted and stored at –20°C 
PMSF stock solution:  1 ml of a 50 nmol/L solution in isopropanol was aliquoted and 
   stored at –20°C. 
 
Experimental procedure: 
HUVEC were cultured in 6-well plates until confluence and were either left untreated or 
stimulated with ANP (10-9 – 10-6 mol/L) for the indicated times. Nuclear extracts were 
prepared as described previously (Kiemer et al. 2002). Briefly, cells were washed with PBS 
and detached with a cell scraper. After resuspension in 400 µl hypotonic buffer A, cells were 
allowed to swell on ice for 15 min. Nonidet P-40 (10%, 25 µl) was added, followed by 10 sec 
of vigorous vortexing. Samples were centrifuged at 12,000 x g for 30 sec. The supernatants 
(containing the cytosolic protein) were removed and frozen at –20°C. The nuclear pellet was 
extracted with 50 µl hypotonic buffer B by shaking at 4°C for 15 min. After centrifugation at 
12,000 x g the supernatants were frozen at –85°C. Protein concentrations were measured 
according to the method of Lowry (Lowry 1951). 
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2.7.2 Binding reaction and electrophoretic separation 
EMSA was performed using a 22-mer double-stranded oligonucleotide probe containing a 
consensus binding-sequence for AP-1 (5`-CGC TTG ATG AGT CAG CCG GAA-3`), 5’end-
labeled with [γ 32P]-ATP (10 µCi) using T4 polynucleotide kinase. Specificity of the DNA-
protein complex was confirmed by competition with a 100-fold excess of unlabeled AP-1 and 
AP-2 (5`-GAT CGA ACT GAC CGC CCG CGG CCC GT-3`) binding sequences, 
respectively.  
Equal amounts of nuclear protein (10 – 20 µg) were incubated (20 min, room temperature) in 
a 15 µl reaction volume containing 10 mmol/L Tris-HCl pH 7.5, 5 x 104 cpm radiolabeled 
oligonucleotide probe, 2 µg poly (dIdC), 4% glycerol, 1 mmol/L MgCl2, 0.5 mmol/L EDTA, 
50 mmol/L NaCl, and 0.5 mmol/L DTT. Nucleoprotein-oligonucleotide complexes were 
resolved by electrophoresis (4.5% non-denaturing polyacrylamide gel, 100 V) and signals 
were detected by phosphorimaging. 
 
 
Determination of cytotoxicity 
2.8 Fluorescence microscopy after Hoechst staining 
Solution: 
Hoechst 33342 stock solution: 1 mg/mL in PBS 
Principle of staining with Hoechst 33342: 
Hoechst 33342 is a fluorescence dye, which freely passes the plasma membrane of intact cells 
as well as damaged cells, therefore it enters viable and apoptotic cells without the need for 
fixation. Hoechst 33342 specifically stains adenine-thymidine-rich regions of double stranded 
DNA and possesses an excitation maximum at 360 nm and an emission maximum at 450 nm. 
After staining with Hoechst, apoptotic cells can be identified by the typical hallmarks of 
apoptosis: chromatin condensation, nuclear fragmentation, cytoplasmatic blebbing and 
formation of apoptotic bodies. The most noticeable feature is the condensed chromatin which 
is detected by strongly increased fluorescence due to a higher concentration of dye in these 
areas. Healthy cells are characterized by a weaker, evenly distributed fluorescence compared 
to the apoptotic cells, as they possess intact nuclei and cytosol and moreover are able to 
eliminate the dye from the cytosol. 
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Experimental procedure: 
HUVEC were grown in 24-well plates until confluence and were either left untreated or 
treated with TNF-α (10 ng/mL) or etoposide (200 µmol/L) in the presence or absence of ANP   
(10-6 mol/L) or aspirin (100 µmol/L) resp. for 16 h. ANP and aspirin were added to the cells  
4 h before addition of TNF-α or etoposide. After 16 h, cells were incubated with Hoechst 
33342 in a final concentration of 10 µg/mL at 37°C for 5 min. Photographs were taken with a 
Zeiss Axioskop MC 80 DX microscope (Zeiss, Munich, Germany) with a 200-fold 
magnification. 
 
 
2.9 Haemacolor staining 
HUVEC (24-well plates) were either left untreated or stimulated with TNF-α (10 ng/mL) or 
etoposide (200 µmol/L) in the presence or absence of ANP (10-6 mol/L) or Aspirin            
(100 µmol/L) for 16 h. ANP and Aspirin were added to the cells 4 h before addition of TNF-α 
or Etoposide. After 16 h cells were washed three times with PBS+ and stained with 
Haemacolor (Merck, Munich, Germany) according to the manufacturer’s instructions. 
Photographs were taken with a Zeiss Axioskop MC 80 DX microscope (Zeiss, Munich, 
Germany) with a 100- or 400-fold magnification. 
 
 
2.10 Caspase-3-like activity measurement 
2.10.1 Principle of the activity measurement 
The activation of the downstream caspase-3, which is considered to be one of the key effector 
caspases (Hengartner 2000), can be determined with an activity assay using the synthetic 
peptide substrate DEVD (asp-glu-val-asp). A fluorophor, bound to this substrate, is cleaved 
after the aspartate residue by activated caspase-3, resulting in an increase in fluorescence 
(Thornberry 1994). Since other downstream caspases belonging to the same subgroup, such as 
caspase-7, possess similar substrate specificity, their activity is measured as well. 
Consequently, this assay does not exclusively acquire caspase-3 activity, and the measured 
activity is therefore named “caspase-3-like activity” considering caspase-3 to be the main 
effector caspase. The DEVD substrate is labeled with a fluorescence dye, called 7-amino-4-
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trifluoromethyl coumarin (AFC), allowing the detection of the cleavage by caspase-3. The 
release of this fluorophor results in a shift from blue to green fluorescence, measured at an 
extinction wavelength of 390 nm and an emission wavelength of 505 nm. AFC is a highly 
sensitive fluorophor with satisfactory stability to allow convenient handling. 
The reaction has a linear progression over at least 2 hours, provided the enzyme is saturated 
with substrate. Since caspases need a thiol group for their catalytic function, they are 
susceptible to changes of redox potential, and the thiol group can be oxidized by agents such 
as air oxygen and traces of metal ions. Therefore, the substrate buffer contained dithiothreitol 
(DTT) as a reducing agent. 
 
2.10.2 Solutions 
Lysis buffer: 
MgCl2 x 6 H2O   5    mmol/L 
EGTA   1    mmol/L 
Triton X-100   0.1 % 
HEPES 50 mM pH 7.5 25    mmol/L 
 
Buffer B: 
HEPES 50    mmol/L 
Sucrose   1    % (m/v) 
CHAPS   0.1 % (m/v) 
 
→ adjusted to pH 7.5 with 4 M NaOH 
 
Substrate buffer: 
Buffer B     8 ml 
DEVD-AFC (10 mmol/L)   45 µl (50 µmol/L) 
DTT (1 mol/L) 100 µl (10 mmol/L) 
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2.10.3 Experimental procedure 
2.10.3.1 Treatment of cells 
HUVEC were cultured in 12-well plates until confluence and were either left untreated or 
treated with TNF (10 ng/mL) or etoposide (200 µmol/L) in the presence or absence of ANP 
(10–6 mol/L) or aspirin (100 µmol/L), respectively. ANP and aspirin were added to the cells 
simultaneously with the cytotoxic agent or preincubated for 4 hours. After 16 hours, the 
medium was removed and cells were washed with ice-cold PBS, followed by addition of      
70 µl cold lysis buffer. Subsequently, the plates were frozen at –85°C until measurement of 
caspase activity. 
2.10.3.2 Caspase-3-like activity assay 
The frozen plates were allowed to thaw on ice, cells were scraped with a cell scraper and 
collected in Eppendorf tubes, followed by centrifugation at 21,910 x g ( 4°C, 10 min) to 
clarify lysates. Supernatants were transferred to microtiter plates (Greiner, Frickenhausen, 
Germany) and caspase-3-like activity was measured according to the method originally 
described by Nicholson (Nicholson et al. 1995). Wells contained either 10 µl of sample 
(triplicates) or extraction buffer in case of blank . The Ac-DEVD-AFC cleavage reaction was 
started by addition of 90 µl of substrate buffer containing the fluorigenic peptide substrate. 
Plates were incubated at 37°C, and formation of free 7-amino-4-trifluoro-methylcoumarin 
(AFC) was kinetically acquired by fluorescence measurement (excitation at 385 nm, emission 
at 505 nm) every 30 minutes with a fluorometer microplate reader (Fluostar, BMG GmbH, 
Offenburg, Germany). Caspase-3-like activity was calculated on the basis of an external AFC 
(Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) standard curve and expressed in 
relation to the protein content of the corresponding samples, measured using the Pierce Assay 
(see below). 
 
2.10.3.3 Protein determination – Pierce Assay (BCA assay) 
The underlying reaction of this photometric assay is the Biuret reaction of proteins with 
copper under alkaline conditions and the interaction of two molecules of bicinchoninic acid 
(BCA) with one copper (I) ion (Cu+). This reaction yields a water soluble purple complex 
possessing a strong absorbance at 562 nm (Smith et al. 1985). 
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Solutions: 
BCA Protein Assay Reagent (Pierce, Rockford, USA): 
Reagent A: Na2CO3, NaHCO3, BCA reagent, and Na-tartrate in 0.2 mol/L NaOH 
Reagent B: 4% aqueous CuSO4 solution 
⇒ 20 ml reagent A + 400 µl reagent B 
BSA standard: 2 mg/ml stock solution 
 
 
Experimental procedure: 
200 µl of the BCA working solution were added to 10 µl of each sample. The plates were 
incubated at 37°C for 30 minutes, followed by measurement of the absorbance at 562 nm in a 
Lambda Bio 20 photometer. Protein content was calculated on the basis of a standard curve, 
obtained by diluting the BSA standard  (0-2,000 µg/mL, Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany) at a ratio of 1:2. 
 
 
2.11 Propidium iodide staining 
2.11.1 Principle 
DNA fragmentation is considered to be a characteristic hallmark of apoptosis. Therefore, 
apoptotic cells can be detected and quantified by propidium iodide staining of their subdiploid 
DNA content in hypotonic buffer, followed by fluorescence activated cell sorting (FACS). 
Propidium iodide is a fluorescence dye that intercalates with DNA and can be measured at an 
excitation wavelength of 535 nm and an emission wavelength of 617 nm. Apoptotic nuclei 
appear as a broad subdiploid peak which is easily discriminable from the narrow peak of cells 
with normal diploid DNA content. 
 
2 MATERIALS AND METHODS 
63 
 
2.11.2 Solutions 
HFS (Hypotonic fluorochrome solution): 
Triton X-100 0.1% 
Sodium citrate 0.1% 
Propidium iodide stock solution 50 µg/mL 
 in PBS  
 
Propidium iodide stock solution: 5 mg/mL 
 
PBS: see under 2.2.1 
 
 
2.11.3 Experimental procedure 
For determination of subdiploid DNA content, HUVEC were grown in 24-well plates until 
confluence and were treated with TNF-α (10 ng/mL) or etoposide (200 µmol/L) in the 
presence or absence of ANP (10-6 mol/L) or aspirin (100 µmol/L) which were added to the 
cells either simultaneously with the cytotoxic agent or 4 h before TNF-α or etoposide, 
respectively. After 16 h, flow cytometric determination of subdiploid DNA content was 
undertaken by a modified procedure as described by Nicoletti (Nicoletti et al. 1991). Culture 
medium, containing dead cells that had detached from the wells, was collected in FACS 
tubes, centrifuged at 600 x g for 10 min at 4°C and washed twice with PBS to remove residual 
medium. The cell pellet was resuspended in 250 µl HFS. In the meantime, wells containing 
living cells and dying cells that have not yet detached, were washed twice with PBS and     
250 µl HFS were added, as well as the corresponding samples containing detached cells. 
Plates were incubated at 4°C overnight. The following day, residual adherent cells were 
detached by pipetting up and down, and the samples were analyzed by flow cytometry. Cell 
death was calculated as % dead cells in relation to TNF-α treated cells, the apoptosis rate of 
which was set as 100%. 
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2.12 MTT-Test 
In order to determine necrotic cell death in addition to apoptosis, an MTT test was performed 
assessing also cells dying independently of apoptotic characteristics. This assay determines 
the activity of mitochondrial enzymes. Only living cells are capable of reducing [3-(4,5-
dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide] (MTT) to the blue coloured 
formazane, a reaction carried out under ATP consumption by NADPH-dependent enzymes. 
This reaction can not take place in dead cells. After dissolution in DMSO, the absorption of 
the generated formazane can be measured at 570 nm. 
 
Reaction: 
figure 9: conversion of MTT into formazane by NADPH-dependent enzymes 
 
Solutions: 
5 mg/ml MTT [3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide] (Sigma, 
Taufkirchen, Germany) in PBS, sterile. 
DMSO 
Experimental procedure: 
For determination of mitochondrial activity, HUVEC were grown in 96-well plates until 
confluence and were stimulated with TNF-α (10 ng/mL) or etoposide (200 µmol/L) in the 
presence or absence of ANP (10-6 mol/L), which was added to the cells either simultaneously 
or 4 h before TNF-α. After 18 h, 5 µl MTT reagent was added followed by incubation at 37°C 
for 6 h. During this time, HUVEC converted tetrazolium bromide into blue formazane 
according to their viability. Afterwards, 250 µl DMSO were added to the wells, and generated 
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formazane crystals were dissolved by rocking on a shaker for at least 2 h in the dark. 
Absorption was measured with an SLT Spectra ELISA reader (SLT Labinstruments, 
Crailsheim, Germany) at 570 nm. 
 
 
 
 
66 
 
 
67 
 
3 RESULTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 RESULTS 
69 
3.1 ANP 
3.1.1 Induction of HO-1 protein expression by ANP 
3.1.1.1 Characterization of HUVEC by Flow Cytometry and 
Immunfluorescence 
HUVEC were prepared as described in Materials and Methods. Since this cell model 
constitutes a primary cell culture, the cells had to be characterized. The identity and purity of 
the cells had to be verified, i.e. the presence of other cell types (e.g. fibroblasts, smooth 
muscle cells) had to be excluded. A typical hallmark for endothelial cells is the presence of 
von Willebrand factor, a large glycoprotein (MW ∼ 220 kD) of complex multimeric structure, 
that mediates attachment of platelets to the subendothelium after vascular injury. Von 
Willebrand protein in HUVEC is present in the endoplasmatic reticulum, stored in Weibel 
Palade bodies, and also in extracellular matrix filaments. It is not found in smooth muscle 
cells or fibroblasts.  
The identity of HUVEC was demonstrated by staining of fixed and permeabilized cells with a 
FITC-labeled anti-human von Willebrand Factor-antibody, followed by microscopic 
investigations as well as flow cytometry (Math. and Meth.). Fluorescence microscopy of the 
cells revealed the typical staining of the rod-shaped Weibel Palade bodies in a granular 
pattern (figure 10). The rods were present throughout the cytoplasm, with greater 
concentrations being located at the periphery of the cells. L929, a mouse fibroblast cell line 
that served as negative control, treated according to the same protocol showed no staining at 
all. Flow cytometric analysis of stained cells allowed the quantification of the amount of von 
Willebrand positive cells. (figure 11). >95 % of isolated cells stained positive for von 
Willebrand factor. The fluorescence intensity of L929 increased as well after treatment with 
the antibody, but to a much lesser extent compared to HUVEC. This observation can be 
ascribed to unspecific binding of the antibody to the cell surface and can clearly be 
distinguished from specific binding to the intracellular localized von Willebrand factor by 
virtue of the different fluorescence intensities. Unspecific binding of the antibody results in 
only weak increases in fluorescence intensity, whereas specific binding to von Willebrand 
factor yielded very high fluorescence values. 
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Figure 10: Characterization of HUVEC by means of von Willebrand factor 
HUVEC were grown in 24-well-plates on cover slips, fixed and permeabilized with an 
Acetone/MeOH 1:1 mixture and photographed with a 400-fold magnification after staining with a 
FITC-conjugated anti-human von Willebrand Factor antibody (Math. and Meth.). The picture 
presented above shows one out of three independent experiments from different cell preparations. 
 
 
Figure 11: Flow cytometric detection of von Willebrand protein 
L929 (panel A) and HUVEC (panel B) were trypsinized, fixed and permeabilized, followed by 
staining with a FITC-conjugated sheep anti-human von Willebrand antibody and analyzed by flow 
cytometry (Math. and Meth., 2.4.2). The identity of the cells was verified by measuring the 
fluorescence of the cells at 530 nm (FL 1). The figure shows one representative experiment out of 
three different experiments from different cell preparations where the fluorescence intensity of the 
A B
Co
L929 + v. Willebrand antibody
Co
HUVEC + v. Willebrand antibody
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cells is displayed versus the cell count. Co: basal fluorescence of L929 or HUVEC, respectively, 
without staining. 
 
3.1.1.2 Evidence for the existence of functional NP receptors 
cGMP levels were determined after 20 min stimulation with ANP (10-6 mol/L) by EIA 
according to Materials and Methods. Treatment with ANP lead to a significant increase of 
total (extracellular and intracellular) cGMP levels compared to untreated control cells (figure 
12). LY 83583 (10-6 mol/L), an inhibitor of the soluble guanylate cyclase, did not reduce this 
ANP induced rise in cGMP, demonstrating that increased cGMP levels originated from the 
particular guanylate cyclase. SNP (10 µg/mL), an activator of the soluble guanylate cyclase, 
served as positive control to test the reliability of the EIA and the inhibitor LY 83583. After 
20 min SNP activated the soluble guanylate cyclase, resulting in significantly elevated cGMP 
levels. This increase was almost completely abrogated by preincubation with LY 83583, 
demonstrating the specific effect of the inhibitor on the soluble guanylate cyclase. 
 
Figure 12: cGMP production in HUVEC after stimulation with ANP 
cGMP production was determined in control cells (Co) and cells treated with ANP (10-6 mol/L) or with 
SNP (10 µg/mL) for 20 min with a commercially available kit as described under Materials and 
Methods. LY 83583 (10-6 mol/L), was added to the cells 10 min before ANP. Results presented above 
are expressed as x-fold increase in cGMP levels compared to the cGMP production in untreated 
control cells and represent mean ± SEM of one representative measurement out of two independent 
experiments performed in triplicates. ∗∗ p<0.01 and ∗ p<0.05 represent significant differences 
compared to control, ++ p<0.01 and + p<0.05 significantly different compared to cells treated without 
LY 83583. 
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3.1.1.3 Time- and concentration dependent induction of HO-1 protein by ANP 
In order to determine the potency of ANP to induce HO-1 protein in HUVEC, cells were 
treated with ANP for different periods of time. Time and concentration courses were 
performed to find the maximum induction of HO-1. HUVEC were treated with different 
concentrations of ANP (10-9 mol/L - 10-6 mol/L) for up to 16 h and HO-1 protein was 
determined by Western blot analysis (Math. and Meth., 2.5). ANP dose- and time-
dependently induced the expression of HO-1 protein with a maximum induction occurring at 
a concentration of 10-6 mol/L between 4 and 6 hours (figure 13 and 14). Therefore the 
following experiments aiming to characterize mechanisms by which ANP leads to HO-1 
upregulation were performed with this concentration and a stimulation time of 5 hours. 
 
Figure 13: Time-dependent induction of HO-1 protein by ANP 
HUVEC were either left untreated or treated with ANP (10-6 mol/L) for different periods of time (2 h - 
16 h) and expression of HO-1 protein was analyzed by Western blot as described under Materials and 
Methods. Results show one representative blot out of three independent experiments with different cell 
preparations. The graph presented below shows the densitometric evaluation of Western blots, 
expressed as x-fold of values obtained for control cells. Data represent means ± SEM out of three 
independent experiments with different cell preparations with ∗ p<0.05 significantly different 
compared to the values seen in untreated cells (Co). 
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Figure 14: Dose-dependent induction of HO-1 protein by ANP 
HUVEC were cultured in medium alone (Co) or were treated with different concentrations of ANP 
(10-6 - 10-9 mol/L) for 5 h. Western blots were performed as described under Materials and Methods. 
Data show one representative  out of four independent Western blots with different cell preparations. 
The graph shows the densitometric evaluation of Western blots, expressed as x-fold induction 
compared to untreated cells. Data represent means ± SEM out of four independent experiments with ∗ 
p<0.05 significantly different compared to control. 
 
3.1.2 No induction of HSP70 after treatment with ANP 
Apart from HO-1, another important member of the family of heat shock proteins was 
investigated, HSP70. In order to investigate the effect of ANP on HSP70 protein expression, 
cells were treated with ANP (10-6 mol/L) for different periods of time and HSP70 protein 
levels were determined by Western blot. In contrast to HO-1, ANP had no effect on HSP70 
expression up to 12 hours (figure 15). 
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figure 15: No effect of ANP on HSP70 protein expression 
HUVEC were either left untreated or treated with ANP (10-6 mol/L) for different periods of time (2 h – 
12 h) and expression of HSP70 protein was determined by Western blot as described under Materials 
and Methods. Results show one representative blot out of three independent experiments with different 
cell preparations. The graph below shows the densitometric evaluation of three Western blots, 
expressed as x-fold of values obtained for untreated control cells. Data represent means ± SEM out of 
three independent experiments. 
3.1.3 Receptor specificity of the ANP effect on HO-1 
Since ANP has been reported to exert its effects via the guanylate cyclase-coupled A receptor 
(NPR-A) (Tremblay et al. 2002) or via its clearance receptor (NPR-C) (Levin et al. 1991) the 
receptor specificity of the ANP effect on HO-1 needed to be determined. For this purpose, the 
influence of the cell-permeable cGMP analogue 8-Br-cGMP as well as of the specific ligand 
of the NPR-C, cANF, on the induction of HO-1 protein were investigated by performing 
Western blots after treatment of the cells with these substances.  
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3.1.3.1 cGMP analogue 8-Br-cGMP 
If the effect of ANP on HO-1 protein expression is mediated via the guanylate cyclase A-
receptor, the cGMP analogue 8-Br-cGMP should be able to mimic this HO-1 upregulation. In 
fact, 8-Br-cGMP (10-3 mol/L) could induce the expression of HO-1 over time with the first 
significant induction occurring after 4 h (figure 16). 
 
 
Figure 16: Induction of HO-1 protein by 8-Br-cGMP 
HUVEC were treated with 8-Br-cGMP (10-3 mol/L) for up to 8 h and HO-1 protein expression was 
determined by Western blot. Upper panel shows one representative out of three independent 
experiments with different cell preparations with similar results. The graph shows the densitometric 
evaluation of three Western blots, data being expressed as x-fold of values obtained for untreated 
control. Data represent means ± SEM out of three independent experiments with different cell 
preparations. ∗ p<0.05 significantly different compared to the values of control cells (Co). 
 
 
3.1.3.2 NPR-C ligand cANF 
The specific NPR-C ligand cANF had no influence on HO-1 protein expression in HUVEC, 
as demonstrated in figure 17. 
These results suggest that the induction of HO-1 protein expression by ANP is mediated via 
the guanylate cyclase coupled NPR-A with cGMP as second messenger, as the cGMP 
analogue 8-Br-cGMP was able to mimick the effect of ANP on HO-1 expression. On the 
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contrary, the NPR-C appears not to be involved, since the specific NPR-C ligand cANF did 
not influence HO-1 protein expression. 
 
figure 17: Influence of the specific NPR-C ligand cANF on HO-1 expression 
HO-1 expression of control cells (Co) and of cells treated with cANF (10-6 M) for different periods of 
time was determined by Western blot as described under Materials and methods. Results show one 
representative out of three independent experiments with different cell preparations. The histogramm 
shows the densitometric evaluation of signal intensities of three independent Western blots ± SEM, 
expressed as x-fold increase compared to untreated cells. 
 
 
3.1.4 Molecular mechanism involved in the HO-1 induction by 
ANP 
The following experiments were performed in order to elucidate the molecular mechanisms 
involved in the induction of HO-1 protein by ANP. The first objective was to determine 
whether the regulation of this heat shock protein occurs at the transcriptional level. For this 
purpose, semi-quantitative RT-PCR experiments to determine HO-1 mRNA were carried out 
as follows.  
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3.1.4.1 Influence of ANP on HO-1 mRNA 
To verify the intactness of the isolated totRNA, the samples were separated on agarose gels 
and stained with ethidium bromide before reverse transcription was performed. In case of 
intact RNA the 28 S and 18 S bands of the ribosomal RNA could be detected at a ratio of 2 : 1  
In the following PCR experiments ANP (10-6 mol/L) induced the expression of HO-1 mRNA 
in a time-dependent manner suggesting that ANP regulates HO-1 on a transcriptional level. 
(figure 18). 
 
figure 18: Time-dependent induction of HO-1 mRNA expression by ANP 
HUVEC were either left untreated (Co) or treated with ANP (10-6 mol/L) for up to 6 h. totRNA was 
isolated and RT-PCR was performed according to Materials and Methods. Amounts of cDNA 
employed in PCR were normalized versus GAPDH. The figure shows one representative agarose gel 
out of 3 independent experiments, the GAPDH gel is shown below. The graph shows the 
densitometric evaluation of signal intensities, expressed as x-fold increase of values for untreated 
control cells. Data show mean ± SEM of four independent experiments with different cell 
preparations. ∗ p<0.05 significantly different compared to control. 
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3.1.4.2 Influence of ANP on the activator protein-1 (AP-1) 
The experiments performed so far suggested a regulation of HO-1 by ANP on the protein as 
well as the transcriptional level, raising the question which transcription factors are involved 
in this signal transduction pathway. One transcription factor previously reported to play a 
pivotal role in the transcriptional induction of HO-1 is the activator protein-1 (AP-1) (Wiesel 
et al. 2000). Therefore, in order to elucidate if ANP mediates its induction of HO-1 expression 
via AP-1, the activation of this transcription factor, which binds to specific promotor 
sequences of the HO-1 gene after translocation to the nucleus, was investigated by 
electrophoretic mobility shift assay (EMSA). 
3.1.4.2.1 Activation of AP-1 by ANP 
To determine a potential effect of ANP on the DNA-binding activity of AP-1, EMSA with 
ANP time and concentration courses was performed (figure 19 and 20 ). 
Treatment with ANP in fact resulted in a significant time-dependent activation of this 
transcription factor, with maximum stimulation occurring after 15 min and a second 
maximum after 90 min, indicating a biphasic time course for AP-1 activation exerted by ANP. 
(figure 19) 
 
figure 19: time course of AP-1 induction by ANP 
HUVEC were either left untreated (Co) or treated with ANP (10-6 mol/L) for up to 2 h. Nuclear protein 
was isolated and binding activity to a radioactively labeled promotor sequence was determined 
(Materials and Methods). The figure shows one representative EMSA out of three independent 
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experiments. For each experiment the binding specificity was assessed by addition of a 100-fold 
excess of unlabeled AP-1 and AP-2 oligonucleotide. 
 
Figure 20 shows the activation of AP-1 in the presence of increasing concentrations of ANP 
(10-8 mol/L – 10-6 mol/L) and clearly demonstrates a maximum induction of AP-1 DNA 
binding activity at a concentration of 10-6 mol/L, consistent with the findings at HO-1 protein 
level, where maximum induction also appeared at an ANP concentration of 10-6 mol/L. 
 
 
figure 20: Dose-dependent induction of AP-1 DNA binding activity by ANP 
HUVEC were treated with different concentrations of ANP (10-6 mol/L – 10-8 mol/L) for 1 h and 
activation of AP-1 was determined by EMSA as described under Materials and Methods. The figure 
shows one representative EMSA out of three independent experiments with different cell preparations. 
 
3.1.4.2.2 Inhibition of AP-1 DNA binding acitivity by U0126 
The observations described above, that expression of HO-1 is significantly elevated at the 
mRNA and protein level after treatment with ANP are consistent with an induction of DNA 
binding activity of the activator protein –1 and point to an involvement of this transcription 
factor in this signaling pathway. Nevertheless, evidence for a causal link between AP-1 and 
HO-1 still had to be supplied.  
In order to determine a direct causal relationship for AP-1 activation in ANP-induced 
upregulation of HO-1, we aimed to perform decoy experiments to prevent AP-1 activation. As 
shown in figure 21, addition of scrambled decoy oligonucleotides, performed as control 
experiment, induced both AP-1 activity as well as HO-1 protein expression, suggesting the 
activation of these stress-related pathways due to the transfection procedure. Consequently, 
this approach revealed not to be suitable for proving a causal relationship between AP-1 
activation and HO-1 induction. 
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Figure 21: Treatment of HUVEC with AP-1 decoy oligonucleotides 
HUVEC were transfected with AP-1 decoy oligonucleotides or scrambled decoy for 4 h or treated 
with transfection reagent without addition of DNA for the same time (Co). EMSA (left panel, A) and 
Western blot (right panel, B) was performed as described under Materials and Methods. Specificity of 
the binding reaction was assessed by using an excess of unlabeled AP-1 or AP-2 DNA 
oligonucleotides to binding reactions of TNF-α-treated cells. Results shown in the left panel represent 
one representative out of three independent experiments from different cell preparations. The blot 
illustrated in the right panel shows one representative out of six independent experiments from 
different cell preparations with similar results. 
 
As an alternative approach to demonstrate a causal link between HO-1 induction and AP-1 
activation, experiments were performed with U0126, a specific pharmacologic inhibitor of 
AP-1 activity. 
The ability of U0126 to inhibit AP-1 DNA binding activity was verified by performing 
EMSA after treatment of the cells with ANP (10-6 mol/L) in the presence and absence of 
U0126 (50 µmol/L). In fact, ANP-induced DNA binding activity of AP-1 could successfully 
be inhibited by this compound, as shown in the shift in figure 22. 
 
Figure 22: Inhibition of AP-1 DNA binding activity by U0126 
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HUVEC were either left untreated (Co) or treated with ANP (10-7 mol/L – 10-6 mol/L) for 1 h in the 
presence or absence of U0126 (50 µmol/L), which was added to the cells 30 min before ANP. AP-1 
DNA binding activity was determined by EMSA as described under Materials and Methods. The 
figure shows one representative shift out of three independent experiments from different cell 
preparations with similar results. 
After the effectivity of U0126 to inhibit AP-1 DNA binding activity had been evidenced, the 
following experiment was performed to demonstrate the causal relationship between HO-1 
induction and ANP induced AP-1 activation. 
HUVEC were preincubated with U0126 (50 µmol/L) for 1 h, followed by stimulation with 
ANP (10-6 mol/L) for 5 h, in accordance with the maximum increase in HO-1 protein between 
4 and 6 h after ANP addition. Whole cell lysates were prepared and HO-1 protein was 
detected with a mouse anti-HO-1 antibody.  
The following Western blot shows that pretreatment with U0126 in fact completely abrogates 
ANP-induced HO-1 protein expression (figure 23), demonstrating the involvement of AP-1 in 
HO-1 upregulation by ANP. U0126 alone did not affect basal HO-1 protein levels. 
 
Figure 23: Inhibition of ANP-induced HO-1 protein expression by U0126 
Cells were either left untreated (Co) or treated with ANP (10-6 mol/L) for 5 h in the presence or 
absence of U0126 (50 µmol/L), which was added 1 h before ANP. HO-1 protein levels were 
determined by Western blot (Materials and Methods). The upper panel shows one representative blot 
out of three independent experiments from different cell preparations. The lower panel illustrates the 
densitometric evaluation of Western blot whereby data are expressed as x-fold of values of signal 
intensities obtained for untreated control cells. Data represent means ± SEM of three independent 
experiments. ∗∗p<0.01 and ∗p<0.05 represent significant differences compared to the values for ANP-
treated cells. 
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This result was confirmed by RT-PCR experiments performed with U0126 (50 µmol/L). The 
cells were preincubated with the inhibitor for 1 h, followed by stimulation with ANP (10–6 
mol/L) for up to 6 h. Consistent with the results at protein level, U0126 completely abrogated 
the expression of HO-1 mRNA induced by ANP at all time points (figure 24). 
 
 
Figure 24: Inhibition of ANP-induced HO-1 mRNA expression by U0126 
HUVEC were either left untreated (Co) or treated with ANP (10-6 mol/L) for up to 6 h in the presence 
or absence of U0126 (50 µmol/L), which was added 1 h before ANP. totRNA was isolated and RT-
PCR was performed according to Materials and Methods. Amounts of cDNA employed in PCR were 
normalized versus GAPDH. The figure shows one representative agarose gel out of 3 independent 
experiments, the GAPDH gel is shown below. 
 
 
3.1.4.3 Involvement of the MAP kinases 
The experiments conducted so far revealed an induction of HO-1 mRNA and protein by ANP 
mediated via the transcription factor AP-1. The following experiments aimed to elucidate the 
mechanisms lying upstream and mediating the activation of AP-1. 
Since the family of MAP kinases is reported to mediate the activation of a large number of 
transcription factors and plays an important role in the regulation of AP-1, the role of this 
family of kinases in AP-1 activation was investigated. Western blots were performed with 
whole cell lysates, probed with phospho-specific antibodies, detecting the activated forms of 
these enzymes. 
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3.1.4.3.1 Effect of ANP on JNK 
Due to the knowledge that AP-1 is predominantly activated via c-jun N-terminal kinase 
(JNK), we investigated JNK for its potential involvement in the activation of AP-1 by ANP. 
As shown in figure 25, ANP significantly elevated JNK activity (p54 and p46) in a time-
dependent fashion, with maximal activation occurring after 30 min, suggesting this action to 
be crucial in the regulation of AP-1 activity. 
 
 
Figure 25: Induction of JNK phosphorylation by ANP 
HUVEC were either left untreated (Co) or treated with ANP (10-6 mol/L) for 15 min up to 60 min. 
Phosphorylation of JNK was investigated by performing Western blots with phospho specific 
antibodies (Materials and Methods). The upper panel shows one representative blot out of six 
experiments with similar results. The lower panel represents the densitometric quantification of signal 
intensities of six independent blots. Data show mean ± SEM with ∗∗ p<0.01 and ∗ p<0.05 significantly 
different from values seen in untreated control cells. 
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The Western blot results presented above suggest a possible role for JNK in the induction of 
HO-1 by ANP. To demonstrate a causal relationship between this MAP kinase and HO-1, we 
investigated the influence of a specific inhibitor of the JNK pathway on HO-1 induction by 
ANP. 
The inhibitor of JNK activity, SP600125 (10 µmol/L) completely abrogated ANP (10-6 
mol/L)-induced expression of HO-1 protein, when preincubated for 1 h, providing evidence 
for the crucial role of this MAPK for the upregulation of HO-1 by ANP (figure 26). The 
inhibitor alone had no effect on HO-1 protein. 
 
 
Figure 26: Effect of the specific JNK inhibitor SP600125 on HO-1 induction by ANP 
HUVEC were either kept in medium alone (Co), in medium with SP600125 (10 µmol/L), or in 
medium containing ANP (10-6 mol/L) in the presence or absence of SP600125 (10 µmol/L) for 5 h. 
SP600125 was added to the cells 1 h prior to ANP. Expression of HO-1 protein was analyzed by 
Western blot as described under Materials and Methods. The upper panel shows one representative 
Western blot out of three independent experiments with different cell preparations. The densitometric 
quantification of signal intensities is illustrated below. Data are expressed as x-fold increase compared 
to untreated control and show mean ± SEM of three experiments. ∗∗ p<0.01 significantly different 
from values for ANP-treated cells. 
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3.1.4.3.2 Effect of ANP on ERK 
Due to the controversially discussed role of ERK activation in HO-1 induction (Numazawa et 
al. 1997, Chen et al 2000, Alam et al. 2000), we tested ERK1/2 for its possible participation in 
ANP-mediated human HO-1 induction. As shown in figure 27 ANP was also able to 
significantly induce phosphorylation of this MAPK (p42 and p44) in a time-dependent 
manner with maximal activation occuring between 15 and 30 min. 
 
Figure 27: Induction of ERK phosphorylation by ANP 
Cells were either left untreated (Co) or treated with ANP (10-6 mol/L) for up to 1 h. Whole cell lysates 
were prepared and ERK phosphorylation was detected by performing Western blots with phospho 
specific antibodies as described under Materials and Methods. The upper panel shows one 
representative blot out of five independent experiments with similar results. The histogramm shows 
the densitometric evaluation of Western blots expressed as x-fold of values obtained for untreated 
cells. Data represent means ± SEM out of five independent experiments with different cell 
preparations with ∗ p<0.05 significantly different compared to untreated cells.  
 
The data presented above suggest a possible participation for ERK1/2 in the induction of  
HO-1 by ANP in addition to JNK. To demonstrate a causal relationship between ERK1/2 and 
HO-1, we investigated the influence of a specific inhibitor of the ERK pathway on HO-1 
upregulation by ANP. 
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As shown in figure 28, cotreatment of the cells with the MEK1/2 inhibitor PD98059 (50 
µmol/L) and ANP (10-6 mol/L) resulted in a significantly attenuated HO-1 induction, 
confirming a participation of ERK1/2 in this signaling pathway. The inhibitor alone did not 
influence HO-1 protein levels. 
 
Figure 28: Effect of the specific MEK 1/2 inhibitor PD98059 on HO-1 induction by ANP 
HUVEC were either left untreated (Co), or treated with ANP (10-6 mol/L) for 5 h in the presence or 
absence of PD98059 (50 µmol/L), which was added to the cells 1 h prior to ANP. HO-1 protein levels 
were determined by performing Western blots (Materials and Methods). The upper panel shows one 
representative blot out of three independent experiments with different cell preparations. In the 
densitometric quantification illustrated below, values for untreated cells were referred to as 1. Data 
show mean ± SEM of three experiments with ∗ p<0.05 significantly different compared to values for 
control cells. 
 
3.1.4.3.3 Effect of ANP on p38 MAPK 
Another MAP kinase investigated in this context was phospho p38 MAPK.  
Western blots were performed according to ERK and JNK/SAPK with whole cell lysates and 
phospho specific antibodies. In contrast to the other two MAP kinases, ANP did not influence 
the phosphorylation of p38 MAPK (figure 29). 
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Figure 29: Influence on p38 MAPK phosphorylation by ANP 
HUVEC were treated with ANP (10-6 mol/L) for 5 min up to 60 min or with TNF (10 ng/mL) for 30 
min. Phosphorylation of p38 MAPK was determined by performing Western blots with phospho 
specific antibodies (Materials and Methods). The upper panel shows one representative blot out of 
four independent experiments with similar results. The lower panel shows the densitometric evaluation 
of Western blots expressed as x-fold of values obtained for untreated cells. Data represent means ± 
SEM out of 4 independent experiments with different cell preparations. 
Taken together, these results demonstrate a significant elevation in JNK and ERK 1/2 activity 
in ANP-treated HUVEC, suggesting the involvement of these two MAP kinases in ANP-
mediated human HO-1 induction, whereas no effect could be detected on p38 MAPK. 
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3.1.5 Potential protective effect of ANP on TNF-α-induced 
cytotoxicity 
HO-1 induction has previously been reported to confer resistance against TNF-α-induced 
cytotoxicity (Polte et al. 2000, Brouard et al. 2000). After investigation of the signaling 
pathway leading to increased HO-1 protein expression in ANP-treated cells, the next aim was 
to clarify whether ANP could confer protection of HUVEC against cytotoxic stimuli via 
induction of this heat shock protein. Since TNF-α can induce both apoptotic and necrotic cell 
death, the following experiments were performed to investigate typical parameters of 
apoptosis and necrosis in TNF-α-treated cells and the potential influence of ANP. 
3.1.5.1.1 Morphological investigations 
The first observation pointing to a possible cytoprotective potential of ANP was that 
cotreatment of the cells with ANP and TNF abrogated the morphological changes caused by 
TNF treatment. Untreated HUVEC displayed the typical cobblestone morphology and grew in 
confluent monolayers. Treatment with TNF-α (10 ng/mL) for 16 h resulted in pronounced 
changes of cell morphology. The cells became elongated and the monolayer started to form 
gaps. ANP could almost completely abrogate these TNF-α-induced morphological changes 
(figure 30). 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: Influence of ANP on TNF-α induced morphological changes 
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HUVEC were either left untreated (Co) or treated with TNF-α (5 nmol/L, or 10 nmol/L) for 16 h in 
the absence or presence of ANP (10-6 mol/L), which was added to the cells simultaneously. Cells were 
stained with Haemacolor according to the manufacturer’s instructions. Photographs were taken with 
a 100-fold magnification and show representative pictures out of three independent experiments. 
3.1.5.1.2 Fluorescence microscopy after staining with Hoechst 33342 
Besides well-described morphological changes, TNF-α induces cell death which was 
analysed on the basis of different parameters of cytotoxicity in the following experiments. 
The first experiment performed in this context aimed to elucidate the mode of cell death 
induced by TNF-α in HUVEC. In order to differentiate between apoptotic and necrotic cell 
death, HUVEC were stained with Hoechst 33342 and examined by fluorescence microscopy. 
As shown in figure 31, HUVEC treated with TNF-α (10 ng/mL) for 16 h exhibited the typical 
morphological hallmarks of apoptosis: TNF-α lead to pronounced accumulation of cells 
displaying chromatin condensation, nuclear fragmentation and formation of apoptotic bodies. 
These characteristic markers for apoptotic cell death could predominantly be observed in cells 
floating in the culture medium, consistent with the fact that HUVEC become detached when 
dying. Untreated cells were characterized by a weaker, evenly distributed fluorescence. 
Cotreatment of the cells with ANP (10-6 mol/L) and TNF-α did not seem to reduce the 
number of cells displaying chromatin condensation. ANP was added to the cells either 
simultaneously (not shown) or 4 h prior to TNF-α since the maximal induction of the 
potentially cytoprotective HO-1 protein was observed between 4 and 6 h after treatment with 
ANP. No difference in the rate of cytotoxicity could be detected between these two 
treatments. 
 
 
 
 
 
 
Figure 31: Influence of ANP on TNF-α -induced chromatin condensation 
HUVEC were either cultured in medium alone (Co) or in medium containing TNF-α (10 ng/mL) in 
the presence or absence of ANP (10-6 mol/L) for 16 h, whereby ANP was preincubated for 4 h. Cells 
were stained with Hoechst 33342 as described in Materials and Methods and examined using a Zeiss 
fluorescence microscope. Pictures presented above were taken with a 200-fold magnification and 
show representative photographs out of three independent experiments. 
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3.1.5.2 Caspase activity measurement 
For the analysis of apoptosis it is required to determine several parameters characteristic for 
apoptotic cell death. In order to investigate the influence of ANP on TNF-α-induced 
apoptosis, caspase-3 like activity measurements were performed, as a specific marker for 
apoptotic cell death. First, a time course for TNF-α-induced caspase activation was carried 
out to find the suitable time point for measuring enzyme activity.   
The time course shown in figure 32 demonstrated that a significant activation of caspase-3- 
like activity occurred after 16 h and 20 h, beginning to decline afterwards. 
 
 
Figure 32: Time course of caspase activation by TNF-α 
HUVEC were either left untreated (Co) or treated with TNF-α (10 ng/mL) for up to 24 h. Caspase-3- 
like activity was determined as described under Materials and Methods. Results are expressed as x-
fold induction of caspase-3-like activity per µg protein compared to untreated control cells. Data show 
means ± SEM of two independent experiments performed in sixlets.∗∗∗ p<0.001 significantly 
different from untreated control cells (Co), 
Since an incubation period with TNF-α for 16 h represented a suitable experimental set-up, 
further measurements were performed at this time point. To test the influence of ANP on 
TNF-α-induced caspase activation, HUVEC were treated with TNF-α for 16 h in the presence 
or absence of ANP, which was preincubated for 4 h or added to the cells simultaneously, and 
enzyme activity measurements were performed. 
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As shown in figure 33, treatment of the cells with TNF-α (10 ng/mL) resulted in marked 
increases in caspase-3-like activity. Neither simultaneous addition of ANP (10-6 mol/L) nor 
pretreatment for 4 h significantly attenuated caspase-3 activity levels. 
 
 
Figure 33: Effect of ANP on TNF- α induced caspase-3 activation 
Caspase-3 like activity was determined in untreated cells (Co) and in cells treated with TNF-α (10 
ng/mL) for 16 h in the presence or absence of ANP (10-6 mol/L), added to the cells 4 h prior to TNF-α 
(p.) or simultaneously (s.), as described under Materials and Methods. Caspase activity in TNF-α- 
treated cells was referred to as 100%. Data show mean ± SEM of four independent experiments with 
different cell preparations performed in triplicates with ∗∗∗ p<0.001 significantly different compared 
to the values obtained in TNF-α-activated cells. 
 
3.1.5.3 Propidium iodide staining – Flow Cytometry 
Another marker for apoptotic cell death is the fragmentation of the chromatin in multiples of 
180 bp occurring downstream of caspase-3 activation. Determination of cells with subdiploid 
DNA content was performed by flow cytometry after permeabilization and staining with 
propidium iodide. 
These experiments confirmed the results obtained by caspase activity measurement, as 
described under 3.1.4.2. Treatment of HUVEC with TNF-α (10 ng/mL) for 16 h resulted in a 
marked induction of apoptotic cell death, as assessed by the percentage of cells with sub-
diploid DNA content. ANP pretreatment (10-6 mol/L) for 4 h did not significantly reduce this 
TNF-α-induced apotosis (figure 34). 
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Figure 34:  Influence of ANP on TNF-α-induced DNA fragmentation/subdiploid DNA 
 content 
HUVEC were either cultured in medium alone (Co) or in medium containing TNF-α (10 ng/mL, 16 h) 
with or without pretreatment with ANP (10–6 mol/L) for 4 h. The percentage of cells with subdiploid 
DNA content was determined by flow cytometry after staining with propidium iodide as described 
under Materials and Methods. The results illustrated in the graph above represent the fraction of viable 
cells with regular DNA content, whereby the viability of untreated control cells was referred to as 
100%. Data show means ± SEM of five independent experiments with different cell preparations 
performed in triplicates with ∗∗∗ p<0.001 significantly different from the values obtained for control 
cells, n.s. not significantly different from TNF-α-treated cells. 
 
3.1.5.4 MTT Test 
After analysis of typical apoptotic characteristics induced by TNF, the following experiment 
was performed in order to acquire not only apoptotic but also necrotic cell death. 
Mitochondrial respiratory activity was assessed by MTT test, recording also cells dying 
independently from apoptotic characteristics. 
Treatment of HUVEC with TNF-α (10 ng/mL) significantly decreased mitochondrial activity. 
Consistent with the results of the previous experiments, pretreatment with ANP (10-6 mol/L) 
did again not affect this cell death parameter (figure 35). 
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Figure 35: Effect of ANP on TNF-α-induced decrease in mitochondrial activity 
Cell viability of untreated cells (Co) and of cells treated with TNF-α (10 ng/mL) for 16 h in the 
presence and absence of ANP (10-6 mol/L, preincubated for 4 h) was assessed by MTT test. Viability 
of cells is expressed as [%] viability of untreated cells, referred to as 100%. Results illustrated in the 
graph above represent means ± SEM of four independent experiments from different cell preparations 
performed in triplicates. ∗∗ p<0.01 represents significant difference compared to the values seen in 
untreated cells, n.s. not significantly different from TNF-α-treated cells. 
Taken together, the results of the experiments conducted to determine apoptotic and necrotic 
cell death revealed that ANP-induced HO-1 protein expression does not confer protection 
against TNF-α-induced cytotoxicity. 
 
3.1.6 Potential protective effect of ANP on etoposide-induced 
cytotoxicity 
As demonstrated in the experiments described above, no protective effect of ANP could be 
detected in TNF-α-treated cells. This is likely to be due to the inhibition of TNF-α-induced 
activation of the potentially cytoprotective NF-κB by ANP. Brouard et al. recently reported a 
crucial role for NF-κB for HO-1 mediated cytoprotection (Brouard et al. 2002). ANP has been 
identified as an inhibitor of TNF-α-induced NF-κB activation in endothelial cells (Kiemer et 
al. 2002e). This inhibitory action might be responsible for the lack of protection conferred by 
ANP-induced HO-1. Therefore the following experiments were performed to investigate the 
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influence of ANP on the apoptotic effects of etoposide on HUVEC, a compound that does not 
induce NF-κB, as demonstrated by etoposide time course experiments followed by 
electrophoretic mobility shift assay (data not shown). Apoptosis was investigated on the basis 
of Hoechst staining, caspase activity measurements, and propidium iodide staining. 
3.1.6.1 Fluorescence microscopy after staining with Hoechst 33342 
Figure 36 shows the results of Hoechst staining after treatment of HUVEC with etoposide in 
the presence and absence of ANP.  
Untreated cells were homogeneously stained with the dye and exhibited a weaker, evenly 
distributed fluorescence. Etoposide (200 µmol/L, 16 h) induced distinct apoptotic cell death in 
HUVEC as assessed by detection of the characteristic morphological hallmarks of apoptosis 
(chromatin condensation, nuclear fragmentation, formation of apoptotic bodies). Cotreatment 
of the cells with ANP (10-6 mol/L) did not reduce the number of cells featuring chromatin 
condensation. Again, no difference could be observed between simultaneous addition of ANP 
and etoposide and preincubation with ANP for 4 h before addition of etoposide 
 
 
 
 
 
Figure 36: Influence of ANP on etoposide-induced chromatin condensation 
HUVEC were either cultured in medium alone (Co) or in medium containing etoposide (200 µmol/L) 
in the presence or absence of ANP (10-6 mol/L) for 16 h, whereby ANP was preincubated for 4 h. 
Cells were stained with Hoechst 33342 as described in Materials and Methods and examined using a 
Zeiss fluorescence microscope. Pictures presented above were taken with a 400-fold magnification 
and show representative photographs out of three independent experiments. 
 
 
3.1.6.2 Caspase activity measurement 
The results of caspase activity measurements in etoposide-treated HUVEC are presented in 
figure 37. Etoposide (200 µmol/L) led to a considerable increase in caspase-3-like activity 
after 16 h. Neither simultaneous addition of ANP (10-6 mol/L) nor pretreatment for 4 h 
significantly inhibited etoposide-induced increases in caspase-3-like activity. 
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Figure 37: Effect of ANP on etoposide-induced caspase-3 activation 
HUVEC were either left untreated (Co) or treated with etoposide (200 µmol/L) in the presence or 
absence of ANP (10-6 mol/L), which was added to the cells 4 h prior to etoposide (p.) or 
simultaneously (s.). Caspase-3 like activity measurements were performed as described under 
Materials and Methods. Caspase activity in etoposide-treated cells was set as 100%. Results show 
mean ± SEM of four independent experiments with different cell preparations performed in triplicates. 
∗∗∗ p<0.001 represents significant difference compared to the values obtained for etoposide-treated 
cells. 
 
3.1.6.3 Propidium iodide staining – Flow Cytometry 
Cells were permeabilized, stained with propidium iodide and the DNA content was 
determined by flow cytometry. Treatment of HUVEC with etoposide (200 µmol/L) for 16 h 
lead to a marked increase in the number of cells possessing subdiploid DNA content. ANP 
(10-6 mol/L), added to the cells 4 h prior to etoposide did not significantly attenuate etoposide-
induced apoptotic cell death consistent with the results presented above (figure 38). 
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Figure 38:  Influence of ANP on etoposide-induced DNA fragmentation/sub-diploid DNA 
content 
Cells were either untreated (Co) or treated with etoposide (200 µmol/L, 16 h). ANP (10-6 mol/L) was 
given to the cells 4 h before etoposide. Sub-diploid DNA content was measured by flow cytometry as 
described under Materials and Methods. Results are expressed as percentage of viable cells, 
possessing regular DNA-content, with 100% representing values for untreated cells. Data show means 
± SEM of five independent experiments from different cell preparations performed in triplicates. ∗∗∗ 
p<0.001 significantly different compared to the values obtained for untreated cells, n.s. not 
significantly different from etoposide-treated cells. 
 
Taken together, these results demonstrate that upregulation of HO-1 protein expression by 
ANP does not confer resistance to etoposide-induced apoptosis. 
120
100
80
60
40
20
0
Co                    etoposide              etoposide+ANP
[%
] v
ia
bi
lit
y
∗∗∗ ∗∗∗
n.s.
[%
] v
ia
bi
lit
y
3 RESULTS 
97 
 
3.2 Aspirin 
3.2.1 Induction of HO-1 protein expression by aspirin 
In addition to the well-known effects of aspirin in the therapy of pain and inflammation, its 
beneficial therapeutic effect in vascular desease has been increasingly recognized (Numano et 
al. 1995, Lauer et al. 2002). Due to the central role of endothelial cell apoptosis in the 
pathophysiology of atherosclerosis (Choy et al. 2001, Guevara et al. 2001) and due to the 
cytoprotective virtues of HO-1 protecting endothelial cells from apoptosis (Siow et al. 1999), 
the following experiments aimed to elucidate whether aspirin influences the expression of 
HO-1 in HUVEC and to determine its potency to confer protection against endothelial 
apoptosis. 
In order to investigate the effect of aspirin on HO-1, time and concentration courses were 
performed and protein levels were determined by Western blot. 
As shown in figure 39, treatment with aspirin (100 µmol/L) resulted in a marked increase in 
HO-1 protein expression in a time-dependent manner with maximal induction occurring 
between 4 h and 8 h after treatment.  
 
 
Figure 39: Time-dependent induction of HO-1 protein expression by aspirin 
HUVEC were either left untreated (Co) or treated with aspirin (100 µmol/L) for the indicated times. 
HO-1 protein levels were determined by Western blot. The figure shows one representative blot out of 
three independent experiments from different cell preparations. 
 
 
The induction of HO-1 protein by aspirin is also dose-dependent with maximum protein 
levels being detectable at a concentration of 100 µmol/L (figure 40). 
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Figure 40: Dose-dependent induction of HO-1 protein expression by aspirin 
Cells were treated with different concentrations of aspirin. Western blot was performed as described 
under Materials and Methods. One representative blot out of three independent experiments from 
different cell preparations is illustrated above. 
 
 
3.2.2 Molecular mechanism involved in the HO-1 induction by 
aspirin 
In the following experiments, the molecular mechanisms mediating the upregulation of HO-1 
protein expression by aspirin were investigated.  
3.2.2.1 Influence of aspirin on HO-1 mRNA 
The objective of the following experiment was to determine whether the regulation of HO-1 
protein expression occurs at the transcriptional level. In this regard, cells were treated with 
aspirin for different periods of time and totRNA was isolated. The effect of aspirin on HO-1 
mRNA was determined by performing semi-quantitative RT-PCR experiments with specific 
primers for human HO-1. Figure 41 shows a marked increase in HO-1 mRNA expression by 
aspirin (100 µmol/L) treatment, suggesting a transcriptional regulation of HO-1. 
 
 
Figure 41: Time-dependent effect of aspirin on HO-1 mRNA expression 
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totRNA was isolated from untreated HUVEC (Co) or after treatment of cells with aspirin (100 
µmol/L) for the indicated times. RT-PCR was performed with specific primers for human HO-1 as 
described under Materials and Methods. Amounts of cDNA employed in PCR experiments were 
compared to GAPDH. The figure shows one representative agarose gel out of three independent 
experiments from different cell preparations. 
 
3.2.2.2 Influence of aspirin on activator protein-1 
After investigating the regulation of HO-1 by aspirin in HUVEC at the mRNA and protein 
level, the following experiments aimed to clarify the signaling cascade mediating these 
effects. Activation of AP-1 transcription factor has previously been suggested to be important 
in the transcriptional induction of HO-1 (Wiesel et al. 2000). Therefore, we investigated a 
potential effect of aspirin on the activation of the DNA-binding activity of this transcription 
factor. For this purpose, nuclear protein was isolated from aspirin treated cells and binding to 
a radioactively labeled promotor sequence was determined (Materials and Methods).  
3.2.2.2.1 Activation of AP-1 by aspirin 
To investigate the influence of aspirin on the DNA-binding activity of AP-1, cells were 
treated with aspirin for different periods of time and EMSA was performed (figure 42). 
Treatment of HUVEC with aspirin (100 µmol/L) in fact resulted in a pronounced time-
dependent activation of AP-1 DNA-binding activity as assessed by EMSA (figure 42). This 
effect of aspirin on AP-1 was maximal after 60 min. 
 
 
Figure 42: Time-dependent activation of AP-1 DNA-binding activity by aspirin 
HUVEC were either left untreated (Co) or treated with aspirin (100 µmol/L) for the indicated times. 
AP-1 EMSA was performed as described under Materials and Methods. Results show one 
representative EMSA out of three independent experiments from different cell preparations. 
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The results presented in figure 43 show that this activation of AP-1 DNA-binding activity by 
aspirin was dose-dependent, with maximal activation occurring at a concentration of 100 
µmol/L. 
 
Figure 43: Dose-dependent activation of AP-1 DNA-binding activity by aspirin 
Cells were treated with aspirin in different concentrations (10-200 µmol/L) for 1 h. AP-1 DNA-
binding activity was assessed by EMSA (Materials and Methods). Results show one representative 
EMSA out of three independent experiments performed with different cell preparations. 
 
 
3.2.2.2.2 Inhibition of AP-1 DNA-binding activity by U0126 
The results presented above suggest a participation of the transcription factor AP-1 in the 
signal transduction of aspirin leading to increased expression of HO-1 protein. The direct 
causal relationship for AP-1 activation in aspirin-induced HO-1 upregulation was 
demonstrated by the use of U0126, a pharmacological inhibitor of AP-1 activity. HUVEC 
were treated with aspirin in the presence and absence of U0126 and the effect of this inhibitor 
on HO-1 protein expression was determined by Western blot. 
As shown in figure 44, pretreatment of HUVEC with U0126 (50 µmol/L) for 1 h abrogated 
aspirin-induced (100 µmol/L) HO-1 expression. U0126 alone did not affect basal HO-1 
protein levels. 
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Figure 44: Effect of the AP-1 inhibitor U0126 on aspirin-induced HO-1 expression 
HUVEC were either left untreated (Co) or treated with aspirin (100 µmol/L) for 5 h in the presence or 
absence of U0126 (50 µmol/L), which was added to the cells 1 h prior to aspirin. HO-1 protein levels 
were determined by performing Western blots as described under Materials and Methods. The blot 
presented in the upper panel shows one representative out of three independent experiments from 
different cell preparations. The graph in the lower panel illustrates the densitometric evaluation of 
signal intensities of three Western blots, expressed as x-fold induction compared to untreated control 
cells (Co). ∗p<0.05 represents significant difference compared to control, +p<0.05 significantly 
different from aspirin-treated cells. 
 
3.2.2.3 Involvement of the MAP kinases 
The investigations carried out so far demonstrated that aspirin upregulates HO-1 at the mRNA 
and protein level, mediated via the transcription factor AP-1. The mechanisms upstream of 
AP-1, involved in the mediation of these effects were studied in the following experiments. In 
order to investigate a potential participation of MAP kinases in this signaling pathway 
Western blots were performed with specific antibodies against the activated form of these 
enzymes. 
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3.2.2.3.1 Effect of aspirin on JNK/SAPK 
Due to the knowledge that AP-1 is activated via c-jun N-terminal kinase (JNK), we assessed 
JNK activation by the use of phospho-specific antibodies. Treatment of HUVEC with aspirin 
(100 µmol/L) in fact significantly elevated JNK activity in a time-dependent manner as shown 
in figure 45. Maximum activation occurred at approx. 30 min after addition of aspirin. 
 
Figure 45: Time-dependent activation of JNK/SAPK by aspirin 
HUVEC were treated with aspirin (100 µmol/L) for 15-60 min or with TNF-α (10 ng/mL) for 30 min. 
Activated JNK (p46 and p54 isoforms) was determined by Western blot as described under Materials 
and Methods using phospho-specific antibodies. Results presented in the upper panel show one 
representative blot out of three independent experiments from different cell preparations. The lower 
panel illustrates the densitometric evaluation of three experiments. Data are expressed as x-fold of 
signal intensities of control cells and show means ± SEM with ∗p<0.05 and ∗∗p<0.01 representing 
significant differences compared to the values seen in untreated cells. 
 
The results of the Western blot experiments presented above point to a possible role for the 
JNK pathway in the induction of HO-1 by aspirin. The participation of JNK in aspirin 
signaling was confirmed by employing the specific JNK inhibtor SP600125. 
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Pretreatment of HUVEC with SP600125 (10 µmol/L) for 1 h completely abolished HO-1 
expression induced by aspirin (100 µmol/L) treatment as shown in figure 46. 
 
 
Figure 46: Effect of the specific JNK inhibitor SP600125 on HO-1 induction by aspirin 
HUVEC were either left untreated (Co), treated with SP600125 (10 µmol/L, SP) or with aspirin (100 
µmol/L, 5 h) in the presence and absence of SP600125 (10 µmol/L, SP), which was added to the cells 
1 h prior to addition of aspirin. HO-1 protein levels were determined by Western blot (Materials and 
Methods). The upper panel shows one representative blot out of three independent experiments from 
different cell preparations. The lower panel illustrates the densitometric evaluation of three 
experiments. Data are expressed as x-fold increase in signal intensities compared to the values 
obtained for untreated control cells and show means ± SEM. ∗∗∗p<0.001 represents significant 
difference compared to the values seen in untreated cells, +++p<0.001 significantly different from 
cells treated with aspirin alone. 
 
3.2.2.3.2 Effect of Aspirin on ERK 
In order to determine whether ERK activation plays a role in aspirin-mediated human HO-1 
upregulation ERK1/2 protein levels were analysed by performing Western blot analysis of 
whole cell lysates using a phospho-specific antibody against the p42 and p44 isoform of ERK. 
These experiments revealed that aspirin (100 µmol/L) did not affect ERK1/2 activity (figure 
47) whereas TNF-α, known to induce ERK activity, lead to a significant phosphorylation of 
both ERK isoforms. 
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Figure 47: No effect of aspirin on ERK activation 
Cells were treated with aspirin (100 µmol/L) for 15-60 min or with TNF-α (10 ng/mL) for 30 min. 
Activated ERK (p42 and p44 isoforms) was assessed by performing Western blot as described under 
Materials and Methods using phospho-specific antibodies. The upper panel shows one representative 
blot out of three independent experiments from different cell preparations. The lower panel illustrates 
the densitometric evaluation of three experiments. Data are expressed as x-fold increase in signal 
intensities compared to the values obtained for untreated control cells and show means ± SEM. 
 
 
3.2.2.3.3 Effect of aspirin on p38 MAPK 
Another member of the MAPK family investigated in this context was phospho p38 MAPK. 
Western blots were performed according to ERK and JNK with whole cell lysates and 
phospho-specific antibodies.  
As shown in figure 48 no effect of aspirin (100 µmol/L) on the activation of this MAPK 
could be detected. 
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Figure 48: No impact of aspirin on p38 MAPK activation 
HUVEC were either left untreated (Co) or treated with aspirin (100 µmol/L) for the indicated times 
(15-60 min) or with TNF-α (10 ng/mL) for 30 min. Activation of p38 MAPK was assessed by 
performing Western blots as described under Materials and Methods using phospho-specific 
antibodies. Results presented in the upper panel show one representative blot out of three independent 
experiments from different cell preparations. The lowel panel shows the densitometric evaluation of 
three experiments. Data are expressed as x-fold increase in signal intensities compared to the values 
obtained for untreated control cells and show means ± SEM. 
 
 
Western blot analysis of the MAPK pathways demonstrated an involvement of JNK in 
aspirin-induced HO-1 upregulation. 
Since aspirin did neither exert an activation of ERK nor of p38 MAPK, a role for these two 
MAP kinases in HO-1 induction by aspirin could be ruled out. 
 
 
 
 
0           10            20           30           40        50 60          70
2.5
2
1.5
1
0.5
0
fo
ld
 in
cr
e a
se
time [min]
Co               15              30           60        TNF
time after aspirin [min]
phospho p38
3 RESULTS 
106 
3.2.2.4 cGMP production after stimulation with aspirin 
Due to reports about increases in intracellular cGMP after treatment with aspirin (De la Cruz 
et al. 2000, Sánchez de Miguel et al. 1998, Schachter et al. 1997) the next investigations 
aimed to determine whether accumulation of intracellular cGMP regulates aspirin-induced 
expression of HO-1 protein. 
To differentiate between cGMP produced by the soluble and the particulate guanylate cyclase, 
an inhibitor of sGC, LY83583, was tested for its influence on cGMP production. 
As shown in figure 49, treatment of HUVEC with aspirin did not affect total (intracellular 
plus extracellular) cGMP levels, suggesting that this second messenger is not involved in the 
mediation of aspirin-induced HO-1 upregulation. ANP (10-6 mol/L, 20 min) and SNP (10 
µg/mL), activators of the particulate and the soluble guanylate cyclase, respectively, served as 
positive control for the reliability of the EIA and the specificity of the inhibitor LY 83583 (see 
3.1.1.2). 
Treatment of HUVEC with ANP for 20 min lead to significantly elevated cGMP levels. This 
increase was not abolished by preincubation with LY 83583, consistent with the activation of 
the particulate guanylate cyclase by ANP. Exposure of the cells to SNP for 20 min 
significantly activated the soluble guanylate cyclase, implicating a marked rise in the amount 
of cGMP, which was almost completely abrogated by LY 83583.  
Figure 49: Influence of aspirin on cGMP levels 
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cGMP levels were determined in untreated cells (Co) and in cells treated with ANP (10-6 mol/L, 20 
min), SNP (10 µg/mL) and aspirin (100 µmol/L) for the indicated times as described under Materials 
and Methods. IBMX (0.5 mmol/L) was given to the culture medium 10 min before the addition of the 
respective stimulus to inhibit phosphodiesterase activity. Results illustrated in the upper panel are 
expressed as x-fold increase compared to the cGMP levels found in untreated control cells and 
represent one representative out of two independent experiments from different cell preparations 
performed in triplicates. Data show mean ± SEM of one experiment with ∗∗ p<0.01 and ∗ p<0.05 
representing significant differences compared to untreated control cells, ++ p<0.01 and + p<0.05 
significantly different compared to cells treated without LY 83583. 
 
3.2.3 Potential protective effect of aspirin on TNF-α-/etoposide-
induced cytotoxicity 
The next investigations performed in this context aimed to determine whether upregulation of 
the potentially protective heat shock protein HO-1 by aspirin treatment was associated with 
protection against cytotoxic stimuli. 
3.2.3.1 Microscopic investigation 
In a first experiment it was investigated whether aspirin could affect TNF-α- or etoposide-
induced chromatin condensation and nuclear fragmentation representing specific markers for 
apoptotic cell death. HUVEC were stained with Hoechst 33342 and examined by fluorescence 
microscopy. 
The photographs presented in figure 50 demonstrate that treatment with TNF-α (10 ng/mL) 
as well as with etoposide (200 µmol/L) for 16 h lead to a marked induction of apoptosis in 
HUVEC, associated with distinct condensation of the chromatin, fragmentation of the DNA 
and occurrence of apoptotic bodies. Untreated cells displayed a weaker, evenly spread 
fluorescence. Pretreatment of the cells with aspirin (100 µmol/L) for 4 h did not influence the 
proportion of cells exhibiting the typical hallmarks of apoptosis. 
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Figure 50: Influence of aspirin on TNF-α- or etoposide-induced chromatin condensation 
HUVEC were either cultured in medium alone (Co) or in medium containing TNF-α (10 ng/mL) or 
etoposide, respectively, in the presence or absence of aspirin (100 µmol/L) for 16 h. Aspirin was 
preincubated for 4 h. Cells were stained with Hoechst 33342 as described in Materials and Methods 
and examined using a Zeiss fluorescence microscope. Pictures presented above were taken with a 200-
fold magnification and show representative photographs out of three independent experiments. 
3.2.3.2 Caspase activity measurement 
The following measurements of caspase-3-like activity aimed to quantify the influence of 
aspirin on TNF-α- or etoposide-induced apoptosis. HUVEC were preincubated with aspirin 
(100 µmol/L) for 4 h and afterwards treated with TNF-α (10 ng/mL) or etoposide (200 
µmol/L) for 16 h. Treatment with TNF-α and etoposide lead to a marked increase in   
caspase-3-like activity. Pretreatment with or simultaneous addition of ANP (10-6 mol/L) did 
not significantly attenuate elevated enzyme activity after TNF-α- (figure 51, panel A) or 
etoposide-treatment (figure 51, panel B), respectively. 
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          B 
Figure 51: Effect of aspirin on TNF- α-/etoposide-induced caspase-3 activation 
Caspase-3-like activity was determined in untreated cells (Co) and in cells treated with TNF-α (10 
ng/mL) or etoposide (200 µmol/L), respectively, for 16 h in the presence or absence of aspirin (100 
µmol/L) as described under Materials and Methods. Aspirin was preincubated for 4 h (p.) or added 
simultaneously (s.) with apoptosis inducers. Caspase activity in TNF-α- or etoposide-treated cells was 
referred to as 100%. Data show mean ± SEM of three independent experiments with different cell 
preparations performed in triplicates with ∗∗∗ p<0.001 significantly different compared to the values 
obtained in TNF-α- or etoposide-activated cells, respectively, n.s. no significant difference from cells 
exposed to TNF-α or etoposide. 
 
 
3.2.4 Characterization of NF-κB activation by TNF-α 
Brouard et al. recently described that NF-κB activation is crucial for HO-1 to exert protective 
effects on TNF-α-induced endothelial apoptosis (Brouard et al. 2002). Taking into account 
that aspirin has been demonstrated to be an inhibitor of NF-κB activation (Weber et al. 1995, 
Tegeder et al. 2001, Joussen et al. 2002), the lack of protection from TNF-α-induced 
cytotoxicity conferred by aspirin-induced HO-1 could be ascribed to attenuated NF-κB 
activation in aspirin-treated cells. The following experiments therefore aimed to elucidate the 
effect of aspirin on TNF-α-induced NF-κB activation in our cell model. 
HUVEC were treated with TNF-α for 1 h in the presence or absence of aspirin (100 µmol/L, 
preincubated for 30 min) and NF-κB DNA-binding activity was assessed by EMSA.  
Figure 52 shows that TNF-α lead to a pronounced activation of NF-κB. Pretreatment with 
aspirin significantly attenuated the activation of this transcription factor, suggesting this 
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inhibitory effect to be a possible cause for the lack of protection exerted by aspirin-induced 
HO-1. 
 
 
Figure 52: Effect of aspirin on TNF-α-induced activation of NF-κB 
EMSA (Materials and Methods) was performed with untreated cells (Co) and with cells treated with 
TNF-α (10 ng/mL) in the presence or absence of aspirin (100 µmol/L, preincubated for 30 min). 
Results in the upper panel show one representative shift out of five independent experiments from 
different cell preparations. The graph in the lower panel illustrates the quantitative evaluation of five 
independent experiments, performed by phosphorimaging. Data are expressed as x-fold increase in 
signal intensities compared to untreated control cells which were referred to as 1.∗∗p<0.01, ∗p<0.05 
represent significant differences compared to the values obtained for untreated control cells. 
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Due to their exposed localization in the vasculature, endothelial cells play a critical role in the 
development of pathological conditions, such as inflammation and atherosclerosis. Under 
inflammatory conditions, endothelial cells become activated by exposure to proinflammatory 
stimuli, promoting vasoconstriction, leukocyte adhesion and activation, as well as coagulation 
and thrombosis. The cytokine TNF-α plays a key role in inflammatory disorders by 
upregulating the expression of adhesion molecules, promoting vascular permeability, 
inducing the release of vasoactive substances, and causing endothelial injury and apoptosis. 
Endothelial apoptosis is a critical event in the pathogenesis of atherosclerosis and contributes 
to the progression of inflammatory diseases by sustaining inflammation and promoting 
vascular thrombosis. In order to counteract cell damage caused by the inflammatory response, 
endothelial cells can upregulate a set of protective proteins, such as the members of the family 
of heat shock proteins. In this context, the effects of ANP and aspirin on the expression of 
HSP70 and HSP32 in HUVEC were investigated. 
4.1 ANP 
4.1.1 ANP induces HO-1 expression via activation of ERK and 
JNK MAP kinases and subsequent induction of AP-1 
DNA-binding activity 
The aim of the first section of this work was to investigate whether ANP could influence the 
expression of protective genes in endothelial cells and confer protection against TNF-α-
induced apoptosis. 
 
4.1.1.1 ANP induces HO-1 expression at the protein and mRNA level, but has 
no effect on HSP70 
The results of the present work demonstrated that ANP is able to upregulate the expression of 
HO-1 at the mRNA and protein level. The induction of HO-1 has been reported to be a stress 
inducible cytoprotective response counteracting a variety of pathophysiological states, such as 
oxidative stress (Poss and Tonegawa 1997a), ischemia-reperfusion injury (Clark et al. 2000), 
inflammation (Willis et al. 1996), and apoptosis (Foresti et al. 1999). Besides the classical 
stress-related inducers of HO-1 expression, involving proinflammatory cytokines and heavy 
metal ions, few other endogenous inducers of HO-1 have been described. Examples are low 
density lipoproteins (Siow et al. 1999), platelet-derived growth factor (Durante et al. 1999), 
and dopamine (Berger et al. 2000). However, molecular mechanisms mediating HO-1 
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induction by these endogenous regulators have not been elucidated yet. Our data therefore 
present for the first time a systematical characterization of the signaling events responsible for 
the induction of this cytoprotective protein by a cardiovascular hormone in a human cell 
system. 
Apart from HO-1, another important member of the family of heat shock proteins, HSP70, 
was investigated. Similar to HO-1, HSP70 has been shown to exert cytoprotective effects in a 
number of pathophysiological conditions, such as heat stress (Cumming et al. 1996), 
ischemia/reperfusion injury (Chen et al. 1997), sepsis (Hotchkiss et al. 1993) and other 
inflammatory diseases (Kohn et al. 2002, Feinstein et al. 1996), as well as apoptosis 
(deMeester et al. 1997). However, in contrast to its effect on HO-1, ANP was not able to 
influence the expression of HSP70 protein, as demonstrated by the results of the present work. 
Apart from heat shock, HSP70 expression is mainly upregulated by stimuli leading to 
different forms of cellular stress, such as oxidized LDL (Zhu et al. 1994), LPS (Flohé et al. 
1999), heavy metal ions (Liu et al. 2001, Wagner et al. 1999) and hydrogen peroxide 
(Madamanchi et al. 2001). Its increased detection in atherosclerotic plaques suggests that 
HSP70 might play a critical role in atherosclerosis (Johnson et al. 1995). Exept from one 
report by Kiemer et al., who demonstrated that ANP prevents the decrease of HSP70 protein 
during reperfusion of rat livers (Kiemer et al. 2002b), no information exists on the influence 
of non-stressful stimuli like ANP on this heat shock protein. Therefore, the present work 
investigated for the first time the effect of ANP on HSP70 expression in a human cell system. 
 
4.1.1.2 cGMP mediates the induction of HO-1 
ANP is known to exert its effects by interaction with the natriuretic peptide A receptor 
coupled to particulate guanylate cyclase and generation of the second messenger cGMP 
(Tremblay et al. 2002). However, ANP also mediates several effects via the clearance 
receptor NPR-C lacking guanylate cyclase activity (Levin 1993). Therefore, it was of interest 
to investigate the receptor specificity of the effects observed after treatment of HUVEC with 
ANP. The cell permeable cGMP analogue, 8-Bromo-cGMP, could mimick the effect of ANP 
on HO-1 expression indicating that the upregulation of HO-1 by ANP is mediated via cGMP. 
Moreover, the specific NPR-C agonist cANF did not influence HO-1 levels, ruling out a 
participation of this natriuretic peptide receptor in mediating the ANP effect. Therefore, the 
data presented in this work demonstrate that ANP induces HO-1 via cGMP. Several reports 
showing an upregulation of HO-1 by cGMP ascribe this observation to an activator of the 
soluble guanylate cyclase, nitric oxide (Polte et al. 2000, Immenschuh et al. 1999). 
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Interestingly, however, reports about the dependency of HO-1 induction by NO on cGMP are 
contradictory. Liang et al. found the HO-1 induction in renal tubular epithelial cells by NO 
donors to be independent of cGMP (Liang et al. 2000), an observation confirmed by 
experiments performed in vascular smooth muscle cells (Durante et al. 1997, Hartsfield et al. 
1997). Alternative cGMP-independent pathways suggested to mediate HO-1 induction by NO 
include the involvement of free radicals, S-nitrosothiols or NO-induced glutathione depletion 
and heme loss (Hartsfield et al. 1997). This discrepancy might reflect cell-type, species- and 
stimulus-dependent differences in HO-1 induction pathways. 
Despite the fact that several groups demonstrated HO-1 induction by cGMP, only the report 
by Immenschuh et al. (Immenschuh et al. 1998) investigated the signal transduction pathway 
involved. This respective work, however, was performed in primary rat hepatocytes and 
reported cGMP to be unable to induce HO-1 in liver endothelial cells. To our knowledge, to 
date no information exists concerning the molecular mechanisms participating in HO-1 
upregulation via cGMP-dependent pathways in a human cell system. 
4.1.1.3 ANP activates JNK and AP-1 DNA-binding  
The activity of the transcription factor AP-1, which has been implicated in the regulation of a 
wide range of genes participating in the regulation of biological processes, such as cell 
proliferation, differentiation, inflammatory processes and apoptosis, has been reported to be 
regulated by several members of the MAPK family at the level of transcription of jun and fos 
genes as well as by posttranslational modifications. Due to the fact that the HO-1 gene 
contains AP-1 binding sites (Lavrovsky et al. 1994) suggesting a possible involvement of this 
transcription factor in HO-1 upregulation by ANP, the effects of ANP on the JNK/AP-1 
pathway were investigated. The results of the present work demonstrate an increase in DNA- 
binding activity of AP-1 in endothelial cells treated with ANP. Only few investigations exist 
concerning the influence of ANP or its second messenger cGMP on AP-1 activation and data 
are controversial. cGMP analogues have been shown to activate transcription from AP-1 
responsive promoters in thyroid follicular cells as well as in fibroblasts (Pilz et al. 1995). 
Interestingly however, in other systems ANP has been found to have no impact on basal AP-1 
activities, but to exert an inhibitory effect on activated AP-1. This observation was made for 
LPS–induced AP-1 activation in murine macrophages (Kiemer et al. 2000a) as well as for 
ischemia-reperfusion-induced AP-1 activity in rat liver (Kiemer et al. 2000b). Moreover, 
Isono and coworkers were able to demonstrate that ANP abrogated AP-1 DNA-binding 
activity in endothelin-1-stimulated glomerular mesangial cells (Isono et al. 1998). This 
respective work additionally reported an inhibitory action of ANP on endothelin-1-induced 
activation of JNK in the same cell model. The inhibition of JNK activity by ANP has also 
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been shown for VEGF-stimulated bovine aortic endothelial cells (Pedram et al. 2001). Our 
work, investigating the effects of ANP on JNK in resident cells, clearly demonstrates an 
increase in JNK activity of both isoforms by ANP.  
These differential roles of ANP, either as an inducer or inhibitor of JNK/AP-1 suggest a 
highly species- and cell type-specific regulation of this signal transduction pathway and an 
important difference between resting and activated cells. These controversial data might also 
be ascribed to the complex regulation of AP-1 activity by the different members of the MAPK 
family at the level of transcription of jun and fos genes as well as by posttranslational 
modifications. The fact that different AP-1 complexes are reported to exhibit different 
transcriptional activities might provide further explanation for the controversial data found 
concerning regulation and activity of this transcription factor. 
 
4.1.1.4 ANP induces the phosphorylation of ERK, but has no effect on p38 
MAPK 
Due to the regulatory effects of ERK and p38 on several AP-1 subunits, the influence of ANP 
on these two MAP kinases was investigated as well. The data presented here demonstrate that 
ANP induces activation of ERK in a time-dependent manner, whereas no influence on p38 
MAPK activity could be detected. Our data for the first time provide evidence that ANP 
induces ERK activation in human endothelial cells. Previous works reported before that ANP 
is able to induce activation of ERK in neonatal rat ventricular myocytes (Silberbach et al. 
1999). On the other hand, ANP was previously shown to inhibit endothelin-1-induced 
activation of ERK in rat mesangial cells (Isono et al. 1998), as well as VEGF-induced ERK 
activity in bovine aortic endothelial cells (Pedram et al. 2001). These results suggest that ANP 
differentially influences ERK in resident or activated cells.  
Reports concerning ANP and p38 MAPK are rare and mostly describe an inhibitory effect of 
this natriuretic peptide on p38 in activated cells. This observation was reported by Tsukagoshi 
and coworkers for IFN-γ-treated RAW macrophages (Tsukagoshi et al. 2001), as well as for 
VEGF-activated bovine aortic endothelial cells (Pedram et al. 2001) and HUVEC exposed to 
TNF-α (Kiemer et al. 2002c). The only study documenting an activation of basal p38 MAPK 
after treatment with ANP comes from our laboratory and was performed in a model of 
ischemia reperfusion injury in the rat liver, preconditioned with ANP, therefore representing a 
completely different cell model (Kiemer et al. 2002d). To our knowledge, no data exist, 
reporting an activation of p38 MAPK in human endothelial cells. 
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4.1.1.5 Role of AP-1, JNK and ERK in the induction of HO-1 
After investigation of the effects of ANP on the MAP kinases ERK and JNK, as well as on 
the transcription factor AP-1, we aimed to causally link these effects to the described ANP-
mediated upregulation of HO-1. In order to demonstrate the causal involvement of the 
JNK/AP-1 and ERK/AP-1 signaling pathway, several inhibitors were tested for their impact 
on HO-1 induction by ANP. U0126, a pharmacologic inhibitor of AP-1 activity, PD 98059, an 
inhibitor of the ERK pathway, as well as SP 600125, a JNK inhibitor, were able to abrogate 
ANP-induced HO-1 upregulation. These results clearly pointed to an involvement of the 
described pathways mediating the ANP effects and causally connect ANP-induced increases 
in HO-1 mRNA and protein levels with the JNK/AP-1 and ERK/AP-1 signaling cascade. AP-
1 has been demonstrated to play an important role in HO-1 regulation, as shown for 
thioredoxin-mediated HO-1 induction in rodent macrophages (Wiesel et al. 2000) as well as 
for HO-1 gene induction in murine macrophages after hyperoxic stress (Lee et al. 2000, Lee et 
al. 1996). The significance of AP-1 for HO-1 induction mediated by cGMP has been reported 
in another rodent cell system, i.e. in rat hepatocytes (Immenschuh et al. 1998). On the other 
hand, Oguro et al. suggested that AP-1 (Oguro et al. 1996) and JNK play a major role in 
phorone-induced HO-1 expression in rats (Oguro et al. 1998). A role for the ERK/AP-1 
pathway in signaling leading to HO-1 upregulation has been described for sodium arsenite-
mediated induction of HO-1 in a chicken hepatoma cell line (Elbirt et al. 1998). Interestingly, 
this work also suggested p38 MAPK to be involved in the signal transduction events leading 
to increased HO-1 gene expression. HO-1 induction has also been reported to occur 
independent of AP-1 in curcumin-treated bovine aortic endothelial cells (Motterlini et al. 
2000). 
Corresponding studies on human HO-1, however, are rare. Only one report by Numazawa et 
al. suggested a role for both AP-1 as well as ERK in HO-1 induction in human fibroblasts 
(Numazawa et al. 1997). Besides, Chen and Maines were able to demonstrate a role for ERK 
in the transcriptional upregulation of human HO-1 by NO (Chen and Maines 2000), but ruled 
out a participation of JNK as well as of AP-1 in the signal transduction pathway. Another 
controversial observation was reported by Alam et al. who described HO-1 induction to occur 
independent of ERK and JNK and to be mediated by p38 MAPK in cadmium-treated MCF-7 
mammary epithelial cells (Alam et al. 2000). Taken together, these data reflect the complex 
regulation of AP-1 and HO-1, being highly dependent on cell-type, species and stimulus. 
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4.1.2 ANP does not confer protection of HUVEC against TNF-α- 
and etoposide-induced cytotoxicity 
The observation that ANP upregulates the expression of HO-1, reported to play a protective 
role in inflammation and oxidative stress, led us to focus on potential protective effects of this 
cardiovascular hormone on cytotoxicity induced by TNF-α, one of the key mediators in 
inflammatory disease. The results of the present work demonstrate that ANP does not 
significantly attenuate TNF-α-mediated apoptosis in HUVEC. 
HO-1 induction has previously been reported to confer protection of endothelial cells against 
TNF-α-induced apoptosis (Brouard et al. 2000). However, most of these investigations were 
performed by expressing large amounts of HO-1 in the respective cells, induced by heavy 
metals, porphyrins or by viral transfer of the HO-1 gene. By means of such approaches it was 
indeed possible to demonstrate a cytoprotective effect against oxidant-induced injury (Yang et 
al. 1999) as well as against oxyhemoglobin-induced endothelial dysfunction (Eguchi et al. 
2001). This observation is supported by studies performed in various other cell models. For 
instance, HO-1 overexpression by gene transfer has been reported to protect against TNF-α-
induced apoptosis in murine L929 fibroblasts (Petrache et al. 2000) and to confer protection 
against heme/hemoglobin-induced toxicity in rabbit coronary microvessel endothelial cells 
(Abraham et al. 1995). Moreover, Motterlini et al. achieved protection against oxidative stress 
by curcumin-mediated HO-1 induction in bovine aortic endothelial cells (Motterlini et al. 
2000). 
On the other hand, there are groups that report that HO-1 expression does not necessarily have 
cytoprotective effects. This observation was recently described by Redaelli et al. who reported 
no protection from ischemia/reperfusion induced apoptosis despite the expression of high 
levels of HO-1 in rat liver grafts (Redaelli et al. 2002). Adenovirus-mediated HO-1 gene 
expression has even been described to stimulate apoptosis in rat vascular smooth muscle cells 
(Liu et al. 2002).  
These contradictory data, reporting either protection by HO-1 or non-protective effects, might 
be ascribed to the interplay of other pathways in the signaling events determining cellular 
survival. In this regard, two signaling pathways were shown to play a crucial role in HO-1-
mediated protection against TNF-α-induced cytotoxicity: activation of p38 MAPK (Brouard 
et al. 2000, Brouard et al. 2002) and activation of NF-κB (Brouard et al. 2002). Brouard et al. 
found the gaseous molecule CO to mediate the antiapoptotic effect of HO-1 and to act via the 
activation of a transduction pathway involving the activation of p38 MAPK (Brouard et al. 
2000). NF-κB mediates the expression of a variety of early responsive anti-apoptotic genes 
after binding of TNF-α to the TNFR-1. Inhibition of NF-κB therefore promotes apoptosis 
induced by TNF-α, whereas NF-κB activation protects cells from cell death (Beg and 
Baltimore 1996, van Antwerp et al. 1996, Wang et al. 1996). Brouard et al. demonstrated that 
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HO-1/CO cooperates with NF-κB-dependent anti-apoptotic genes to protect endothelial cells 
from TNF-α-mediated apoptosis and that the ability of HO-1/CO to activate the p38 MAPK 
pathway was necessary for this effect (Brouard et al. 2002). This observation is further 
supported by the findings of Madrid et al. who reported that p38 MAPK together with IKK 
participates in the stimulation of the transactivation potential of the p65 subunit of NF-κB by 
the serine/threonine kinase Akt (Madrid et al. 2001). 
However, both the p38 MAPK (Tsukagoshi et al. 2001, Kiemer et al. 2002) as well as the NF-
κB (Kiemer and Vollmar 1998, Kiemer et al. 2000b, Kiemer et al. 2002e) pathway have 
previously been shown to be inhibited by ANP. Due to the important role in cell survival 
attributed to these pathways, the HO-1 protein upregulated by ANP might not be sufficient to 
confer protection against TNF-α. 
On this basis, controversial reports in the literature of either cytoprotective or cell damaging 
effects of ANP might also be explained. Observations exist about ANP to be either an inducer 
of apoptosis or to protect from cytotoxic cell damage. For instance, ANP was found to protect 
endothelial cells from lysophosphatidylcholine-induced cytotoxicity (Murohara et al. 1999), 
to attenuate kidney damage induced by different stimuli (Polte et al. 2002, Murakami et al. 
1999), to reduce hepatic ischemia reperfusion injury (Gerbes et al. 1998), to prevent Kupffer 
cell-induced oxidant injury in the rat liver (Bilzer et al. 1999), and to reduce apoptosis in 
serum-deprived PC12 cells (Fiscus et al. 2001). On the other hand, there are reports that 
describe the induction of apoptosis in rat aortic endothelial cells (Suenobu et al. 1999) and in 
cardiac myocytes (Wu et al. 1997). These contradictory observations might be ascribed to the 
interplay of protective as well as deleterious signaling pathways modulated by ANP.  
Since TNF-α alone already induces NF-κB activity and therefore the expression of 
antiapoptotic proteins, we tested another well-known apoptosis-inducing drug, etoposide, in 
the same experimental setting for its influence on NF-κB and cell viability. In contrast to 
TNF-α, etoposide does not activate NF-κB in HUVEC, as shown by our experiments. 
Besides, to our knowledge, no reports exists reporting the activation of NF-κB after etoposide 
in endothelial cells. Therefore, the NF-κB-regulated antiapoptotic mechanisms, described in 
response to TNF-α, do not influence apoptosis elicited by etoposide. Nevertheless, the results 
of the present work indicate that ANP does not confer significant protection against 
etoposide-mediated apoptosis in HUVEC, either.  
Although ANP was not able to protect HUVEC against TNF-α- and etoposide-induced 
apoptosis, it had a strong effect on morphological changes occuring after treatment with   
TNF-α. The pronounced changes of cell morphology, including elongation of the cells and 
formation of gaps in the endothelial monolayer, were almost completely abrogated by ANP, 
indicating that ANP has a regulatory effect on TNF-α-exposed HUVEC. The mechanisms 
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underlying this effect were investigated in another project by Nina Weber and published by 
Kiemer et al. (Kiemer et al. 2002c). 
 
 
4.2 Aspirin 
 
4.2.1 Aspirin induces HO-1 expression via activation of 
JNK/SAPK and subsequent induction of AP-1 DNA binding 
activity 
In recent years, an increasing number of studies have reported protective effects of aspirin 
against colon cancer and cardiovascular disease, as well as its ability to delay the onset of 
Alzheimer disease. Inhibition of COX activity can only in part account for these recently 
observed effects, suggesting that aspirin may exert part of its anti-inflammatory and antitumor 
activity by modulating cyclooxygenase-independent pathways. Therefore, the aim of the 
second part of the present work was to investigate the signaling pathway leading to aspirin-
induced upregulation of HO-1, a potential new target through which aspirin might exert 
protective effects on endothelial cells. Aspirin has previously been shown to confer protection 
of the vascular endothelium against oxidative stress (Podhaisky et al. 1997). This effect, in 
addition to platelet inhibition, might represent an effective approach to influence the 
triggering events of atherosclerosis and to reduce the incidence of occlusive cardio- and 
cerebrovascular diseases. However, data on the mechanisms of this protective effect are rather 
sparse. 
4.2.1.1 Aspirin induces HO-1 expression at the mRNA and protein level 
In the present study, we characterized the effects of aspirin on the heat shock protein HO-1 
and provided data indicating that aspirin can induce the expression of heme oxygenase 
mRNA and protein. These findings provide an interesting new target through which aspirin 
might be able to interfere with pathological conditions, since HO-1 has been reported to 
confer protection in a variety of different experimental settings. This might indeed be of 
relevance to the therapeutic actions of aspirin in vivo, since we were able to demonstrate a 
marked induction of HO-1 with doses as low as 10 µM aspirin, which is in a dose range 
achieved upon systemic administration during anti-inflammatory therapy (1-2 mM) 
(Abramson and Weissmann 1989, Furst et al. 1987, Cianferoni et al. 2001, Kopp and Gosh 
1994). In addition to aspirin, other pharmacological inducers of HO-1 have been described. 
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The highly cytotoxic drug doxorubicin, for instance, has been documented to exert 
hepatoprotective effects by inducing HO-1 (Ito et al. 2000). Moreover, polyphenolic 
compounds, such as curcumin, have been identified as inducers of HO-1 (Scapagnini et al. 
2002). Our findings that aspirin upregulates HO-1 might be connected to findings 
demonstrating an aspirin-induced increase in ferritin synthesis in bovine aortic endothelial 
cells (Oberle et al. 1998). Since HO-1 is known to liberate iron by heme catabolism (Maines 
1997, Immenschuh and Ramadori 2000, Suematsu and Ishimura 2000) and free iron in turn 
induces ferritin synthesis (Eisenstein and Munro 1990), we suggest that upregulation of HO-1 
might be responsible for aspirin-induced ferritin production. Besides its effect on HO-1, there 
exists also evidence indicating an influence of aspirin on other members of the family of heat 
shock proteins. For instance, aspirin has been described previously to induce HSP72 in vivo in 
rat gastric mucosa (Jin et al. 1999). Data on the influence of aspirin on heat shock proteins, 
however, are rare and contradictory, as shown by another report demonstrating an inhibition 
of heat-induced HSP72 expression in chicken testis (Mezquita et al. 2001) whereby mM 
concentrations of aspirin were employed. Moreover, Chen et al. recently reported an 
inhibitory effect of aspirin on LPS/IFN-gamma-induced HO-1 protein expression in RAW 
macrophages (Chen et al. 2002). 
 
4.2.1.2 Aspirin activates AP-1 and JNK 
Due to the reported role of the transcription factor AP-1 in HO-1 induction (Numazawa et al. 
1997) and our own results described under 4.1., our findings that aspirin induces HO-1 
protein as well as mRNA levels raised the question whether AP-1 might as well be involved 
in signaling by aspirin. The results presented in this work demonstrate that aspirin induces 
AP-1 DNA-binding as well as JNK activity in HUVEC. These observations differ from the 
data published on this issue by other investigators, the majority of which investigated the 
effects of aspirin on cells activated by diverse stimuli. To date, there is only one further group 
reporting a stimulatory effect on the transcription factor AP-1 by aspirin-like drugs in human 
T lymphocytes (Flescher et al. 1995). On the other hand, numerous studies have documented 
an inhibitory action of aspirin on AP-1 DNA-binding activity in different in vitro and in vivo 
systems. For instance, aspirin was shown to inhibit AP-1 activity elicited by UV-B radiation 
in transgenic mice (Huang et al. 1997) as well as angiotensin II-induced AP-1 activity in a 
transgenic rat model (Muller et al. 2001). Similar findings have been reported in another 
rodent cell system, i.e. in a mouse epidermal cell line by Chen et al. who demonstrated aspirin 
to interfere with arsenite-induced AP-1 activation (Chen et al. 2001). However, all these 
studies have demonstrated inhibitory effects of aspirin in cell systems activated by diverse 
stimuli and reports on basal effects of aspirin are very limited.  
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Respective studies in human cell systems are rather rare and there are no data on the effects of 
aspirin on AP-1 in human endothelial cells. A recent study by Abiru and coworkers provides 
evidence indicating that aspirin inhibits hepatocyte growth factor-induced AP-1 activity in 
human hepatoma cells (Abiru et al. 2002). Murono et al. reported aspirin to suppress AP-1 
DNA-binding activity enhanced after treatment of human cervical cancer cells with EBV 
latent membrane protein 1 (Murono et al. 2000).  
Data on the influence of aspirin on JNK activity are extremely contradictory and most works 
on the influence on JNK investigated the aspirin metabolite sodium salicylate. Sodium 
salicylate was demonstrated to activate JNK in human peripheral blood eosinophils (Wong et 
al. 2000) as well as in COS-1 and HT-29 human colon adenocarcinoma cells (Schwenger et 
al. 1999). However, the latter group could detect no activation in normal human diploid FS4 
fibroblasts (Schwenger et al. 1999), an observation consistent with the findings of Chen et al. 
in mouse epidermal JB6 cells after treatment with aspirin (Chen et al. 2001). On the other 
hand, other investigators reported an inhibitory effect of aspirin on JNK activity in a variety 
of cell systems, such as UV B radiation-activated transgenic mice (Huang et al. 1997). 
Sodium salicylate was shown to suppress JNK activation by TNF-α in normal human diploid 
FS4 fibroblasts (Schwenger et al. 1997) as well as in LPS-stimulated macrophages 
(Vittimberga et al. 1999). 
However, all of these studies were performed with high concentrations of aspirin and sodium 
salicylate, mostly ranging from 0.5 up to 5 mM or 20 mM, respectively, whereas our 
experiments were carried out with an aspirin concentration of 100 µM, raising the possibility 
that the effect of aspirin on AP-1 might be dependent on the concentration used. This idea is 
supported by the findings of Muller et al. who documented a strictly dose-dependent effect of 
aspirin on the transcription factors AP-1 and NF-κB (Muller et al. 2001). Another possible 
explanation for these contradictory results may lie in the fact that actions of aspirin occur to 
be cell type-specific. Consistent with this idea, examples of cell type-specific actions of 
aspirin and salicylates have been presented by Schwenger et al. who reported a coordinate 
activation of p38 MAPK and JNK in COS-1 and HT-29 cells, but merely an effect on p38 
MAPK and no activation of JNK in FS 4 fibroblasts (Schwenger et al. 1999). Moreover, 
Weyand et al. failed to demonstrate an inhibitory effect of aspirin on NF-κB in a recent study 
in an inflammatory mouse model although this effect has been widely documented in a 
variety of different cell systems (Weyand et al. 2002). Most importantly, it always has to be 
distinguished between basal effects and effects on activated cells. Studies reporting an 
inhibitory effect of aspirin on JNK activity were performed in cells treated with different 
stimuli whereas our experiments investigated aspirin effects on basal JNK activity levels. 
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4.2.1.3 Aspirin has no effect on the phosphorylation of ERK and p38 MAPK 
Since ERK and p38 participate in the regulation of several AP-1 subunits, we also tested the 
possibility that aspirin might exert part of its effect on AP-1 activity by influencing these two 
MAP kinases. The results of the present work clearly indicate that aspirin does neither 
interfere with the phosphorylation status of ERK nor with p38 MAPK activation in HUVEC.  
The observations concerning ERK activity are in agreement with the findings of other 
investigators. For instance, Dong et al. investigated the influence of aspirin on ERK activity 
in TPA-activated mouse epidermal JB6 cells and found the phosphorylation of this MAP 
kinase not to be influenced by aspirin (Wong et al. 2000). The same observation has been 
described in transgenic mice exposed to asbestos (Ding et al. 1999). In other cell systems, 
aspirin has been reported to exert an inhibitory effect on ERK phosphorylation, such as in 
hepatocyte growth factor-activated human hepatoma cells (Abiru et al. 2002), in 
formylmethionyl-leucyl-phenylalanine-stimulated neutrophils (Pillinger et al. 1998) and in 
transgenic mice exposed to UV B radiation (Huang et al. 1997). However, it should be noted 
that the majority of the studies focused on the effects of aspirin on cells activated with the 
respective stimuli, whereas only few works assessed the influence of aspirin on basal levels of 
phosphorylated ERK, as it was the case in our experiments. 
Data concerning the effects of aspirin on p38 MAPK are rather controverse. Aspirin has been 
reported to induce p38 MAPK activity in normal human diploid FS4 fibroblasts (Schwenger 
et al. 1999), an effect that has been observed in the same cell system after treatment with 
sodium salicylate (Schwenger et al. 1997). Moreover, sodium salicylate has been shown to 
activate p38 MAPK in human peripheral blood eosinophils (Wong et al. 2000). On the other 
hand, Wang et Brecher presented results indicating that salicylate has no effect on p38 MAPK 
activity (Wang and Brecher 1999) consistent with the observations of Chen et al. in arsenite-
activated mouse epidermal JB6 cells treated with aspirin (Chen et al. 2001). An inhibitory 
effect of aspirin on p38 MAPK phosphorylation has been documented in different stimulated 
cell models (Huang et al. 1997, Paccani et al. 2002). Taken together, these diverging 
observations again support the idea that effects of aspirin might be extremely dependent on 
the concentration used as well as on the cell system in which the respective investigation is 
performed. 
 
4.2.1.4 Role of JNK/AP-1 in the induction of HO-1 by aspirin 
In view of the results presented so far, we aimed to establish a causal relationship between 
upregulation of HO-1 mRNA and protein by aspirin and the activation of the JNK/AP-1 
pathway. In order to examine the role of JNK/AP-1 in the signaling leading to HO-1 
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upregulation, we tested U0126, a pharmacologic inhibitor of AP-1 activity, as well as SP 
600125, a JNK inhibitor, for their ability to attenuate HO-1 induction by aspirin. Both 
inhibitors were able to abrogate aspirin-induced HO-1 upregulation, suggesting the JNK/AP-1 
pathway to play a major role in the signaling events responsible for increased HO-1 protein 
and mRNA levels after treatment with aspirin. 
As discussed under 4.1.1.5, AP-1 has previously been documented to play a central role in the 
regulation of HO-1 expression, as evidenced for thioredoxin-mediated HO-1 induction in 
rodent macrophages (Wiesel et al. 2000), as well as for cGMP-mediated HO-1 induction in rat 
hepatocytes (Immenschuh et al. 1998) and HO-1 induction in human fibroblasts (Numazawa 
et al. 1997). Interestingly, Hill-Kapturczak et al. reported the polyphenolic compound 
curcumin, a well-known inhibitor of AP-1, to induce HO-1 in human renal proximal tubule 
cells (Hill-Kapturczak et al. 2001). 
 
 
4.2.2 Aspirin is not able to protect HUVEC against TNF-α- or 
etoposide-induced cytotoxicity 
Due to the fact that aspirin was able to induce the expression of HO-1, we considered the 
possibility that aspirin could confer protection against TNF-α-induced cytoxicity via this heat 
shock protein. The results of the present work, however, provide evidence that aspirin does 
not significantly interfere with apoptosis induced by TNF-α, a central signaling molecule in 
inflammatory states, in HUVEC. 
As described under 4.1.2, cytoprotective effects have been attributed to HO-1 expression in a 
variety of cell systems exposed to different deleterious stimuli, such as endothelial cells 
treated with TNF-α (Brouard et al. 2000).  
On the other hand, there is evidence indicating that HO-1 expression does not necessarily 
elicit cytoprotective effects, such as a recent study by Redaelli et al. who detected no 
protection from ischemia/reperfusion-induced apoptosis despite the expression of high levels 
of HO-1 in rat liver grafts (Redaelli et al. 2002) and a work by Liu et al showing the induction 
of apoptosis in rat vascular smooth muscle cells by adenovirus-mediated HO-1 gene 
expression (Liu et al. 2002). As mentioned under 4.1.2, these controversial data, reporting 
either protection by HO-1 or non-protective effects, might be accounted for by the interplay 
of other pathways. The two signaling components demonstrated to play a pivotal role in HO-
1-mediated protection against TNF-α-induced cytotoxicity are activated p38 MAPK (Brouard 
et al.2000, Brouard et al. 2002) and activated NF-κB (Brouard et al. 2002). 
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Aspirin has been demonstated to interfere with both p38 MAPK and the NF-κB activity. 
While reports concerning the influence of aspirin on p38 MAPK are quite contradictory, as 
mentioned under 4.1.3.3, its inhibitory effect on NF-κB has been widely documented in a 
great variety of cell systems, such as in TNF-α-stimulated HT-29 human colon 
adenocarcinoma cells and COS-1 African green monkey kidney cells (Schwenger et al. 1997, 
Alpert et al. 1999), in LPS- or TNF-α-treated Jurkat cells (Kopp and Gosh 1994, Yin et al. 
1998) and in LPS-stimulated macrophages (Vittimberga et al. 1999). We also observed the 
inhibition of NF-κB DNA-binding activity in TNF-α-treated cells in our cell model. 
On account of the pivotal role of these pathways and the evidence for their inhibition by 
aspirin, the HO-1 protein upregulated by aspirin might not be sufficient to confer protection 
against TNF-α. Besides, the influence of aspirin on other pathways might also play an 
important role in the regulation of cell viability. One example are the MAPK. ERKs are 
characteristically associated with cell proliferation and have previously been demonstrated to 
protect cells from apoptosis in a number of cell systems (Xia et al. 1995), whereas JNK 
(Tournier et al. 2000) and p38 MAPK (Schwenger et al. 1997) are able to promote apoptosis 
in several experimental settings. In view of these findings, the lack of effect of aspirin on 
ERK together with the activation of JNK observed in the present study, might also contribute 
to the inability of aspirin to protect HUVEC against apoptosis elicited by TNF-α. 
These observations might as well provide a possible explanation for the controversial reports 
in the literature describing aspirin as an either cytoprotective or apoptosis-inducing drug. 
Aspirin has previously been shown to protect endothelial cells from H2O2-induced 
cytotoxicity (Podhaisky et al. 1997). The induction of ferritin was suggested to contribute to 
this cytoprotective action (Oberle et al. 1998). Further evidence in favour of a cytoprotective 
action of aspirin was provided by a study on arsenite-induced apoptosis in mouse epidermal 
JB6 cells (Chen et al. 2001) as well as by Grilli et al. who demonstrated neuroprotective 
properties of aspirin against toxicity elicited by glutamate in rat primary neuronal cultures 
(Grilli et al. 1996). In an in vivo rat model, aspirin was found to protect from angiotensin II-
induced organ damage (Muller et al. 2001). On the other hand, aspirin has been reported to 
induce apoptosis in gastric (Tomisato et al. 2001) and oral (Slomiany and Slomiany 2001) 
mucosal cells, as well as in HeLa cells (Callejas et al. 2002). Consistent with these findings, 
Schwenger et al. documented that sodium salicylate induces apoptosis in normal human 
diploid FS4 fibroblasts (Schwenger et al. 1997), an observation also described in human 
peripheral blood eosinophils (Wong et al. 2000). 
In another set of experiments, we examined the influence of aspirin on etoposide-induced 
apoptosis in HUVEC. As mentioned under 4.1.2, compared to TNF-α, etoposide has the 
advantage that this chemotherapeutic drug is not an activator of NF-κB in our cell model, as 
confirmed by the literature and our own experiments. The data presented in this work 
demonstrate that aspirin can not confer protection to HUVEC exposed to etoposide. In the 
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literature, one report exists documenting protection of colon carcinoma cells from etoposide-
induced apoptosis by aspirin (Ricchi et al. 2002). This might reflect cell type-specific 
differences in the regulation of apoptosis by aspirin. 
4.3 Outlook 
The results on the influence of ANP and aspirin on TNF-α- and etoposide-treated HUVEC 
suggest that HO-1 upregulation alone might not be sufficient to confer significant protection 
to HUVEC treated with different apoptosis-inducing agents. Protection seems to require the 
induction of additional protective pathways, such as NF-κB and p38, shown to be inhibited by 
ANP and aspirin. This observation raises the question what physiological function the 
induction of HO-1 by ANP and aspirin might serve. Although HO-1 has mainly been 
described to play an important role in cytoprotection, other regulatory functions of this 
inducible protein have been reported. In this context, HO-1 has been demonstrated to reduce 
vasoconstriction and inhibit cell proliferation during vascular injury (Duckers et al. 2001) as 
well as to attenuate the expression of COX-2, a well-known mediator of inflammatory 
responses (Haider et al. 2002). Since the antiproliferative potential of ANP is well-known 
(Appel 1992) and ANP has been shown to reduce COX-2 induction (Kiemer et al. 2002a), a 
causal relationship between these regulatory actions of ANP and HO-1 induction might be 
suggested. Antiproliferative effects of aspirin and salicylates have been reported as well 
(Marra and Liao 2001, Marra et al. 2000). Moreover, HO-1 has been suggested to modulate 
NO production by NO synthase (Maines 1997). An inhibitory effect on the expression of the 
inducible NO synthase has also been demonstrated for ANP (Kiemer and Vollmar 1998, 
Kiemer and Vollmar 2001a, Kiemer and Vollmar 2001b), an effect that might be mediated by 
HO-1 induction by ANP. Aspirin has been shown to inhibit iNOS expression in a variety of 
cell models (Amin et al. 1995, Katsuyama et al. 1999). 
Taken together, these data demonstrate that there are various potential targets apart from 
cytoprotection, through which ANP- and aspirin-mediated HO-1 induction might confer 
regulatory effects to endothelial cells. 
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5.1 ANP 
In the present work, we could demonstrate a significant time- and dose-dependent induction 
of HO-1 protein and mRNA levels by ANP which was mediated via binding to its particulate 
guanylate-cyclase-coupled receptor. Concerning the molecular mechanism leading to the 
upregulation of HO-1, we were able to show that ANP increased the DNA-binding activity of 
the transcription factor AP-1. In Western blot experiments performed with phospho-specific 
antibodies for the MAP kinases JNK, ERK and p38, we could further demonstrate an 
activation of JNK as well as ERK after treatment with ANP, whereas it had no effect on p38 
MAPK. The causal relationship between the observed ANP-induced increases in AP-1, JNK 
and ERK activity and the induction of HO-1 was proven by the use of specific 
pharmacological inhibitors. Taken together, we demonstrated that ANP induces HO-1 mRNA 
and protein expression via binding to its particulate guanylate-cyclase-coupled receptor, 
activation of the MAP kinases JNK and ERK, and subsequent activation of the transcription 
factor AP-1. 
The cytokine TNF-α as well as the topoisomerase inhibitor etoposide induce apoptosis in 
human endothelial cells. Despite the induction of HO-1, neither simultaneous addition nor 
preincubation with ANP was able to confer significant protection of HUVEC against TNF-α- 
or etoposide-induced apoptotic cell death.  
 
5.2 Aspirin 
In the present work, we could report for the first time that aspirin induces the expression of 
HO-1 at protein and mRNA level in a time- and dose-dependent manner. The aspirin 
concentrations effective in upregulating HO-1 were within the dose range of plasma levels 
achieved during antiinflammatory therapy. Moreover, we were able to elucidate the molecular 
mechanism leading to the observed HO-1 induction. Aspirin was shown to increase the DNA-
binding activity of AP-1 as well as JNK activation, whereas it did not affect the MAP kinases 
ERK and p38. The causal involvement of the effects of aspirin on AP-1 and JNK in the 
induction of HO-1 was demonstrated by employing specific pharmacological inhibitors. 
Moreover, we report here that aspirin was not able to protect endothelial cells against TNF-α- 
and etoposide-induced apoptosis.  
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Taken together, the data presented in the present work provide for the first time a 
characterization of the molecular mechanisms leading to the induction of HO-1 in human 
endothelial cells after treatment with ANP, as well as aspirin for which the influence on this 
heat shock protein was shown for the first time. Heat shock proteins are of central importance 
for the protein homeostasis of the cell due to their function as molecular chaperones under 
physiologic as well as stress conditions. Therefore, it is of vital importance to elucidate the 
mechanisms controlling the expression of heat shock proteins and the present work represents 
an important contribution to the understanding of the regulation of the heat shock protein HO-
1. Although the upregulation of HO-1 by ANP and aspirin was not sufficient to protect 
endothelial cells against apoptosis induced by the cytokine TNF-α, this heat shock proteins 
might unfold its cytoprotective potential by acting on other attractive targets, such as COX-2 
or NO synthase, important mediators of the inflammatory response. 
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6.1 Abbreviations 
AIDS Aquired immuno deficiency syndrome 
ANP Atrial natriuretic peptide 
AP-1 Activator protein 1 
APS Ammonium persulphate 
ATP Adenosine-5’-triphosphate 
BNP Brain natriuretic peptide 
bp Basepair 
BSA Bovine serum albumine 
cAMP cyclic Adenosine-5’-monophosphate 
cDNA complementary DNA 
cGMP cyclic Guanosine-5’-monophosphate 
CNP C-type natriuretic peptide 
Co Control 
COX Cyclooxygenase 
Da Dalton 
dATP 2’-Desoxyadenosine-5’-triphosphate 
dCTP 2’-Desoxycytosine-5’-triphosphate 
dGTP 2’-Desoxyguanosine-5’-triphosphate 
DMSO Dimethylsulphoxide 
DNA Desoxyribonucleic acid 
dNTP Desoxynucleosidtriphosphate 
dsDNA double strand DNA 
DTT Dithiothreitol 
ECL Enhanced Chemoluminescence reagent 
EDTA Ethylene diamine-N,N,N’,N’-tetra acid 
EGF Endothelial growth factor 
EGTA  
EMSA Electrophoretic mobility shift assay 
ERK Extracellular related kinase 
EtBr Ethidium bromide 
EtOH Ethanol 
FACS Fluorescence activated cell sorting 
FITC Fluoresceinisothiocyanate 
FCS Fetal calf serum 
GAPDH Glyceraldehyde phosphate dehydrogenase 
GTP Guanosine-5’-triphosphate 
h Hour 
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HFS hypotonic fluorochrome solution 
HO-1 Heme oxygenase-1 
HSP Heat shock protein 
HUVEC Human Umbilical Vein Endothelial Cells 
IBMX Isobutylmethylxanthine 
IFN γ Interferon gamma 
IκB (α/β) Inhibitory protein kappa (α/β) 
iNOS inducible NO synthase 
JNK c-jun N-terminal kinase 
kDa kilo Dalton 
L Liter 
LDL Low density lipoprotein 
LPS Lipopolysaccharide 
m milli (10-3) 
M Molar 
MAPK mitogen-activated protein kinase 
MCP-1 Monocyte chemoattractant protein-1 
MeOH Methanol 
MW molecular weight 
µ micro (10-6) 
min Minute 
mRNA messenger Ribonucleic acid 
% (m/v) mass per volume per cent 
n nano (10-9) 
NF-κB Nuclear Factor κB 
NP Natriuretic peptides 
NPR Natriuretic peptide receptor 
NSAID non steroidal antiinflammatory drug 
NTP ATP, CTP, GTP, or TTP 
OD Optical density 
PAA Polyacrylamide 
PAGE Polyacrylamide-gel-electrophoresis 
PBS Phosphate buffered saline solution 
PCR Polymerase chain reaction 
PMSF Phenylmethylsulfonylfluoride 
RNA Ribonucleic acid 
Rnase Ribonuclease 
rpm Rotations per minute 
RT Room temperature 
SAPK stress-activated protein kinase 
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sec Second 
SEM Standard error of the mean value 
SDS Sodium dodecyl sulfate 
SMC Smooth muscle cells 
SNP Sodium nitroprusside 
ssDNA single strand DNA 
TAE Tris, acetate, EDTA buffer 
TBS-T Phosphate buffered saline solution with Tween 
TE Tris-EDTA buffer 
TEMED N,N,N’,N’-tetramethylethylendiamine 
TNF-α Tumor necrosis factor alpha 
totRNA total RNA 
TRIS Tris-hydroxymethyl-aminomethan 
TXA2 Thromboxane A2 
UV ultra violet 
V Volt 
VEGF Vascular endothelial growth factor 
% (v/v) volume per volume per cent 
W Watt 
 
6.2 Alphabetical order of companies 
Alexis Biochemicals  (Grünberg, Germany) 
Amersham  (Braunschweig, Germany) 
Beckmann Instruments  (Munich, Germany) 
Becton Dickinson  (San Jose, CY, USA/Heidelberg, Germany) 
Biochrom  (Berlin, Germany) 
Biometra  (Göttingen, Germany) 
BioRad Laboratories  (Munich, Germany) 
Calbiochem  (Schwalbach, Germany) 
Carl Roth  (Karlsruhe, Germany) 
Cell Signaling  (Frankfurt/M, Germany) 
Eppendorf  (Maintal, Germany) 
Fluostar, BMG GmbH  (Offenburg, Germany) 
Gibco/BRL  (Eggenstein,Germany) 
Greiner  (Nürtingen, Germany) 
Heraeus Instruments  (Munich, Germany) 
Jackson Immunolab  (Hamburg, Germany) 
Kodak digital science  (Stuttgart, Germany) 
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Merck-Eurolab  (Munich, Germany) 
Millipore  (Eschborn, Germany) 
MWG-biotech  (Ebersberg, Germany) 
NEN  (Cologne, Germany) 
NUNC  (Wiesbaden, Germany) 
PAN  (Aidenbach, Germany) 
PE Applied Biosystems (Weiterstadt, Germany) 
Peske  (Aindling-Pichl, Germany) 
Promega  (Mannheim, Germany) 
Promocell  (Heidelberg, Germany) 
Qiagen  (Hilden, Germany) 
Roche  (Mannheim, Germany) 
Roth  (Nürnberg,Germany) 
Santa Cruz  (Heidelberg, Germany) 
Saxon Biochemicals  (Hannover, Germany) 
Schleicher & Schüll  (Dassel, Germany) 
Serotec LTD  (Wiesbaden, Germany) 
Sigma  (Taufkirchen, Germany) 
SLT Labinstruments  (Crailsheim, Germany) 
Thermo Life Sciences  (Egelsbach, Germany) 
Zeiss  (Munich, Germany) 
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6.3 Publications 
 
Parts of this work are published or are in preparation for publication: 
 
Poster: 
Nina C. Weber, Nicole Bildner, Angelika M. Vollmar, Alexandra K. Kiemer, 2002, ANP 
inhibits TNF-α-induced expression of adhesion molecules in endothelial cells via induction of 
IκB. Naunyn-Schmiedeberg’s Archives of Pharmacology, Suppl.1 to Vol.365, March 2002. 
 
Alexandra K. Kiemer, Nina C. Weber, Nicole Bildner, Angelika M. Vollmar, 1999, ANP 
verhindert TNF-α-induzierte Veränderungen von Morphologie und Zytoskelett in 
Endothelzellen. Proceedings 7. Tagung für Zell- und Gewebeschädigung in Weinheim. 
 
Alexandra K. Kiemer, Nicole Bildner, Nina C. Weber, Angelika M. Vollmar, HO-1 induction 
by ANP is mediated via MAPK activation and does not confer protection against apoptosis. 
VIII. NO Forum der deutscHSPrachigen Länder, Frankfurt 2002. 
 
Original publications: 
 
Alexandra K. Kiemer, Nina C. Weber, Robert Fürst, Nicole Bildner, Stefanie Kulhanek-
Heinze, Angelika M. Vollmar, 2002. Inhibition of p38 MAPK activation via induction of 
MKP-1: Atrial Natriuretic Peptide reduces TNF-α-induced actin polymerization and 
endothelial permeability. Circulation research, May 2002. 
 
Alexandra K. Kiemer, Nicole Bildner, Nina C. Weber, Angelika M. Vollmar, 2002. 
Characterization of Heme Oxygenase 1 (HSP 32) induction by Atrial Natriuretic Peptide in 
human endothelial cells. Endocrinology, submitted for publication. 
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